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ABSTRACT
Malignant catarrhal fever (MCF) is a fatal lymphoproliferative disease of Artiodactyla.
The disease is caused by infection of susceptible hosts with one of two
gammaherpesviruses, Alcelaphine herpesvirus-1 (AHV-1) or Ovine herpesvirus-2
(OHV-2).
On primary isolation, AHV-1 infectivity is cell-associated and the virus can induce
MCF following inoculation into susceptible hosts. Cell free virus which is pathogenic
for cattle is observed following low serial passage of the virus in cell cultures. After
further serial passage cell free virus is observed, but this virus cannot produce disease
experimentally. AHV-1 genomic rearrangements occur during the transition from
virulence to attenuation. Two genes, encoding putative protein 5 (P-5) and protein 1 (P-
1), are truncated during this rearrangement. The aim of this study was determine the
importance of these putative proteins in the pathogenesis ofAHV-1.
Sequence encoding each of these proteins was cloned and the proteins expressed in
vitro. Rabbits, a laboratory model for AHV-1, were successfully immunised with these
proteins. Neither of these proteins however induced a protective immune response.
Although both proteins are expressed in vitro, transcripts for these proteins could not be
detected in vivo in animals reacting with MCF.
During the course of this study, the complete sequence of the AHV-1 genome was
published. P-l and P-5 were shown to form part of open reading frames (ORF) 50 and
A7 respectively. These ORFs were therefore re-assessed to determine their positions in
the attenuated and virulent virus. New isolates were obtained from cattle showing
clinical MCF and also from wildebeest. Analysis of viral DNA derived from the new
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isolates has shown that ORF 50 and ORF A7 are conserved between isolates and the
virulent laboratory adapted isolate. The results presented here show that a block of
sequence in the attenuated virus, which includes sequence for ORF 50 and its promoter,
are translocated from a position in the middle of the unique DNA to a terminal position
where it is inverted with respect to its transcriptional orientation in the virulent virus.
The ORF is transcriptionally silent in the attenuated virus and the results presented here
show that this is due to the inactivity of the truncated ORF 50 promoter in the
attenuated virus.
v
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Malignant catarrhal fever (MCF) is a clinico-pathologic syndrome of Artiodactyla
characterised by fever and high mortality but generally low morbidity, worldwide
distribution and defined by characteristic histopathologic changes (Plowright 1986,
Locken et al, 1998). MCF has been recognised as a sporadic disease of cattle since
the early part of this century (Goetze, 1930) but outbreaks have also been reported in
cattle and deer (Daubney and Hudson, 1936, Plowright, 1968, Reid et al, 1979).
Cases of MCF have been reported in at least 39 species of Bovidae and Cervidae
(Reid and Buxton, 1984, Heuschele et al, 1988 a,b, Metzler 1991) and recently in
farmed and exotic pigs in Norway (Locken et al, 1998).
In regions of Africa the disease is economically important as it affects cattle. In Asia,
the water buffalo (Bubalus bubalis) and banteng cattle (Bos javanicus) are
particularly susceptible and the disease has become more important in the UK, New
Zealand and Australia following the development of deer farming (Denholm and
Westbury, 1982, Reid et al, 1984). In Africa, the disease is caused by infection with a
gammaherpesvirus, Alcelaphine herpesvirus 1 (AHV-1) which is readily isolated
from affected cattle and inapparently affected wildebeest (Connochaetes taurinus),
(Plowright et al, 1960). In other parts of the world the disease is associated with
Ovine herpesvirus 2 (OHV-2) which has not been isolated but sheep are the natural
hosts of the virus (Rossiter 1980b, Baxter et al, 1993). The disease can be caused by
either of the two viruses. These viruses are antigenically and genetically related and
the disease picture following infection of susceptible hosts with either aetiological
agent is generally similar.
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1. 2. The disease
1. 2. 1. Clinical disease
The clinical features of MCF are variable and have been categorised into; peracute,
acute head and eye form, intestinal, mild and chronic forms (Plowright 1968). The
majority of cases in cattle are acute while in deer the peracute form is the most
common (Plowright 1986). Following an incubation period which may vary from a
few weeks to several months, the animal is usually noticed as being dull and
inappetant while the milk yield in lactating animals rapidly drops. This is generally
followed by lacrimation, salivation and secretion of watery nasal discharge which
progresses to become profuse and mucopurulent (Plowright 1968, Selman et al,
1974). This is followed a few days later by severe congestion, necrosis and erosion of
the nasal and ocular mucosae (Reid and Buxton 1984, reviewed by Plowright, 1986,
and see figure 1.1). Lacrimation sometimes becomes mucopurulent and is
accompanied by centripetal corneal opacity and blindness. There is generalised
enlargement of superficial lymph nodes and this may occur several days before onset
of fever. Less frequent signs include laminitis and dermatitis and these have only
been seen in disease associated with OHV-2 (Plowright, 1986). An unusual case of
MCF in a yearling bull where the only symptoms seen were lameness and exudative
dermatitis which resulted in multiple skin fissures has also been reported (Holiman et
al, 1994). Neurological symptoms are not uncommon and are characterised by
muscular tremors, incoordination, hyperaethesia and head pressing (Daubney and
Hudson, 1936, Selman et al, 1974). The disease in deer is often hyperacute with a
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short course and the clinical picture may be less dramatic than in cattle. The disease
in deer may include slight lymphadenopathy, mild congestion of the buccal mucosae,
slight nasal discharge and diarrhoea (Oliver et al, 1983, Reid and Buxton, 1984) or it
may be acute as observed in cattle (Westbury and Denholm, 1982).
Experimental transmission is only possible with suspensions of viable cells prepared
from affected tissues.
The disease is experimentally reproducible in cattle and rabbits following inoculation
with AHV-1 though less readily with OHV-2 and the symptoms seen are largely
similar to those seen in natural cases. The average incubation time in experimentally
infected cattle is 30 days for AHV-1 and 32 days for OHV-2 (Piercy et al, 1952a,
1952b). The course of the disease lasted 12 days in cattle infected with AHV-1 and
only 4 days in OHV-2 affected animals. In rabbits the disease has an incubation
period of 11- 12 days (Piercy 1955, Rossiter 1981). In rabbits inoculated
intracerebrally there is sudden onset of fever which subsides in 2-3 days. Death
usually occurs 2 to 3 days after fever without any other symptoms. In some rabbits
however symptoms appear during pyrexia and these are characterised by "paddling",
"circling", muscular tremors, incoordination and paralysis. In rabbits that are
inoculated by the intraperitoneal route or intravenously, the animals may become
pyrexic and then die without any other signs but some may show ocular and nasal
discharges which may become mucopurulent. Other signs include mucoid diarrhoea
and enlarged peripheral lymph nodes (Piercy, 1955).
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Figure 1.1; Typical case of a bull affected with the head and eye form ofMCI
Note the oral, nasal, muzzle erosions and oral discharge and closed eyes
1. 2. 2. Epizootiology
1. 2. 2.1. Natural hosts
The close association between MCF in cattle and the wildebeest calving season has
been recognised since the last century, (Cummings, 1850, Mettam, 1923). The virus
was however isolated later from normal pregnant wildebeest and yearling calves
(Plowright et al, 1960). Although some wildebeest calves acquire infection
congenitally, transmission is thought to be mainly horizontal from contaminated
pastures during the neonatal period (Plowright et al, 1965a,b , Mushi et al, 1980b,
1981a). In infected calves the virus most probably replicates in the corneal and
turbinate mucosa from where it is shed in a cell free form (Mushi et al, 1981c). Virus
shedding continues until the calves are about 3 months old following production of
surface IgA and appearance of virus neutralising antibody in the blood (Plowright,
1965, Mushi et al, 1981c, Rurangirwaet al, 1982,).
AHV-1 has been isolated from adult wildebeest following treatment with
corticosteroids or under the stress of confinement, malnutrition or pregnancy
(Plowright, 1965, Rweyemamu et al, 1974). The disease in Africa is therefore
observed during and immediately after the wildebeest calving season (Plowright,
1965, Mushi et al, 1981c) and the disease in zoological collections has been shown to
follow the same pattern (Heuschele et al, 1988a,b).
Most cases of OHV-2 infection are associated with close contact between sheep and
clinically susceptible hosts, particularly during the lambing season, indicating that
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lambs play a similar role to that played by wildebeest calves (Plowright, 1986).
Polymerase chain reaction test (PCR) has shown that virus is present in colostrum of
suckling ewes and lambs up to 12 weeks of age (Li et al, 1995b) and that all adult
sheep tested had antibody to OHV-2 (Rossiter, 1982). The PCR has now been used to
detect OHV-2 DNA in nasal secretions of lambs within a period of two months
following birth. Viral DNA was also detected in epithelial cells of the cornea,
turbinates and pharynx which led to the proposal that the cornea and turbinates are
the primary sources of OHV-2 infection in lambs (Baxter et al, 1997). Perinatal
infection of lambs is low but infection rates rise rapidly after nursing indicating that
the major source of OHV-2 infections is milk (Li et al, 1998).
1. 2. 2. 3, Other possible hosts
Serological studies have shown prevalence of antibody in at least 33 species within
the subfamilies Alcelaphinae, Hippotraginae, Caprinae and Reduncinae (Hamblin
and Hedger, 1984, Heuschele et al, 1984, Metzler, 1991). Whether the antibody is a
response to AHV-1, OHV-2 or antigenically related viruses is unclear. However
distinct but antigenically related viruses have been isolated from the hartebeest,
(.Alcelciphus buselaphus) (Reid and Rowe, 1973), topi (Damaliscus korrigum) (Mushi
et al, 1981b) and the roan antelope (.Hippotragus equinus) (Reid and Bridgen, 1991).
These viruses though present in the natural host at a high prevalence do not appear to
spread to other species and cause MCF.
7
1. 2. 2. 4. Transmission
The most probable source of AHV-1 infection for cattle is infective ocular and nasal
secretions from wildebeest calves (Mushi et al, 1980a, b, 1981c). Infected cattle are
dead-end hosts and this is believed to be due to cattle shedding cell-associated virus
(Mushi et al, 1981c). The method of transmission for OHV-2 has not been elucidated
though it is believed to be similar to that observed with AHV-1. PCR has shown that
OHV-2 is present in B lymphocytes of adult sheep and that lambs may acquire virus
from milk (Li et al, 1995b, Baxter et al, 1997). The virus then replicates in the upper
respiratory mucosae from where the virus is shed via nasal secretions (Baxter et al,
1997). Experimental transmission can be demonstrated using blood or cell
suspensions of tissues from cattle, rabbits and deer affected with either of the two
viruses (Daubney and Hudson 1936, Selman et al, 1974, Buxton and Reid, 1980,
Westbury and Denholm 1982). Transmission to hamsters has also been achieved
with OHV-2 and the C500 isolate of AHV-1 while only AHV-1 would transmit to
rats (Reid et al, 1986 Jacoby et al, 1988a)
1. 2. 3 Pathology
1. 2. 3.1 Gross pathology
Although the general pathology of MCF was first reported by Daubney and Hudson
in 1936, detailed systematic pathology was described later by Plowright (1968) and
Selman et al, (1974, 1978) following natural and experimental infection of cattle with
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AHV-1 and OHV-2 respectively. The pathology in deer is similar to that of cattle
following infection with either virus (Huck et al, 1961, Plowright, 1968). MCF is a
disseminated disease and lesions are found in all organs and tissues. In the alimentary
system the lesions may vary from severe congestion to erosions and necrotic patches
in the buccal and pharangeal mucosae; the abomasal and intestinal mucosae may be
reddened or haemorrhagic (figure 1.2) and button ulcers have been observed in
abomasal folds in some chronic cases of MCF (Daubney and Hudson, 1936,
Plowright, 1968, Selman et al, 1974). The peripheral and mesenteric lymph nodes are
enlarged, soft and they may be haemorrrhagic and oedematous or necrotic (Plowright
1968, Selman 1974 Westbury and Denholm, 1982). The spleen is markedly enlarged
with prominent white pulp (Plowright, 1968). Lesions in the respiratory system are
severe in animals affected with AHV-1 and are characterised by congestion,
haemorrhage and necrosis of the upper respiratory tract but involvement of the lungs
is rare. In the parenchymatous organs, the liver is usually congested and enlarged
(Daubney and Hudson, 1936) and the kidney lesion is characterised by cortical
infarcts which are surrounded by areas of haemorrhage.
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Figure I 2; Typical appearance of the gut in a steer with the head and eye form ofMCF
Note the hyperemia and ulcers in the intestinal mucosa
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1. 2. 3. 2 Histopathology
The most striking histopathological feature of MCF is infiltration of all organs with
mononuclear cells and the presence of vascular lesions (Selman et al, 1974).
Multifocal, degenerative and necrotic changes are observed in all respiratory and
digestive system mucous membranes and squamous epithelia in AHV-1 or OHV-2
affected animals and these are associated with lymphocytic infiltration (Selman et al,
1974, Liggitt et al, 1978, Liggitt and DeMartini, 1980b, c). In the kidneys, foci of
mononuclear cell infiltration correspond to the grey-foci seen macroscopically
although there is development of infarcts as a result of necrotising arteritis and
thrombosis. The vessels affected are mainly the small and medium arteries of most
tissues, the most commonly affected being the oro-pharangeal epithelium, eye, nose,
kidney, liver, lung and brain. Ultrastructural studies showed that the infiltrative cells
were mainly lymphocytes, lymphoblasts and macrophages (Liggit and DeMartini,
1980b, c). lymphoid cell accumulations in lesions carry T-cell surface markers
(Schock, 1996). In recovered animals or chronically affected cattle, chronic
obliteropathic lesions are seen with infiltrative cells predominantly found in the
tunica media and intima resulting in the occlusion of blood vessels (O'Toole et al,
1995).
1. 2. 3. 3 Pathogenesis
Following infection with AHV-1 by inoculation of cattle with infective blood,
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viraemia occurs after 8-17 days (Plowright, 1968). The first overt sign of disease
however is pyrexia which is observed 3-5 days after viraemia. The virus then appears
in the lymphoid organs before it becomes disseminated. Pathological changes then
occur in all organs and tissues and death usually occurs 5-8 days after the onset of
pyrexia. Work done using rabbits inoculated with OHV-2 (Buxton and Reid 1980)
showed that earliest changes are characterised by thickening of the appendix (a
lymphoid organ in lagomorphs). This is followed 2 days later by enlargement of
superficial lymph nodes and the mesenteric lymph nodes, spleen, and alveolar
emphysema. Edington and Patel (1981) inoculated rabbits intravenously with AHV-1
infective tissue suspensions and showed that the primary target organ for the virus
was the spleen. They also suggested that the secondary target sites were the lymphoid
glands.
One striking feature of MCF however is the lack of direct virus cytopathology
(Plowright 1986). Although virus infectivity can be readily demonstrated in tissues,
no virus specific antigens have been detected (Rossiter, 1980a) and DNA
hybridisation can detect only 1 out of 104 infected cells in affected tissues (Bridgen et
al, 1992).
There are generally three major processes of cellular damage in virus infections.
These processes are direct cellular damage due to virus replication, cell
transformation, and pathology due to immune activation or suppression following
infection of cells by virus. All these processes however involve various viral
molecular determinants of virulence.
Earlier theories suggested that the pathology in MCF observed was due to antibody
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dependent complexes (Rweyemamu et al, 1974), or hypersensitivity (Plowright,
1968), or virus induced cell destruction (Selman et al, 1974, Liggit and De Martini
1980b), or virus induced lymphoid transformation (Hunt and Billups 1979) or
immune tolerance (Mushi and Rurangirwa 1981c). These theories however cannot
adequately account for the T cell hyperplasia that occurs before cell destruction and
death.
The hypothesis that best satisfies the clinico pathological picture and the final
outcome of the disease is the one proposed by Reid et al (1985). They propose that
the virus induced deregulation of lymphocytes is the fundamental mechanism which
leads to the production of large granular lymphocytes with natural killer
characteristics. They suggest that the target cell for the virus is the large granular
lymphocyte and that such infected cells produce lymphokine or interleukins which
leads to the T cell proliferation that is seen. The suggestion is supported by the
generation of lymphoblastoid cell lines with the phenotypic and functional
characteristics of large granular lymphocytes from cattle and deer with OHV-2
induced MCF and rabbits affected with MCF induced by either OHV-2 or AHV-1
(section 1.3.1.2). The tissue destruction may therefore be a direct result of the large
granular lymphocytes with natural killer activity affecting tissues in vivo. Such
granular lymphocytes have been shown to transmit disease to cattle, deer and rabbits
without showing detectable viral antigens indicating that these cells are latently
infected (Reid et al, 1985). These cells have also been shown to possess T cell
surface markers (Burrells and Reid, 1991). Further evidence of the involvement of
these cells in the pathogenesis of MCF has been reported using surface markers to
analyse cells found in infected tissues (Ellis et al, 1992, Nakajima et al, 1992).
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Studies on the pathogenesis of MCF have mainly been hampered by the inability to
detect viral antigens in infected cells or tissues and the inability to culture OHV-2.
Molecular studies on AHV-1 genome are discussed under genome organisation
(section 1.3.4). The complete sequence and organisation of the virulent AHV-1
genome has now been published (Ensser et al, 1997). This has opened an opportunity
for elucidation of the mechanisms involved in the pathogenesis of MCF using
molecular and immunological techniques.
1. 2. 4 Immunity
1. 2. 4.1 Response to infection
Various tests have been developed to detect and assay antibody to AHV-1 and OHV-
2 (Plowright, 1967, Mushi and Plowright, 1979, Rossiter , 1981, 1982b, Li et al,
1995a). Neutralising antibodies have been found in all free living wildebeest
examined and in a few cattle that recover from MCF (Plowright 1968, 1965) but only
in 25 -70 % of experimentally infected cattle that develop the disease. The indirect
immunofluorescence test has been the most useful test for routine use in serological
studies and the test has been used to show that the majority of sheep in the UK and
elsewhere have antibody which reacts with AHV-1 (Rossiter et al, 1980b). The
drawback with this test is that it is only 90% specific probably due to cross reactions
with BHV-2 and BHV-4 (Rossiter et al, 1989).
Wildebeest calves become infected in utero or soon after birth and such calves
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continue to shed virus until they are 3 months old (Mushi et al, 1980a,b).
Neutralising antibody initially derived from colostrum followed by seroconversion is
usually detectable in calves. Infection generally occurs in the presence of maternal
antibody (Plowright, 1967). Secretory IgA has also been detected in nasal secretions
of these calves and this may be important in limiting shedding of virus in the
wildebeest calves (Rurangirwa et al, 1982).
The antibody response following experimental infection of cattle and rabbits infected
with AHV-1 has been studied by Rossiter (1982b). He showed that the
immunofluorescence type of antibody appears in cattle and rabbits 6-7 days before
pyrexia and that the titres continue to rise until death. Neutralising antibodies are
detectable shortly before fever in the majority of rabbits but no antibody was detected
in cattle up to three days after pyrexia. Rossiter (1982b) used the immunoperoxidase
test to show that infected rabbits develop IgG and IgM class antibodies although the
IgG antibody was present in higher titre than the IgM.
Studies have been carried out to elucidate the viral structural polypeptides which sera
from cattle, sheep and wildebeest recognise (Herring et al, 1989). Wildebeest sera
were shown to react consistently with 6 polypeptides but sheep and bovine sera from
clinical cases of MCF reacted with only a subset of that recognised by wildebeest
sera. Cattle sera reacted with 3 of the 6 polypeptides and the authors suggested that
this is probably due to low level of replication of the virus or due to incomplete
expression of the full genetic repertoire of the virus in cattle.
Cattle that recover from the experimental AHV-1 form of the disease are immune as
they fail to succumb to subsequent virulent virus challenge. In these animals, the
virus persists in a latent form, as offspring of a recovered dam developed MCF soon
after birth (Plowright et al, 1972) and recrudescence of virus has been induced in an
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apparently recovered animal following treatment with dexamethasone (Heuschele et
al, 1984).
1. 2. 4. 2 Response to vaccination
Several attempts have been made to immunise cattle and rabbits using different
immunogens and vaccination regimens with varying results. Reid and Rowe (1973)
attempted to immunise cattle with a cell free high passage AHV-2. Two out of three
cattle resisted challenge with homologous virulent cell associated virus but
succumbed to challenge with virulent AHV-1. Attempts have also been made to
immunise cattle with live or formalin inactivated virus preparations with adjuvant
(Plowright et al, 1975). Though these cattle had high and persistent humoral antibody
responses they were not protected from virulent challenge. Edington and Plowright
(1980) showed that rabbits could be protected against cell free virulent virus but not
against cell associated AHV-1 after inoculation with inactivated vaccine. In an
elaborate experiment involving a regimen of three inoculations with virus inactivated
by ultrasonication or acetylethylenediamine, Russell (1980) was able to protect 4/6
rabbits from virulent AHV-1. Rossiter (1982a) protected 2/4 immunised rabbits using
a vaccination regimen which entailed 3 inoculations with formaldehyde or
glutaraldehyde inactivated infected cells. Though these results indicate that
vaccination against MCF is possible they are of limited practical value in the
vaccination of cattle.
Thus there is no vaccine available for cattle or other susceptible animals.
Furthermore the ability of AHV-1 to maintain latency in cattle that recover after
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clinical MCF (Plowright et al, 1972, Rweyemamu et al, 1976) is of prime
consideration in the development of vaccines against AHV-1 and OHV-2.
1. 2. 5 Diagnosis
Tentative diagnosis is possible from the presenting clinical-pathological picture
especially if there is a history of contact of the sick animals with either of the natural
hosts. The disease however may be confused with various other diseases. These
include; theileriosis, rinderpest, Ibaraki, or Jembrana diseases in Africa and Asia or
with mucosal disease or infectious bovine rhinotracheitis world-wide (Plowright,
1986).
Virus isolation in cell culture is confirmatory but this is only useful with infections
with AHV-1 since OHV-2 has not been isolated in culture. With AHV-1 induced
MCF virus may be isolated in bovine thyroid, turbinate or testes cell cultures
although the former are the most satisfactory using peripheral blood lymphocytes or
lymphocyte cell suspensions from affected tissues (Plowright et al, 1960). Typical
herpesvirus syncytia normally occur 12-20 days after inoculation of cultures and such
cells may be stained using immunohistochemical reagents to identify AHV-1 specific
antigens (Ferris et al, 1976, Rossiter, 1981).
The molecular cloning and sequencing of the AHV-1 genome has facilitated the
development of a PCR as an aid in the diagnosis of MCF. The PCR for detection of
AHV-1 DNA was developed by Hsu et al, (1990b) and Michel, (1993) whereas the
technique for detection of OHV-2 has been developed by Baxter et al, (1993). This
test is invaluable in the diagnosis of MCF caused by OHV-2 and it has been used to
detect OHV-2 in colostrum of lactating sheep (Li et al, 1998) and also in normal
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sheep and infected cattle (Wiyono et al, 1994, Baxter et al, 1997)
Various serological tests are available for diagnosis of MCF. These include
neutralisation test (Plowright, 1967, Mushi et al, 1979), indirect immunofluorescence
(Rossiter, 1980b), and recently a competitive ELISA (Li et al, 1994a) has been
described. These tests have limited use in diagnosis as not all affected animals
develop antibody, and AHV-1 and OHV-2 antibody have been shown to cross-react
with BHV-4 (Rossiter , 1980a,b, Rossiter et al, 1989).
1. 3 Etiology
The transmission of disease with whole blood from cattle affected with the
wildebeest form ofMCF to susceptible cattle proved that the disease was caused by a
cell associated pathogenic agent (Daubney and Hudson 1936). The name malignant
catarrhal fever derives from the clinico-pathologic features seen, though
epidemiologic studies indicated that the disease could be acquired by infection from
two different sources, i. e. the wildebeest in Africa (shown in figure 1.3) and sheep
in Europe.
A virus that caused MCF was first isolated in 1959 (Plowright et al, 1960) from five
out of 35 blue wildebeest (Connochaetes taurinus ). The virus was shown to cause
MCF in cattle following inoculation of the virus. Studies on the cytopathology and
electron microscopy of the virus in cell cultures showed that the virus was closely
related to the human herpesviruses. The virus was therefore included in the
herpesvirus group (Plowright, 1965). The virus is now designated AHV-1 as its
natural host is the wildebeest which belongs to the subfamily Alcelaphinae of the
family Bovidae (Roizman et al, 1981).
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Viruses have also been isolated by cultivation of primary thyroid cultures from
hartebeest (Alcelaphus buselaphus) (Reid and Rowe, 1973) and also from topi
(.Damaliscus korrigum) (Mushi et al, 1981b). The former isolate was shown to be
antigenically related to AHV-1 and has been designated Alcelaphine herpesvirus -2
(AHV-2) (Roizman et al, 1992). Another virus was isolated by co-cultivation of
buffy coats from a roan antelope (Hippotragus equinus) showing no signs
reminiscent of MCF (Reid and Bridgen, 1991). This virus was shown to induce
clinical MCF following injection into rabbits and to be related to AHV-1 using
antigenic and DNA cross-hybridisition methods. This virus is now designated
Hippotragine herpesvirus-1 (Hip HV-1) (Reid and Bridgen, 1991, Roizman et al,
1992).
The virus that causes the sheep associated MCF has been designated OHV-2
(Roizman 1992). Although this virus has not been isolated in culture epidemiological
and molecular evidence implicate sheep as the source of infection for susceptible
hosts (Rossiter 1980b, Herring et al, 1989, Baxter et al, 1993, 1997, Li et al, 1994a).
These viruses are now classified within the family Herpesviridae (Roizman 1992).
The remainder of this section describes the properties of AHV-1 but reference will be
made to OHV-2 where appropriate.
1. 3.1 In vitro culture characteristics
1. 3.1.1 Cytopathology
AHV-1 causes typical cytopathic effects (cpe) characterised by syncytia and
multinucleated cells following co-cultivation of lymphocytes from normal or infected
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cattle with bovine thyroid cell cultures (Plowright et al, 1960, 1963). The virus is
strictly cell associated and infectivity cannot be demonstrated in cell culture fluids of
these infected cells. Such infected cultures show Cowdry type A inclusions which
become increasingly basophilic. AHV-1 antigens can be demonstrated by
immunofluorescence 24hr post infection although cpe normally occur 3-22 days
after infection (Ferris et al, 1976, Wibberley , 1976)
Plowright (1963) developed a strain of AHV-1 recovered from wildebeest by in vitro
passage to a stage where it could be passaged by inoculation of cell-free fluids. Serial
passage in culture was also shown to result in increasing presence of cpe.
characterised by cell rounding (Plowright , 1968). An isolate of AHV-1, designated
WC11 (Plowright, 1965) was shown to become cell free but still retained virulence
for cattle after 42 passages in calf kidney cultures (Plowright, 1968). After a further
52-55 passages in calf kidney cells the virus was shown to lose virulence for cattle
but the same virus retained virulence for 2/3 cattle following serial passages in calf
thyroid cells. A virulent clone of strain C500 (Plowright et al, 1975) which was cell
associated was shown to become attenuated after 30 passages in bovine turbinate
cells (Handley et al, 1995). Attenuation was also accompanied by production of
increasingly cell free virus. There is no clear relationship between loss of virulence
and passage level.
Electron microscopic studies on infected cells reveal margination of chromatin and
absence of the nucleoli and presence of intranuclear, cytoplasmic and extracellular
herpes-like virions (Plowright, et al, 1963, Castro et al, 1981, 1985). The
extracellular particles are composed of enveloped and non-enveloped virions ranging
in size from 140 to 220nm with an inner capsid core of lOOnm (Plowright et al, 1963,
Castro et al, 1982). Within the infected cell, the virions are icosahedral, develop in
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the nucleus and acquire one or more envelopes (Castro et al, 1982). The morphology
of AHV-1 has been confirmed using purified virus preparations (Seal et al, 1988).
1. 3. 1. 2 Cell immortalisation
A cell line with characteristics of large granular lymphocytes following cocultivation
of lymph node and spleen suspensions from a rabbit experimentally infected with
OHV-2 with feeder cell cultures was described by Reid et al, (1983). These cells
were dependent on feeder cultures and, or interleukin 2 (IL-2) but became
independent of these substrates after prolonged subculturing. Similar cells have
subsequently been cultured from a wide range of tissues derived from animals
affected with OHV-2 induced MCF (Reid et al, 1989). These immortalised cells have
been shown to be distinctly T-lymphoblastoid as they all possess at least one T-cell
surface marker, CD2 (Burrells and Reid, 1991).
Similar cells are also readily produced from AHV-1 infected tissues from
experimentally infected rabbits (Reid, personal communication). Furthermore, a cell
line derived from AHV-1 infected rabbit cells has been shown to possess some
characteristics of lymphokine activated killer cells (Wilkinson et al, 1992).
Immortalised cells derived from rabbit, deer and cattle infected with OHV-2 have
been shown to be virulent for rabbit without any evidence of virus particles or
antigens (Reid et al, 1983, 1989).
Hybridisation experiments using OHV-2 infected cells have shown that these
immortalised cells possess DNA homologous with AHV-1 DNA. Handley (1993)
extracted OHV-2 DNA from immortalised T lymphocytes infected with OHV-2 and
performed a PCR using primers which amplify sequences of AHV-1 and. found that
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in the OHV-2 DNA there was a sequence, homologous to the AHV-1 DNA, which
represents part of the peptide 1 of AHV-1 (discussed in section 1.3.4). So far
however, there is no evidence as to which viral transcripts are expressed by these
cells.
1. 3. 2 Nomenclature and classification
The herpesvirus group of the International Committee for the Taxonomy of viruses
recommended a binomial system of nomenclature based on three main biological
determinants; (1) the first name should reflect the family of the natural host of the
virus (when the name should end in -id) or subfamily (when the name should end in -
ine) (2) the second name should be herpesvirus and (3) different herpesviruses with
the same primary host should be given sequential arabic numbers (Roizman et al,
1981). The virus of wildebeest is therefore called Alcelaphine herpesvirus-1 to
denote the subfamily of the natural host (Reid et al, 1975, Roizman et al, 1981).
Previously the biological criteria used to classify herpesviruses was based on simple
but practical measurements and observations (Roizman et al, 1981). The
herpesviruses were divided into three subfamilies; Alphaherpesviruses,
Betaherpesviruses, and Gammaherpesviruses to which the viruses ofMCF belong .
A method of classification based on genomic organisation of the herpesviruses has
also been used . AHV-1 has been classified as a member of group B (figure 1.4) on
the basis of its genomic structure (Bridgen et al, 1989).
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1. 3. 3 Gammaherpesviruses
All members of the gammaherpesvirus subfamily replicate in lymphoblastoid cells,
and some also cause lytic infections in fibroblastic cells in vitro. The viruses in this
group are specific for either T or B lymphocytes. In the lymphocyte the infection is
either prelytic or lytic but without production of infectious progeny (Roizman et al,
1981)
The subfamily is at present divided into 2 genera, namely the Lymphocryptovirus,
members of which are typically B-lymphotropic, and Rhadinovirus, members of
which are typically isolated from T-lymphocytes. A list of animal
gammaherpesviruses is presented in table 1.1.
AHV-1 is classified as a gammaherpesvirus of the Rhadinovirus group. Prototype
viruses in this group are; Ateline herpesvirus-2, Saimirine herpesvirus-2 ( referred to
as Herpesvirus saimiri, HVS), Bovine herpesvirus-4 and Murid herpesvirus-4,
(commonly referred to as mouse herpesvirus 68), as defined by Roizman et al, 1992
Herpesviruses are also classified according to their genomic arrangements (Roizman
et al, 1992, presented here in Figure 1.4). Herpesvirus DNA is characterised by a long
stretch of unique DNA with low G+C ratio flanked by tandem repeats with high G+C
ratio. AHV-1 has been included within the B group of the gammaherpesviruses (Seal
et al, 1989, Bridgen and Reid, 1991). The viral DNA in this group of viruses is
arranged in such a way that the terminal sequence is directly repeated several times at
both termini (Roizman et al, 1992).
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Figure 1.3; Group of adult blue wildebeest in the Masai Mara
i
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Key to figure 1.4
LTR and RTR - left and right terminal repeat in group A
R1 to R4 - internal repeats of group C
IR and TR - internal and terminal repeats of group D
a and b - repeats in group E
n - number of repeated sequences
UL and US - unique long and short sequences in group E
Figure 1.4. Classification of Herpesviruses on the basis of genomic arrangement
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A. Channel catfish herpesvirus
B. Herpesvirus Saimiri
C. Epstein Barr virus
D. Varicella Zoster virus
E. Herpes Simplex virus
F. Tree Shrew herpesvirus
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1. 3. 4 Genomic organisation
The first characterisation of the AHV-1 genome was performed by Bridgen et al,
(1989) using DNA of the attenuated WC11 strain (Plowright et al, 1965a,b) and the
virulent strain C500 (Plowright et al, 1975). The genome of the attenuated strain was
found to comprise of a region of unique DNA of approximately 130Kbp with a G+C
content of 50%, and approximately 30Kbp of additional direct repeats with a G+C of
72%. Although the virulent strain of AHV-1 DNA had a similar restriction profile to
WC11, the repeat sequence was shown to be 1050bp in length whereas that of the
attenuated strain was 950bp. These repeats were shown to be terminal in location,
(Seal et al, 1989, Bridgen and Reid, 1991), and it was suggested that this virus be
included in the B group of the gammaherpesviruses which includes Herpesvirus
saimiri (Albrecht et al, 1992) and equine herpesvirus-2 (Telford et al, 1995).
Further restriction maps have been produced to determine the genetic relationships
between AHV-1 and other viruses isolated from cattle and also with related viruses
isolated from the Alcelaphinae subfamily, (Seal et al, 1989, Shih et al, 1989). Shih et
al, (1989) compared genomes of herpesviruses associated with MCF and assigned the
viruses into two distinct groups; one group comprising isolates from blue wildebeest
(Connochaetes taurinus taurinus), Formosan sika deer (Cervus nippon taiouanus)
and Siberian ibex (Capra ibex sibirica) and the other group comprising of isolates
from greater kudu (Tragelaphus strepsiceros), cape hartebeest (Alcelaphus,
buselaphus), white tailed wildebeest (Connochates gnu), white bearded wildebeest
(Connochaetes taurinus albojubatus) and the cattle isolate C500. Seal et al, (1989)
compared the wildebeest isolates with isolates from the topi and hartebeest and found
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that these were two isolates, each distinct from the other and different from the cattle
isolates. These viruses are now designated AHV-1 and AHV-2 (Roizman et al,
1992).
Studies have been carried out to sequence the L-DNA adjacent the terminal repeats
(Handley, 1993, Handley et al, 1995). The main objective was to determine whether
there were sequences homologous to the transforming ORFs identified in another
gammaherpesvirus, the herpesvirus saimiri (Beisinger et al, 1990). This work was
carried out by comparing the virulent isolate, C500 (CA) (Plowright et al, 1975), the
attenuated isolate, WC11 (Plowright et al, 1960) and a high passage avirulent cell
free C500 (CFA). Clones of DNA from these virus isolates derived from the region
adjacent to the terminal repeats were used to prepare restriction maps and subclones
to facilitate sequencing.
The results showed that the virulent C500 contains two copies of a sequence of
approximately 2Kbp adjacent to the terminal repeats at the left end of the molecule.
In the attenuated virus there were also two copies of the 2Kbp sequence but these
were located at both ends of the molecule, adjacent to the terminal repeats. Analysis
of amino acid translations of these sequences revealed 9 hypothetical polypeptides.
One open reading frame (ORF), designated polypeptide 5, was altered on attenuation
such that the 3' end of the molecule was lost (Handley, 1993). However comparison
of this alteration with the deletion that occurs in another B group rhadinovirus led to
the changes being orientated towards the left end of the genome (Handley et al, 1995)
This ORF, of 496bp, was compared to all other sequences in the databases and no
significant homology was observed. Analysis showed that this ORF would generate a
polypeptide of 140 amino acids and would contain a region of 15-20 hydrophobic
residues. The polypeptide would also contain a region of 100-130 aminoacids that
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was highly antigenic. Comparison of the location of this reading frame and other B-
group rhadinoviruses, suggested that this ORF was similar to the Saimiri
transforming proteins, STP-A11 and STP-C488 of HVS subgroups All and C488
respectively (Murphy et al, 1989, Biesinger et al, 1990, Albrecht et al, 1992). Passage
of HVS in culture results in the deletion of the STP-A11 gene that is associated with
transformation (Murphy et al, 1989, Biesinger et al, 1990). The authors therefore
suggested that polypeptide 5 in AHV-1 may be responsible for virulence.
Another open reading frame, encoding a hypothetical polypeptide designated
polypeptide 1, consisting of 300 amino acids, was common to all isolates. Analysis of
this ORF showed structural homology to the Tyrosine kinase interacting protein
(TIP) of HVS, (Murphy et al, 1989, Beisinger et al, 1990). The presence of two
copies of this reading frame however indicated that this protein may not have a
similar functional role (Handley, 1993). The presence of this ORF in the virulent and
the attenuated viruses and also in immortalised cells is important in diagnosis and
expression studies.
During the course of this work, the complete sequence for virulent virus has been
published and the organisation of the AHV-1 genome confirmed using a cell free but
virulent derivative of the C500 isolate (Ensser et al, 1997). This is presented in figure
1.5. and table 1.2
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Figure 1.5 Organisation of the AHVI C500 genome (after Ensser et al, 1997).
Putative homologues of the potential ORFs are described in table 1.2.
ORFs have been coloured to reflect the conservation of genes between the a, P and y
subfamilies of the Herpesviridae as indicated below.
ORFs specific to AHV1
ORFs specific to the Y subfamily
ORFs specific to the P + Y subfamilies
ORFs specific to the a +Y subfamilies
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Processsing and transport protein
Glycoprotein B
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Probable GPCR membrane protein
Raji LF1 after reconstruction of deletion site































686 Late spliced gene, DNA packaging, possible
terminase
- 52824 51682 380 Late spliced gene,DNA packaging protein,
possible terminase, exon 2
+ 52840 53097 85
+ 53016 53693 225
+ 53642 55066 474
+ 55056 56063 335
- 56970 56053 306 Late spliced gene, DNA packaging protein,
possible terminase, exon 1
+ 56969 58000 343
+ 57957 58415 152
+ 58318 59682 454 Phosphotransferase, possible tyrosine kinase
+ 59615 61072 485 Alkaline exonuclease
+ 61027 61206 59 Myristylated in HSV
~ 62374 61250 374 Integral membrane protein, glycoprotein M
(CMV)
+ 62481 63917 478 Helicase-primase complex
+ 63996 64523 175 Helicase-primase complex
- 65293 64520 257
- 66950 65277 557 Minor capsid protein, virion protein
+ 66940 69291 783 Helicase
- 70055 69348 235
- 70846 70058 252 Uracil-DNA glycosylase
- 71285 70779 168 Glycoprotein L (CMV)
- 72662 71402 419












































































Rta homolog, exon 1
RtA homolog, exon 2
Signal peptide





Transcriptional control exon 1 homolog
Transcriptional control exon 2 homolog
Transcriptional control IE52 homolog
Processivity factor/subunit of DNA
polymerase
Ribonucleotide reductase (small unit)
Ribonucleotide reductase (large unit)



















Probable major envelope glycoprotein




+/- indicates whether the ORF is on the positive or negative strand of the AHV-1
genome.
* indicates the positions of start and stop codons.
a indicates the number of amino acids in the ORF.
b Possible functions of the AHV-1 proteins are deduced from the homologous ORFs
described in other herpesviruses.
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1. 3. 5 Viral Proteins
Analysis of purified virion proteins using PAGE polypeptide profiles of AHV-1 and
AHV-2 indicated that these viruses contain at least 36 polypepetides with molecular
weights ranging from 12kDa to 275kDa (Seal et al, 1989). Further characterisation of
cell free AHV-1 polypeptides using polyclonal serum in an immunoprecipitation
experiment identified a complex of polypeptides with molecular weights, 115, 110,
105, 78, and 45kDa. (Li et al, 1995a). The 45kDa moiety however was the only
polypeptide recognised by monoclonal antibodies raised to a conserved epitope of
AHV-1 isolates from the zoological collections in the USA. The polypeptide profile
observed was similar to that observed on viral envelope proteins characterised by
Adams and Hutt-Fletcher (1990).
Studies have been performed to screen cDNA libraries derived from mRNA
transcribed in AHV-1 infected cell cultures (Lahijani et al, 1994). A cDNA clone, of
833bp was identified which coded an immunoreactive protein of 15kDa. This
sequence showed greater than 40% DNA homology to the B group
gammaherpesviruses HVS, EBV and the cottontail tamarin virus (Saguinus oedipus
oedipus). This clone was shown to hybridise to a 4.4kbp AHV-1 DNA fragment in a
Hind III digest. This Hind m fragment has been shown to be derived from the unique
region of the AHV-1 near to the terminal repeats (Bridgen, 1990).
1.3.6 Replication of gammaherpesviruses
Studies on replication of gammaherpesviruses have mainly been conducted in EBV (
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Kieff and Liebowitz, 1990). EBV is a gammaherpesvirus that infects humans and
may cause various forms of cancer in humans (Kieff and Liebowitz, 1990). The virus
can latently infect and immortalise B lymphocytes (Pope, 1968, Nilsson et al, 1971)
but a proportion of these latently infected cells do replicate virus with production of
mature virus particles. In latently infected cells only a few viral genes are expressed
and productive virus replication does not occur (Dambaugh et al, 1984). However
some of these cells have been shown to spontaneously allow lytic replication of EBV
with production of mature virus. Induction of the lytic phase of EBV replication can
also be induced with phorbol-esters e.g. TPA G with release ofmature virus particles
(Zur Hansen et al, 1978).
T cells can be derived from rabbits experimentally infected with AHV-1 although
such latently infected cells do not enter a lytic phase of replication with productive
virus replication (Reid-personal communication). Studies have been conducted to
elucidate the mediators and mechanisms involved in the maintenance of latency and
the factors involved in the switch of these cells into the productive cycle of virus
replication in herpesviruses.
In EBV, viral DNA circularises following entry into peripheral blood lymphocytes
and the episomal DNA can be detected in the nuclei of these cells 24 hr after
infection (Alfieri et al, 1991). Large cytotoxic lymphocytes (LCL) stably infected
with EBV contain multiple copies of circularised EBV viral DNA (Adams and
Lindahl, 1975) and also in LCL immortalised by AHV-1 (Bridgen et al, 1989). The
initial amplification of the EBV episomal virus occurs at the start of latency during
the S phase of the cell cycle as only single copies of viral DNA are present before the
S phase (Sudgen et al, 1979, Alfieri et al, 1991). Replication in latency is
bidirectional and originates from a site in the episomal DNA called oriP. Replication
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is dependent on expression of viral proteins, designated EBNA1, EBNA2 and LMP1
(Alfieri et al, 1991) and is facilitated by cellular DNA polymerase. There are
however no homologues for EBNAs or LMP1 in rhadinoviruses (Kieff and
Liebowitz 1996, Albrecht et al, 1992) indicating that viruses in this group of
gammaherpesviruses probably utilise different effector proteins. Viral DNA
replication during latency is synchronised with the cell cycle as viral DNA copy
number is maintained in daughter cells.
Establishment of latency is also accompanied by methylation of viral DNA and
treatment of cells with chemical agents that reduce DNA methylation increases the
level of spontaneous activation to the lytic phase (Saemundsen et al, 1980, 1983,
Ben-Sasson and Klien, 1981)
Induction of the lytic replication in EBV is accompanied by increase in copy number
of circular viral DNA which is dependent on viral DNA polymerase ( Shaw 1985).
Replication is also dependent on transcription of two immediate early proteins,
encoded by BZLF2 and BRLF1 (Chevallier-Greco et al, 1986, Ragoczy et al, 1998)
Replication is initiated from either of two regions on the viral genome at any one
time, called oriLyt to yield head to tail concatamere (Hammerschimdt and Sudgen,
1988). During the lytic phase of EBV replication, many copies of viral DNA are
produced showing that this type of replication is independent of cellular DNA
replication.
Probably the terminal repeats in AHV-1 generated DNA during lytic replication
serves as signals for cleavage and packaging as observed in alphaherpesviruses
(Spaete and Flenkel, 1982).
Infection of wildebeest is accompanied by lytic cycle of AHV-1 replication probably
in the nasal and upper respiratory mucosae and shedding of mature virus before
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establishment of latency in peripheral blood lymphocytes (Plowright 1986). In cattle
however, there is no lytic replication of virus and the infection is essentially latent
since no cell free virus is shed. It is therefore probable that the lytic phase of vims
replication is a prerequisite to the development of immunity in AHV-1. In the natural
host the absence of a clinical response following infection may be due to presence of
cellular factors that induce lytic vims replication or may be a consequence of
immunological response to viral proteins that are expressed during the lytic cycle of
AHV-1 replication.
39
1.4 AIMS OF THIS PROPOSAL
During the initiation of this work, the aim was to clone, express and determine the
role played by the putative proteins of virulence described by Handley (1993),
Handley et al, (1995) in MCF. Subsequently, the complete sequence of the virulent
AHV-1 genome showed that the ORFs were only part of longer ORFs and that the
ORF for both proteins were located in the middle of the genome (Ensser et al, 1997).
Since the virus used was a 1975 isolate which has undergone various passages in
tissue culture, the genotype of this virus may have been altered.
The second aim of this proposal was therefore to obtain fresh isolates of AHV-1 and
compare viral DNA derived from these isolates with AHV-1 DNA derived from low
and high passage C500 isolate in tissue culture monolayers as well as viral DNA
obtained from the attenuated WC11 isolate to determine the extent to which some of
the putative genes of virulence are conserved.
Isolation and characterisation of new isolates of AHV-1 was conducted at the NVRC,






Analar grade chemicals were purchased from BDH, Fisons, Sigma, Boehringer
Mannheim, Invitrogen, Qiagen, Amersham or Biorad. All bacteriological media and
reagents were purchased from Invitrogen and molecular biology reagents were
purchased from Bethesda Research Laboratories, Invitrogen, Qiagen, Amersham or
Boehringer Mannheim. Immunological reagents were purchased from Scottish
Antibody Production Unit (SAPU), Boehringer Mannheim, Sigma, or Invitrogen. The
list of suppliers and addresses are listed (see page xvi)
2. 2 Formulation of general solutions
TE 10 mM Tris-HCl pH 8.0, 1 mM EDTA
TNT 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.05%Tween 20
TBE 134 mM Tris base, 44 mM Boric acid, 2.6 mM EDTA (10X stock )
DNA loading dye 10% (w/v) Ficoll, 0.05% (w/v) Xylene cyanol, 0.025% (w/v)
bromophenol blue
RNA loading dye 0.75 ml formamide, 0.15 ml lOx MOPS, 0.24 ml formaldehyde,
0.1 ml glycerol, 0.1 ml 10% (w/v) bromophenol blue
PBS 150 mM NaCl, 6 mM K2HP04, 4 mM KH2P04 pH 7.2
20XSSC 3.0 M NaCl, 0.3M Sodium citrate
10X MOPS 0.2 M MOPS, 50 mM Sodium acetate, 1 mM EDTA, pH 7. 0
Ponceau stain 2% Ponceau, 30% Sulfasalicylic acid, 30%Trichloroacetic Acid
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2. 3 Virological methods
2.3.1 Cell culture and cultivation of virus
Propagation of large granular lymphocytes was conducted by Dr. H. Reid, MRI as
described in Reid and Buxton (1985). Cultivation of virulent virus in bovine
turbinate cell monolayer cultures was conducted by Miss I. Pow at MRI. The virulent
virus was cell associated or cell free derivatives of the C500 isolate (Plowright et al,
1975)
2.3.2 Preparation of DNA from AHV-1 infected bovine turbinate (BT) cultures
Extraction of viral DNA from BT cultures was conducted at MRI. Cell associated
virus was harvested when over 80% of the cells exhibited cytopathic effect (cpe).
Since the cpe. resulted in the majority of the monolayer cells forming loosely
attached syncytia, these cells were easily incorporated into the supernatant and any
residual cells were removed from the flask walls by rocking briefly with sterile glass
beads. The culture supernatant was then spun at 3000g for 10 min at room
temperature and the cell pellet washed with PBS. The cells were resuspended and
lysed in 0.5% (v/v) NP40 in RSB (10 mM NaCl, 1 mM MgCl2, 10 mM Tris-HCl, pH
7.5) by gentle homogenisation. Chromatin and cellular debris were removed by
centrifugation at lOOOg for 10 min at room temperature. The supernatant was layered
over 25% sucrose in RSB and the viral nucleocapsids were isolated by centrifugation
at 114,000g for 30 min at RT. The resultant pellet was resuspended in TNE and
digested with proteinase K (Boehringer Mannheim) at 200pg ml"1 in the presence of
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1% SDS at 37°C for 2hr with gentle agitation. Contaminants were extracted with
phenol and the DNA precipitated with ethanol.
2.4 Bacteriological techniques
2.4.1 Strains of E.coli used in this study
strain genotype reference
JM109 recAl supE44 endAl hsdRYl gyrA96 Yannitch-Perron et al 1985
relAl thi-D(lac-proAB) F' [traD
proAB+/acIq/acAM 15]
G1724 F, 1", lacq, lacPL8, ampC::PtrpC / Invitrogen
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2. 4. 2 Growth media
TABLE 2.1; media used for culture of E.coli
RM Media 16.7 mM Na2HP04, 22 mM KH2P04, 8.5 mM, 8.5 mM NaCl,
18.7mM NH4C1, ImM MgCl2, 0.2 % (w/v) Casamino acids
Induction Media As RM plus 0.5 % (w/v) Glucose
2x TY 1.6% (w/v) Tryptone, 1% (w/v) yeast extract, 0.5% (w/v) NaCl
LB Broth 1% (w/v) Tryptone, 1% (w/v) yeast extract, 1% (w/v) NaCl
L Agar LB containing 15 g/1 Difco agar
RMG RM media plus 2% Casamino acids, ImM MgCl2, 1.5% agar
SOC 2% (w/v) tryptone, 0.5% yeast extract, lOmM NaCl, 2.5mM
KC1, 20mM Mg2+, 20mM Glucose, pH 7.0
All media except SOC were sterilised by autoclaving for 15 min at 1.05 Kg cm"2.
Ampicillin was added to 100 pgrnl"1 after autoclaving. SOC was sterilised by filtering
through 0.2pM millipore filters
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2. 4. 3 Preparation of competent bacteria
E. coli were streaked on LB plates and incubated overnight at 37° C. A single colony
was picked and used to inoculate 100 ml of LB broth. The bacteria were allowed to
grow to an OD600 of between 0.5 to 0.6 when the cells were transferred to prechilled
tubes and incubated on ice for 10 min. The bacteria were then spun down using a
Beckman rotor J2-21 at 4000rpm for 10 min. The media was decanted and the
resuspended in ice cold 0.1M CaCl2 and then placed on ice for 30 min. The bacteria
were pelleted again at 4000rpm for 10 min and then resuspended in a volume of
CaCl2 containing 15% (w/v) glycerol corresponding to 1/ 50 of the original volume
of medium. The bacteria could then be used directly or stored at -70° C.
2. 5 Molecular biology techniques
TABLE 2.2; Cloning vectors used in this study
Vector- Type size(kbp) Markers- Replicon Promoters
pGEX Plasmid 4. 94 Amp/acZ fl T7
pGEM-T Plasmid 3.0 amp lacZ fl T7, SP6
pBluescript
(KS+/")
Plasmid 2.96 amp lacZ fl T3,T7
pGL2 Plasmid 5.0 amp luc+ ColEl, fl SV40
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TABLE 2.3; Vectors and cloning sites
VECTOR MULTIPLE CLONING SITES
pBluescript*
(KS+/")(Stratagene)
Sacl, Bst I, Not I, Eag I, Xba I, Spe I, Bam HI, Sma I, Pst I,
EcoRV, Hind III, Acc I, Sal I, Xho I, Apa I, Dra I, Kpn I
pTRX (Invitrogen) Kpn I, Sma I, BamH I, Xba I, Acc I, Sal I, Pst I
pGEM-T*
(Promega)
Apa I, Aat n, Sph I, BstZ I, Nco I, Sac n, Spe I, Not I, Pst I, Sal
I, Nde I, Sac I, BstX I, Nsi I
pGL2 (Promega) Kpn I, Sac I, Mlu I, Nhe I, Sma I, Xho I, Bgl H
*Successful cloning of insert into these vectors interrupts the p-galactosidase
sequences. Competent bacteria transformed with these recombinant plasmids
therefore form white colonies instead of blue colonies when grown on agar
containing X-gal and IPTG.
2. 5. 2 Restriction endonuclease digestion of DNA
Restriction enzyme digestions were performed to create ligation sites in viral DNA
PCR products and plasmids and to confirm the presence of these inserts in the
recombinant plasmids. DNA digestions were performed with enzymes at a final
concentration of lOunits/pg of DNA. The restriction enzymes and the respective
buffers were purchased from Boehringer Mannheim and used according to the
manufacturer's instructions. Between 100 ng and 200 ng of DNA was used for each
reaction and RNase was added when required to a final concentration of lOpg ml"1 .
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Reaction volume was adjusted to 20 jul and digestions were performed by incubating
the reaction mixtures at 37°C for lhr.
2. 5. 3 DNA ligation
DNA ligation reaction mixtures with all plasmids used in this study except for
pGEM-T were prepared using appropriate amounts of insert DNA and vector DNA
(at a vector/insert ratio of 1:5), and lOx ligation buffer (30mM Tris-HCl, pH
7.5/10mM MgCyiOmM DTT/lmM ATP) (Promega). 1 pi of T4 DNA ligase
(Promega) was added and the reaction volumes were adjusted to 20 pi with water.
Ligations were performed at 37° C for 2 hrs or overnight at 4°C.
PCR products were also cloned into the pGEM-T vector. The vector system takes
advantage of the non-template dependent addition of a single deoxyadenosine to the
3' end of PCR products by thermostable Taq which can then be ligated into pGEM-T
using the T4 ligase enzyme (Promega). Total reaction volume was made up of lpl:T4
DNA ligase buffer, 50ng vector DNA, insert DNA ( at an insert/ vector ratio of 5:1)
and 1 Wiess Unit of T4 DNA ligase (Promega). Tubes were incubated overnight at
4°C
2. 5. 4 Transformation of competent E.Coli
lOng of plasmid were added to 50 pi of competent E.coli and the contents gently
mixed. The tube was kept on ice for 30 min. The cells were heat shocked at 42°C for
90 sec, chilled immediately on ice for two min and then plated on suitable agar
plates. The plates were kept overnight at 30°C when growing E.coli G1724 and 37°C
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when growing JM 109 cells. Transformed E.coli were selected by the ability to grow
in presence of ampicillin. This method was found to be unsuitable for transforming
JM109 cells with pGEM-T recombinant plasmids as the efficiency of transformation
was always low. A modified method was therefore used. Bacteria transfected with
pGEM-T plasmid were heat shocked for exactly 2 minutes at 42°C and placed
immediately on ice for 2 minutes. 900pl of cold SOC medium was added to the
transformation reaction and incubated for 60 minutes at 37° C in a shaking incubator
(approximately 225rpm). The cells were pelleted by centrifugation at lOOOxg for 10
minutes and the cells resuspended in lOOpl of SOC. The cells were then plated out on
LB or 2xTY plates and incubated at 37° C for colonies to grow.
2. 5. 5 Small scale preparation of plasmid DNA
Plasmid DNA was prepared from 10 ml overnight cultures. Bacteria were pelleted by
centrifugation in a microfuge at 9000g for 5 min and then resuspended in 0.2 ml of
glucose buffer. 0.4 ml of 0.2M NaOH, 1% SDS was added to the contents of the
tube, mixed by inversion and the tube placed on ice for 5 min. 0.3 ml of High Salt
(3M Potassium acetate, 1.8M formic acid) solution was then added and the contents
mixed by inverting the tube. The contents were incubated on ice for 15 minutes and
the tube centrifuged for 5 min at 9000g to pellet the cellular debris. 0.8 ml of the
supernatant was then mixed with 0.48 ml of isopropanol. DNA was pelleted by
spinning the tube at 9000g for 10 min. DNA pellet was washed with 75% ethanol and
the pellet resuspended in 50 pi TE.
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2. 5. 6. Large scale preparation of plasmid DNA
A single bacterial colony was inoculated into 10 ml of suitable media and grown for
a few hours at 37° C with shaking. This culture was then used to inoculate 500 ml of
media. This bulk culture was grown overnight at 37° C with shaking. The bacteria
were pelleted by centrifugation at 4000g for 30min at 4° C. The bacterial cells were
resuspended in 20 ml of glucose buffer (50mM Glucose, 25mM Tris-HCl, pH 8.0,
lOmM EDTA and 40 ml of 0.2M NaOH with 1%SDS added. The contents were
mixed gently and 30 ml of High Salt solution (3M Potassium acetate, 1.8M formic
acid) added, and shaken before being placed on ice for 30min. Cellular debris was
pelleted by centrifugation at 4000g for 30min and 80 ml of the supernatant added to
48 ml of isopropanol. The tubes were placed on ice for 30min and the DNA pelleted
by centrifugation at 4000g for 30min. The pellet was resuspended in 8 ml of T.E, 1.0
ml of lOmg ml"1 ethidium bromide solution and 9g CsCl were added. The contents
were transfered to "quickseal" centrifuge tubes. The tubes were spun at 40000rpm in
a Beckman Ti70 rotor for 36 hrs. The lower band containing plasmid DNA was
collected using an 18 gauge needle. Ethidium bromide was removed from the DNA
by extracting with water saturated butan-l-ol, and the DNA precipitated by addition
of 1 volume of water and 2 volumes of ethanol. The concentration of the plasmid
DNA was determined using a spectrophotometer
2.5.7 Preparation of plasmid ssDNA
A single colony known to contain the plasmid of interest was inoculated into 2ml of
LB containing VCS-M13 helper phage (Stratagene) at a concentration of 107pfu/ml.
The bacteria were incubated at 37°C for 90 minutes in a shaking incubator when
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Kanamycin was added to a final concentration of 70pg/ml. The cells were incubated
overnight in a shaker at 37°C. The bacteria were pelleted by centrifugation at 9000g
for 10 minutes and 1.2 ml of the supernatant transferred to a microfuge tube
containing 300pl of 20%PEG/2.5M NaCl. The contents were mixed and kept at room
temperature for 15 minutes. The contents were centrifuged at 9000g for 10 minutes to
precipitate the phage. The phage pellet was resuspended in lOOpl of TE. 50pl of
water saturated phenol was added and the contents vortexed for 30 seconds. The
contents were kept at room temperature for 15 minutes and the contents vortexed for
30seconds. The mixture was spun at 9000g for 5 minutes and the top aqueous phase
removed. lOp.1 of 4M lithium chloride and 2.5 volumes of ethanol were added to the
aqueous phase and the contents mixed. The mixture was kept at -70°C for 20 minutes
and the DNA pelleted by centifugation at 9000g for 10 minutes. The DNA pellet was
resuspended in 20pl of ImM Tris, 0.ImM EDTA pH 8.0. This DNA was
subsequently used for sequencing. During the initiation of this work sequencing was
conducted at Moredun Research Institute using the T7 Di-deoxy chain termination
technique. Subsequent sequencing was kindly conducted by Mr Ian Bennet at the
DNA sequencing facility, Department of Veterinary Pathology, Summerhall,
University of Edinburgh.
2.5.8. Preparation of plasmid double stranded DNA for automated sequencing
This procedure and reagents were based on a kit provided by Promega in a "Wizard
DNA purification kit" (Cat.Number A7100). Single colonies were picked from LB
plates and grown overnight in 10ml of LB broth containing 50pg/ml ampicillin. The
cells were pelleted by centrifugation at 10,000xg for 10 min. and the supernatant
wv. a'-:.
discarded. The cell pellet was resuspended completely in 400pl of cell suspension
solution and transferred to a 1.5ml microfuge tube. 400pl of cell lysis solution was
added and the contents mixed by inverting the tube 4 times. 400pl of neutralisation
solution was added to the clear suspension and the contents mixed by inverting the
tube 4 times. The lysate was spun in a microcentrifuge at 10,000xg for 10 min. and
the supernatant transferred to a barrel of a minicolumn/syringe assembly containing
lml of resuspended resin. The stopcocks were opened and vacuum applied to pull the
resin/lysate mixture through the column. The vacuum was then released and 2 ml of
column wash solution added to the barrel. Vacuum was applied to draw the solution
through the minicolumn and the resin dried by continuing to draw vacuum for a
further 30 seconds after the wash solution had been drawn through the column. The
syringe barrel was removed and the minicolumn transferred to a microcentrifuge
tube. The minicolumn was spun at 10,000xg in the microcentrifuge tube to remove
excess wash solution and the minicolumn transfered to another microfuge tube. 50pl
of water was added into the minicolumn and the tube centrifuged for 30 seconds to
elute the DNA. The concentration was adjusted to 250ng/pl and the plasmid DNA
sequenced using forward and reverse primers.
2. 5. 9 Di-deoxy chain termination sequencing of DNA using T7 polymerase
T7 polymerase sequencing was carried out using commercially available T7
sequencing kit (Pharmacia), which provided all the necessary reagents to carry out all
the reactions by the dideoxy termination method of Sanger et al (1977), except for the
[35S] dATP, which was obtained from Amersham. All reactions were carried out
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according to the manufacturers instructions. Plasmid DNA was sequenced to verify
that the insert contained the desired viral DNA sequences.
Approximately lpg per reaction was first denatured by adding NaOH to a final
concentration of 0.4M NaOH and incubating for 10 min at room temperature. The
DNA was then precipitated by the addition of 0.3 volumes sodium acetate, 0.7
volumes distilled water and 2 volumes ethanol. The DNA was pelleted and
redissolved in 50pl of water. 2 pi of "annealing buffer" (a buffer solution containing
MgCl2 and DTT) and 1 pi of primer were added to the DNA, mixed gently, then
incubated at 65°C for 2 min then left to anneal while cooling to room temperature.
"An enzyme premix" was prepared by adding 3 units of T7 polymerase in "enzyme
dilution buffer" (Buffer solution containing Glycerol, BSA, and DTT) to 1 pi (lOpCi)
of [35S] dATP, 3 pi of "labelling mix A" (dCTP, dGTP, dTTP in solution) and 1 pi of
distilled water. 6 pi of "enzyme premix" was added to the annealed template and
primer and incubated for 5 min at RT during which time the newly synthesised DNA
was labelled by incorporation of [35S] dATP. Chain termination was effected by the
addition of 4 pi from this reaction to each of 4 tubes containing 2. 5 pi of "G", "A",
"T", and "C" mixes respectively (each mix contained deoxy and di-deoxy forms of
the respective base) and incubating for 5 min at 37°C. 5 pi of "stop solution" was
added to each tube prior to storage at -20°C.
The sequencing samples were resolved by PAGE. 6% acrylamide gel solution was
prepared from a 40% acrylamide stock (38% (w/v) acrylamide, 2% bis-acrylamide)
with urea added to a final concentration of 7M and 10X TBE at a dilution of 1: 10.
1% (w/v) APS and 0.05% (w/v) TEMED were added immediately before pouring the
gel. Electrophoresis in IX TBE buffer was carried out using the S2 (BRL) apparatus.
The gels were pre-run for 30 min before loading freshly denatured samples (heated to
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80°C for 2 min). The gels were fixed by immersing in 10% (v/v) methanol, 10% (v/v)
ethanoic acid then transferred to Whatman 3MM filter and dried under vacuum at
80°C for 30 min.
Detection of [35S]- labelled nucleic acids in sequencing gels was achieved by
exposure to medical X-ray film (Fuji) in radiography cassettes. The X-ray film was
developed and fixed in "Photosol" CDL8 developer and "Photosol" CF40 fixer
(Genetic Research Instrumentation Limited). Automated sequencing was performed
at the Royal Dick Veterinary School, Summerhall on a LICOR machine.
2.5.10 Computer analysis of DNA sequences
The sequence analysis software package of the University of Wisconsin Genetics
Group (UWGCG) was used. The package was available to the User Group,
Daresbury Laboratory, Daresbury supported by Vax 3600 mainframe computer.
2. 5.10.1. Data Base Searching
The FastA programme (PEARSON) was used to match DNA sequences with the
sequences contained in the EMBL and GENBANK databases.
2.5.10.2 Data sequence comparisons
The GAP and FastA program (UWGCG) were used to make comparisons between
two sequences and to construct optimal alignment by inserting gaps to maximise the
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number of matches. BESTFIT programme was used to determine homologies
between cloned DNA fragments and AHV1 sequences in the databases.
2. 5.11 DNA restriction enzyme analysis
DNASTAR set of programs was used to construct restriction maps of a viral DNA
2. 5.12 Agarose gel electrophoresis of DNA
Nucleic acid grade agarose (BRL) was used at 1% concentration in TBE buffer.
Electrophoresis was carried out at 1-4 Volts cm"1 until the required resolution was
achieved and DNA fragments were visualised by fluorescence of the intercalated
ethidium bromide in the U/V light of 302nm wavelength. DNA size estimation was
achieved by comparison with the lkbp ladder (GIBCO-BRL)
2. 5.13 Quantification of nucleic acids
Nucleic acid was quantified by spectrophotometry. DNA and RNA have
characteristic UV spectra, the peak of absobance is at 260nm, while the absorbance at
280nm is a measure of contaminating protein that is present (Sambrook et al 1989).
The absorbance at 260 nm gives a measure of the concentration of nucleic acid in the
sample. An absorbance of 1 ODU260 corresponds to a concentration of 50pg ml"1 for
double stranded DNA and 40pg ml"1 for RNA. The ratio OD260/OD280 is
approximately 1.8 and 2.0 for clean DNA and RNA respectively.
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2. 5.14 Extraction and purification of DNA from gels
The method and reagents used were based on a "GenecleanR Kit" (Stratatech
Scientific). The piece of gel containing the DNA was weighed, and 4. 5 volumes of
Nal and 0.5 volumes of TBE inhibitor added. The agar was melted at 55°C for 5min.
10 pi of silica were added and the suspension placed on ice for 5 min. The
suspension was then spun at 9000g for 30 sec and the pellet washed three times in 0.5
ml of Easiclene washing solution. The mixture was then pelleted by centrifugation at
9000g for 30sec. The pellet was finally resuspended in 30 pi of water and incubated
at 55°C for 5min. The DNA was recovered from the supernatant following
centrifugation. This DNA could then be ligated to plasmid or labelled for use as a
probe.
2. 5.15 Polymerase chain reaction (PCR)
Two procedures were used to amplify sequences in DNA. Primers used with either
protocol were purchased from Oswel or MWG-Biotech GmbH. Various
oligonocleotide sequences were used to amplify different fragments of viral DNA.
Primers used to amplify fragments to be used in ligation reactions were engineered so
that they contained useful restriction sites. Pairs of primers for amplifying specific
fragments of the AHV-1 genome are described when appropriate.
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2.5.15.1 PCR using Taq
Amplification reactions were performed according to the methods described by Saiki
et al (1985 and 1988). PCR was set up by adding 0.2 mM dNTPs, 0.2 mM of each
pair of primers, lx PCR buffer (10 mM Tris-HCl, 1. 5 mM MgCl2, 50 mM KC1,
0.1 mg ml"1 gelatine) and 2. 5 units of Taq polymerase enzyme (buffer and enzyme
supplied by Boehringer Mannheim) to the DNA. The reaction volume was adjusted
to 50 pi with water. Target DNA was 50 ng of AHV-1 genomic DNA or 2 pi of
cDNA from the reverse transcriptase step (Chapter 3). The reactions were overlaid
with 50 pi of mineral oil before being amplified using a Hybaid Omnigene thermal
cycler.
2.5.15.2. Amplification of DNA using the Expand ™ Long Template PCR
System
The Boehringer Mannheim Expand™ Long Template system reagents were used for
PCR according to the manufacturer's conditions. This method was used to amplify
long (over 1 kb) sequences. This method differs from the conventional PCR in that
the system uses an enzyme mix containing the thermostable Taq and two Pwo DNA
polymerases. PCR was set up by adding 0.35 mM dNTPs, 0.3 mM of each pair of
primers (MWG- Biotech GmbH) specific for each viral DNA fragment to be
amplified, lx PCR buffer (10 mM Tris-HCl, 1.75 mM MgCl2, ) and 2.5 units of Taq
polymerase enzyme the DNA. The reaction volume was adjusted to 50 pi with water.
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Elongation steps were performed at 68°C and the elongation times were varied
according to the length of the required product.
The cycle used was similar when amplifying all templates, the only difference being
the annealing temperatures. The cycle used is detailed in Table 2.5
TABLE 2.4. Cycle used in the Expand long template PCR
Temperature 0 C Time cycles
92 2 minutes 1
92 10 seconds 1
57 30 seconds 1
X 5 minutes 10
92 10 minutes 1
57 30 seconds 1
68 5 minutes 25
92 10 seconds 1
68 7 minutes 1
X= Annealing temperatures for different pairs of primers. These are given for each
specific amplification reaction when appropriate.
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CHAPTER 3
EXPRESSION OF PEPTIDE 1 AND PEPTIDE 5 IN VITRO
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3.1 INTRODUCTION
Most of the studies on AHV1 virus have been conducted using an isolate (C500)
derived from a cow showing clinical MCF (Plowright et al, 1975) and an isolate
(WC11) obtained from a one week old wildebeest calf (Plowright et al, 1963). The
WC11 isolate was shown to become cell free but still retained virulence for cattle
following passage in cell culture. Further passage in culture resulted in attenuation of
the virus. The attenuated virus however did not protect cattle following challenge
with virulent virus. Attempts at developing vaccines using conventional methods
have been unsuccessful (discussed in Chapter 1). Developments in molecular
biological techniques have resulted in studies being carried out to elucidate the
structure and genome organisation of the AHV-1 DNA (Bridgen et al, 1989,
Flandley et al, 1995).
The first characterisation of the AHV1 genome was conducted by Bridgen et al
(1989). They showed that the genome comprises 130kbp of unique DNA flanked by
up to 30kb of lkb direct terminal repeats. Handley et al (1995) cloned and sequenced
DNA from the unique region adjacent the terminal repeats of the attenuated and the
virulent strains of AHV1. Differences in nucleotide sequences were observed
between the clones derived from virulent and attenuated viral DNA. DNA and amino
acid analysis of these clones revealed nine putative proteins. One polypeptide,
designated protein 5 (P-5) was truncated in the attenuated virus. This ORF, of 496bp,
was compared to all other sequence in the databases and no significant homology
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was observed. The P-5 ORF was shown to contain a region coding for 100-130
amino acids that was highly antigenic. The ORF was positionally equivalent to the
transforming gene of herpesvirus saimiri (HVS) subtype A strain ll(STP-All)
(Beisinger et al, 1990). Passage of HVS in culture results in the deletion of STP-A11
gene that is associated with transformation (Biesinger et al 1990, Murphy et al,
1989). It was therefore suggested that this protein could be responsible for virulence.
Another open reading frame, encoding a hypothetical polypeptide designated
polypeptide 1, consisting of 300 amino acids, was common to the virulent isolate,
low passage virulent derivative and the attenuated virus. This ORF was also shown to
be present in OHV-2 induced cell lines (LCL) (Handley, 1993). Analysis of this ORF
showed limited structural homology to the Tyrosine interacting kinase protein (TIP)
ofHVS, STP-A11 (Beisinger et al, 1992). The presence of two copies of this reading
frame however indicated that this protein may not have a similar functional role
(Handley, 1993). The presence of this ORF in the virulent and the attenuated viruses
and also in immortalised cells suggests that it may be useful in diagnosis and
expression studies.
A cell line with characteristics of large granular lymphocytes following cocultivation
of lymph node and spleen suspensions from a rabbit infected with OHV-2 with
feeder cell cultures was described by Reid et al, (1984). The cells were shown to be
dependent on feeder monolayers and other substrates but gradually became
independent of these substrates after prolonged culture. These immortalised cells,
with characteristics of large granular lymphocytes derived from an OHV-2 infected
rabbit are virulent for rabbits without any evidence of virus particles or antigens
(Reid et al 1989, Reid et al, 1984). Similar cells are readily produced from tissues
derived from C500 infected rabbits (Reid, personal communication). The ability to
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establish LCL immortalised by either AHV-1 or OHV-2 provides an invaluable in
vitro system to study the molecular basis for virulence, most importantly in OHV-2
because it has never been isolated in culture.
The aim of this chapter is to determine whether polypeptide-1 (P-l) and polypeptide-
5 (P-5) are expressed in vivo and in vitro, and to determine whether either or both of
these polypeptides play any role in the final outcome of disease in infected animals.
The objectives were:
(1) To clone and express P-l and P-5 in suitable expression systems
(2) To use the expressed proteins to immunise rabbits and then challenge these
rabbits to determine the protective potential of these polypeptides in rabbits.
(3) To use the rabbit antisera to determine whether these polypeptides are expressed
in AHV-1 immortalised LCL and monolayer cell cultures productively infected with
the virulent (C500) and the attenuated (WC11) virus.




Propagation of LCL and cultivation of C500 and WC11 in bovine turbinate cultures
was conducted by Dr H. Reid and Miss I. Pow, MRI (section 2.3.1). Preparation of
viral DNA is described in section 2.3.2.
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3.2.2 PCR to Amplify P-l and P-5 sequences in AHV-1 DNA
The primers used to amplify the P-5 were engineered to contain a Pst I and a BamH 1
site. Primers used to amplify a 400bp internal segment of the P-l sequence were
engineered so that they contained a BamH I and an EcoR I restriction site. The
positions of the primers in the AHV-1 genome are shown in appendix 6.1.
P-l primers
BamH I
318; 5'- TACGGATCCCCTGACATTTCATCTCTTTTG- 3'
EcoR I
317; 5' -ATAGAATTCTGATGTGGCAGATGCATCTAT- 3'
P-5 primers
BamH I
S21; (76590) 5' -CCTGCGGATCCCATGCTGCCTTCCCCGTAAA -3' (76619)
Pst I
S20; (77045) 5' -CCTCTGCAGATATCCTGGTCTCGTAAGGTG -3' (77074)
PCR was also conducted with S21 and a primer;
T64; 5' -ATATTCTGGGGAGTATAAAG -3' which is upstream of S20 (77023-
77004). The PCR would amplify a fragment of 433bp. This PCR reaction was
conducted on cDNA obtained from reverse transcription of LCL (section 3.2.15). To
amplify peptide 5 sequences, DNA was denatured at 95°C, and annealed at 50°C, and
extension was carried out at 72°C for 3 min. 30 cycles were performed. To amplify
peptide 1 sequences, the DNA was denatured at 95°C and annealed at 65°C.
Extension was done at 72°C for 3 min and a total of 25 cycles were performed.
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3.2.3 Cloning and expression of peptide 1 and peptide 5
PCR was used to amplify the relevant sequences coding for these proteins using
purified viral DNA obtained from cell cultures infected with virulent AHV-1 strain
C500. The PCR products were enzyme restricted to create ligation sites for insertion
into plasmids and the recombinant plasmids used to transform competent bacteria. P-
5 was inserted into pTRX and P-l into pGEX.. pTRX recombinants were used to
transform G1724 E.coli cells and pGEX plasmids were used to transform JM109
E.coli cells. Sequencing was conducted to confirm orientation of ligation and
positive clones used for expression studies. Polyacrylamide gels were then run on
bacterial lysates to confirm presence of the protein of interest. E.coli cells
transformed with plasmids without inserts were used as negative controls.
3.2.4. Protein expression in E. coli
3.2.4.1 Expression of pGEX recombinant P-l in JM109 cells
A single colony of cells transformed by pGEX or recombinant pGEX was grown
overnight in 1ml of LB at 37°C. The bacteria were then grown in 10ml of LB media
until the OD was between 0.4 and 0.6. The bacteria were then induced by the
addition of IPTG to a final concentration of ImM. The cells were grown for a further
4 hr and the cells used for protein extraction.
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3.2.4.2 Expression of recombinant P-5 in pTRX in G1724 cells
A single colony of bacteria transformed by pTRX or the recombinant pTRX was
grown overnight at 30°C in RM media. The cells were then grown in 10ml of
induction media at 30° C until the OD600 was between 0.4 and 0.6. The cells were
then induced by growing the bacteria at 37°C after addition of tryptophan to a final
concentration of ImM. The cells were then allowed to grow for 4hr and the cells
used for protein extraction
3.2.5 Extraction of proteins from E coli
3.2.5.1 Extraction by lysis
Bacteria were pelleted by centrifugation at 800g for lOmin and resuspended in 1/10
volume of 50 mM Tris-HCl pH 8.0, 2 mM EDTA . Freshly made lysozyme solution
(10mg/ ml) was added to a final concentration of 100pg/ ml together with 0.1% (w/v)
Tween 20 detergent. Lysis was allowed to occur at 30°C for 30min . The lysate was
then made 8mM with respect to MgCl, and the nucleic acids digested by addition of
5pl DNAse 1 (lOU/ml) and 5pi of RNAse (lOpg/ml) for 30 min at 0°C. The lysate
was centrifuged at 10,000g for 5min. The supernatant was harvested and the pellet
resuspended in lOOpl of water. Both the pellet and the supernatant were analysed for
the presence of the protein of interest.
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3.2.5.2 Extraction by sonication
Bacteria were pelleted by centrifugation at 800g for lOmin and the cells resuspended
in 1/50 of the original volume of either 1 mM Tris, or lx MOPS, or 1 mM HEPES,
all of these buffers containing 1 mM P-Mercaptoethanol, 1 mM p-APMSF. The cells
were then sonicated by 3 cycles of 10 seconds using a Heat systems Ultrasonic, Inc.
Model W-385 set at maximum output. The sonicate was centrifuged at 10,000g for 5
minutes. The supernatant was kept and the pellet resuspended in the original volume
of water. Both the supernatant and the pellet were assayed for protein by
electrophoresis.
3.2.6 Polyacrylamide gel electrophoresis of proteins
Electrophoresis was based on the method of Laemmli, (1970) using "Mini" or
"Maxi" Protean apparatus (Biorad). Either 15% or 10% acrylamide gels were
prepared using the appropriate volumes of 30% acrylamide: 10% SDS: 1.5M Tris-
HC1, pH 8.8 (resolving gel) or 1M Tris-HCl pH 6.8 (stacking gel): 10% freshly made
ammonium persulphate: TEMED: H20. Samples were diluted 1:1 with loading buffer
(50 mM Tris-HCl pH6. 8, 25 mM SDS, 0.1 M Bromophenol blue, 10% glycerol, 100
mM DTT) and boiled for 5min before loading into wells. Gels were then run at a
constant voltage setting of 100V for 2-3hr. The gel was removed and the proteins in
the gel transferred to membranes or stained. Proteins were visualised by staining with
Coomassie blue. Molecular weights were determined by running samples in parallel
with protein molecular weight markers (Sigma) of known concentration.
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3.2.7 Western blotting
3.2.7.1 Transfer of protein onto membranes
Gels were removed from Protean tanks and equilibrated in transfer buffer (lOmM
Tris, lOOrnM Glycine, 25% (v/v) methanol) for 15 min. PVDF western blotting
membranes (Boehringer Mannheim) were placed in methanol for 30sec and rinsed in
water for 5min. The membranes were then equilibrated in transfer buffer (250ml
Methanol in 750ml ImM Tris-HCl, pH 8.0, 200mM Glycine) for 5min. The method
used was the semi-dry method using apparatus supplied by BIORAD. Whatman
3MM filter previously wetted in transfer buffer was placed on the anode electrode.
The PDVF membrane was then placed on top of the paper and gel placed on the
membrane. Finally, a buffer- wetted 3MM was placed on the gel. The apparatus was
then assembled and transfer performed at 150mA for 20-30min. The filter was
stained in Ponceau and rapidly destained with water to visualize the proteins. The
membrane could then be used directly for blotting or air-dried and kept at 4°C until
required.
3.2.7.2 Antibody detection of protein
PVDV filters were placed in blocking solution (washing buffer containing 10% milk
powder) for lhr at room temperature with gentle agitation and then washed three
times for 15min each in washing buffer (lx TBS, 0.01%Tween). The filter was then
incubated in primary antibody diluted 1: 40 for P-5 and P-l antisera, and
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1:5000 for mouse anti-thioredoxin monoclonal antibody (Invitrogen) or anti-GST
monoclonal antibody in blocking solution for lhr at room temperature with gentle
agitation. The membrane was washed again for 15 min with three changes of
washing solution. The membrane was then incubated for lhr at room temperature
with secondary antibody [sheep anti-mouse IgG, (Sigma) or donkey anti-bovine IgG
(SAPU) conjugated to horse radish peroxide] diluted (1: 2000) in blocking solution.
The filter was washed again for 15min with three changes of washing solution and
then rinsed in water for 5min. 20 ml of TMB substrate (Sigma) were added per
100cm"2 of filter and the membrane placed in the dark for lOmin for colour to
develop. The reaction was stopped by washing the membrane with water for 5min.
The filter was used for photography or air-dried before storage at room temperature.
3.2.8 Electroelution of proteins from gels
Proteins were run on a preparative "mini" or "maxi" Protean gel apparatus
(BIORAD) in parallel with markers. A longitudinal strip of gel containing the desired
protein was excised with a scalpel blade and placed in a Petri dish containing 5 ml of
cathode buffer (0.01M Tris-HCl, pH 8.0, 0.05% SDS). The gel was cut into small
(approximately 2 mm) blocks and these pieces were placed in the cathode chamber of
the electroeluter apparatus (Genetic Research Instruments). Anode buffer (0.01M
Tris-HCl, pH 8.0 , 0 05M Glycine) was placed in the anode chamber until the buffer
flowed into the cathode tank. Both tanks were then carefully filled with anode buffer
without disturbing the gel pieces and buffer in the cathode tank. Electroelution was
then performed at 50V for 12 to 16 hr. The bottom 5 ml of the anode buffer was then
retained and placed in a CentriconR tube with a molecular wt. cut off of 30,000 kDa
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(Amicon). The Centricon tube was then centrifuged at 3000g for lhour to concentrate
the protein.
3.2.9 Immunisation of rabbits
Each adult New Zealand white rabbit conventionally reared at MRI was immunised
by intramuscular (i/m) inoculation of 1 ml of a 1:1 (v/v) emulsion containing 50pg
of protein and Freund's complete adjuvant. Each rabbit was boosted i/m again with a
1 ml of a 1:1 (v/v) emulsion containing 50pg of protein and Freund's incomplete
adjuvant after 28 days. The rabbits were then inoculated intravenously 14 days later
with 50pg of protein without adjuvant (table 3.1). Rabbits were bled for serum before
each inoculation and the serum used for antibody assay. A large volume
(approximately 100ml) of blood was collected 10 days after the last inoculation.
TABLE 3.1: RABBIT IMMUNISATION AND CHALLENGE (C500)














3.2.11 Indirect immunofluorescence antibody test
This test was performed to detect P-5 and P-l antigens in monolayer cell cultures
grown on cover slips infected with virulent (C500) and attenuated (WC11) strains
of AHV-1 and also in LCL immortalised by OHV-2 and AHV-1. Bovine turbinate
cells grown on cover slips were infected at a multiplicity of infection of 0.1 and the
cells fixed when the cytopathic effect was about 50% by placing the coverslips in
cold acetone at 4°C for 10 minutes. The coverslips were mounted onto glass slides,
cells uppermost, with DPX. Such coverslips could be used immediately or stored at -
20°C until required. Cytospin preparation of LCL grown in suspension or peripheral
blood lymphocytes obtained from cattle experimentally infected with either AHV-1
or BHV-1 were adjusted to 2-5 x 106/ ml in Minimum Essential Media (MEM)
(supplied by GIBCO). Two hundred microlitres of these cells were spun for 5
minutes at 1500rpm in a Cytospin (Shandon, Cytospin3) and the cells on the glass
slides fixed in acetone for 10 minutes and then treated as the coverslip cells mounted
on slides.
To reduce non-specific binding, cells were blocked by flooding with a 1:20 dilution
of horse serum and incubating at 37°C in a moist chamber for 30 minutes. The cells
were then washed for 10 minutes with two changes of PBS, air dried and 50pl of
various dilutions of rabbit serum added onto the cells. The coverslips were incubated
again at 37°C for 30 minutes and the cells washed as before. The cells were stained
by adding 50pl of 1:40 dilution of goat anti- rabbit FITC conjugate (Sigma) onto the
coverslips and the slides incubated as before. The cells were washed for 10 minutes
with two changes of PBS and the cells air dried. The coverlips were then examined
under UV microscope at 1:40 magnification.
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3.2.11 ELISA Test
This test was performed to detect and assay P-5 and P-l antibodies in immunised
rabbits, experimentally infected cattle and wildebeest sera. ELISA (Dynatech) plates
were coated with 50pl of protein (lpg) in coating buffer and the plates incubated
overnight at 4°C. The contents were discarded and the wells washed 5 times by
flooding with coating buffer. 50pl of antibody dilutions in coating buffer containing
10% (w/v) milk powder was added into each well and the plates incubated for 30
minutes at room temperature. The contents were discarded and the plates washed
again with 5 changes of washing buffer. 50pi of anti-rabbit immunoglobulin Horse
Radish Peroxide conjugate (SAPU) diluted 1: 1000 in washing buffer containing
10% (w/v) milk powder. Donkey Anti-bovine IgG (Sigma) was used for both cattle
and wildebeest sera and sheep anti-rabbit IgG with rabbit sera. The conjugate was
removed and the plates washed again with 5 changes of washing buffer and 50pl of
conjugate (25.2 mg ortho-phenyldiamine tablet and 268mg phosphate-citrate buffer
with urea hydrogen peroxide tablet, Sigma) added into each well. The plates were
then incubated in the dark at room temperature for colour to develop. The reaction
was stopped by adding 50pl of 2.5M H2S04 and antibody levels determined by
colorimetry using an ELISA reader at a wavelength of 492nm.
3.2.13 Extraction of RNA from LCL or Peripheral blood lymphocytes (PBL)
This was a modification of the method described by Chomczynski and Saachi
(1987). Extractions were done using the protocol and reagents from an "RNA
Extraction Kit" (Stratagene). PBL were recovered from blood in EDTA obtained
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from cattle experimentally infected with either AHV-1 or BHV-1 (section 3.2.22).
EDTA blood was spun at 1800x g for 10 min and the buffy coat layer removed. The
buffy coats were resuspended in 10ml of PBS and the cells pelleted by spinning at
1800x g for 10 minutes. The cells were washed again in PBS and 108 cells
resuspended in 10ml of freshly made denaturing solution, guanidine isothiocyanate
(GITC) supplied in the kit. LCL grown in suspension were pelleted by centrifugation
at 800g for 10 minutes and washed once with PBS. lx 108 cells were then
resuspended in 10 ml of freshly made denaturing solution. The PBL or LCL were left
at room temperature for lmin. One ml of 2M sodium acetate (pH 4.0) was then
added and the contents mixed by inversion. Ten mis of water saturated phenol was
added to the mixture and the contents vigorously mixed by inversion. Finally 2.0 ml
of chloroform: isoamyl alcohol (24:1) was added and the contents vigorously mixed
for 10 sec. The mixture was placed on ice for 15min and then centrifuged at lOOOOg
for 20min at 4° C. The aqueous phase was removed and mixed with an equal volume
of isopropanol. The mixture was cooled at -20°C for lhr and the RNA precipitated by
centrifugation at lOOOOg for 20min at 4°C. The RNA pellet was resuspended in 3 ml
of denaturing solution and an equal volume of isopropanol added. The mixture was
incubated at -20°C for lhr and then the RNA was pelleted by centrifugation at
lOOOOg for lOmin at 4°C. The RNA was resuspended in sterile water and the
concentration adjusted to 100 ng/ml or 500 ng/ml after quantification by UV
spectrophotometry.
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3.2.14 Agarose gel electrophoresis of RNA
Agarose gels were prepared by dissolving lg of "ultra pure" agarose in lx MOPS by
boiling. The mixture was allowed to cool to 50°C and then formaldehyde was added
to a final concentration of 7.5%. RNA samples were diluted 1:4 in RNA loading
buffer and then mixed briefly by vortexing. The RNA was denatured at 65°C for 5
min and chilled immediately on ice before loading into the wells. The gel was run at
5V cm'1 for lhr and the RNA visualised using a UV transilluminator.
3.2.14 cDNA synthesis
cDNA synthesis was conducted using reagents contained in a commercial kit
(Invitrogen). The method used was based on instructions of the manufacturer. Ten pg
ofRNA (extracted from LCL or PBL) in 11.5 pi of water were placed in a microfuge
tube and 1 pi of random hexamers added. For a control reaction, lpg of "kit" MS2
mRNA and a specific 17mer primer was used. The sample was heated to 65°C for
lOmin and then allowed to cool at room temperature for 2min. The following
reagents were then added in the order indicated; 1 pi RNAse inhibitor, 4 pi 5x RT
buffer (250 mM Tris-HCl, 40 mM MgCl2 150 mM KC1, 5 mM DTT pH 8.5), 2 pi
100 mM dNTPs, 0.5 pi reverse transcriptase enzyme. The contents were mixed
gently and incubated at 42°C for lhr. The sample was then used for PCR.
3.2. 15 Southern transfer of DNA onto membranes
This method was used to transfer DNA from agarose gels onto Hybond N
(Amersham) membranes. The gel was placed in denaturing solution (0.5M NaOFI,
1.5M NaCl) and incubated for 30 min. The gel was then briefly rinsed in distilled
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water and placed in transfer buffer (1M NH4C1, 0.02M NaOH) for lhr. Nylon
membrane previously soaked in the transfer buffer was then placed on top of the gel
and three sheets of Whatman 3MM, paper previously soaked in transfer buffer placed
on top of the membrane. Finally a stack of paper towels were placed together with a
500g weight on top of the paper. Transfer was allowed to proceed overnight. DNA
was then fixed to the membrane by cross-linking using a UV transilluminator for 1
min.
3.2.16 Preparation of digoxigenin labelled probes
Probes were made from P-5 and P-l PCR products. P-5 probe was also made from
restriction enzyme products of recombinant plasmid DNA. The procedure was
performed according to the manufacturer's instructions with a slight modification.
300ng of template DNA was denatured by boiling for 10 min in a total volume of
15 pi and then chilled quickly on ice. 2 pi hexanucleotide mix were added followed
by 2 pi dNTPs and 1 pi of Klenow enzyme provided in the "DIG DNA labelling kit".
The reaction proceeded for 2hr at 37°C and then stopped by adding 2 pi 0.2M EDTA.
3.2.17 Hybridisation of "DIG" labelled probes
Hybridisations were carried out as recommended by the manufacturer's (Boehringer
Mannheim). Membranes were prehydridised by incubating in hybridisation buffer
(5x SSC, 0.5% N-Laurylsarcosine, 0.2% (w/v) SDS, lx blocking reagent, pH 7.0)
(20 ml 100 cm"2 of membrane) for lhr at 42°C when using P-5 probe and 65° C when
using P-l probe. The solution was then decanted and fresh hybridisation buffer added
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containing the probe which had been denatured by boiling for 5 min. Hybridisation
was carried out for 2-16 hr at the appropriate temperature and the filters washed
twice in 0.2xSSC, 0.1%SDS at the same temperatures for 30min.
3.2.18 Detection of bound "DIG" labelled probes
The detection of bound probe was performed using reagents and according to the
manufacturer's (Boehringer Mannheim) instructions. Filters were incubated in
blocking buffer (100 mM Tris-HCl pH 7.0, 150 mM NaCl) containing 0.5% blocking
reagent, for 30min. The filters were then incubated for lhr in blocking buffer (5 ml
cm"2) containing a 1:5000 dilution of alkaline phosphatase conjugate. The membrane
was then washed twice in TN buffer (100 mM Tris-HCl, pH 7.0, 150 mM NaCl ) for
15 min. The filters were placed in TNM (100 mM Tris-HCl, pH 8.0, 100 mM NaCl,
50 mM MgCl, pH 9. 5) for 5 min. 10 ml of TNM to which had been added 45 pi
Nitro blue tetrazolium (NBT) and 35 pi X-phosphate were then added. The filters
were kept static in the dark for 30min-4hr until the colour developed to the required
intensity. The reaction was stopped by rinsing the filters in water for 5min after
which the filters were air-dried.
3.2.19 Virus isolates used to infect cattle
The virulent C500 isolate (Plowright et al, 1975) used was kindly provided as a cell
culture infected flask by Dr. H. Reid. The cells were harvested by trypsinisation
when cpe covered approximately 50% of the cell sheet and resuspended in lOmls of
cell culture media.
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The WC11 strain (Plowright et al, 1965) used was an attenuated virus that had been
previously passaged 49 times in bovine calf kidney cells and 50 times in bovine
thyroid cultures. This virus was revived from -70°C and passaged 3 times in bovine
kidney cells.
The Bovine herpesvirus 1 (BHV1) virus used was an Oxford strain (Dawson et al,
1962) that was revived from -70° C and passaged twice in bovine kidney cell
cultures.
3.2.20 Titration of viruses
Cell free WC11 AHV-1 isolate and the Oxford strain of BHV1 were titrated before
inoculation into cattle. Titrations were carried out in microplates. Twenty five
microlitres of HEPES buffered growth media [(14mM HEPES in GMEM (GIBCO)]
was dispensed into each well. Twenty five microlitres of a suitable dilution of virus
was added into four wells. Additional doubling dilutions were then carried out. To
each well was added lOOpl of cell suspension containing 2x 105 cells/ml. The plates
were then sealed, incubated at 37°C and observed microscopically for cpe for up to
10 days after inoculation. Titres were calculated by the method of Reed and Muench
(1938) and expressed as 50% tissue culture infective doses (TCID50)
3.2.21 Virus neutralisation test
Virus neutralisation tests were carried out to screen sera from 1-2 year old cattle for
AHV1 and BHV1 antibodies. These cattle were either Holstein Friesian or Zebu
breeds. The tests were carried out in tissue culture microtitre plates using secondary
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bovine kidney cells. Sera for testing was heat inactivated at 56° C for 30 minutes and
diluted lin 2 in MEM. 50|al of each test sera was added to 4 wells containing 100-
200 TCID50 of either virus (BHV-1 or AHV-1). Finally 100 j_il of 2xl05 cells /ml was
added to all wells. Controls were sera obtained from rabbits previously immunised
with either virus that had been freeze-dried and stored at -20°C. The plates were
sealed and incubated at 37° C and read microscopically after 9 days. Only those wells
showing cpe at a serum dilution of 1:4 were considered to be negative for antibody.
3.2.22 Inoculation of cattle
Two steers of the Zebu breed, seronegative for BHV-1 and AHV-1 were used for
inoculation intravenously with 2ml of each virus strain or isolate. Virus titres were
calculated using the method of Spearman-Karber (Lenette et al, 1969). The titre of
BHV1 inoculum was 2.3 xlO6 TCID50/ml and the titre of attenuated WC11 was 3.2 x
104 TCID50/ml. The C500 virus isolate used was a suspension of infected bovine
turbinate cells kindly provided by Dr. H. Reid.
3.3 RESULTS
3.3.1. Construction of P-5 clones
The 496bp ORF corresponding to polypeptide -5 described by Handley et al (1995)
from C500 DNA was cloned in frame into the thioredoxin expression vector pTRX.
The cloning sites were Pst I and BamH I and these were introduced into the viral
DNA PCR primers.
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The recombinant plasmids were used to transform G1724 E coli and the recombinant
clones determined by their Amp+ phenotype and confirmed by agarose-
electrophoresis of the recombinants after digestion with Pst I and BamH I. Two
recombinant clones, designated clones 11 and 12 were found to possess the P-5 insert
and these were used in subsequent expression studies. Sequencing of the insert was
performed to verify the presence of P-5 sequences in the insert.
3.3.2 Construction of P-l clones
A 400bp fragment of the putative P-l ORF that had been shown to be highly
antigenic using the Fastscan program (Handley et al, 1995), was successfully cloned
in frame into the BamH I and EcoRI sites of pGEX. The recombinant molecules were
used to transform JM109 E coli grown in LB broth, and the recombinant clones
determined by their Amp+, LacZ' phenotype. Small scale DNA preparations were
made from these clones and the insert sizes determined. Sequencing of the insert was
performed to confirm presence of the P-l sequences.
3.3.3 Expression of P-5
To determine whether the recombinant clones were able to express the foreign C500
virus sequences, cellular protein was extracted from induced G1724 cells by lysis or
sonication and analysed in acrylamide gels. Results showed that the fusion protein
was only present in the insoluble fraction of the lysates or sonicates whereas the
control thioredoxin protein was present in the supernatant (Figure 3.1). Both methods
of extraction however gave similar and reproducible results. The recombinant protein
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was 29K whereas the thioredoxin was 12K. Attempts to increase the solubility of the
fusion protein by inducing expression at low temperatures (18°C and 30°C) were
unsuccessful. A strain of E coli, G1624 which is almost isogenic to G1724 but
expresses fusion protein at less than 30°C was also used but the P-5 fusion protein
was found to be insoluble.
To confirm that protein band at 29K in the induced cells was indeed the fusion
protein, western blots were made from induced and uninduced lysates from
transformed cells. The blots were reacted with a monoclonal antibody specific for the
thioredoxin fusion partner (Invitrogen) (data not shown). Results indicated that the
monoclonal reacted strongly with the recombinant protein and the thioredoxin
protein but not with any bacterial proteins from the induced and uninduced E coli.
ELISA results using antisera from immunised rabbits indicated that the P-5 fusion
protein was highly antigenic as the polyclonal sera reacted more strongly with the
fusion protein as compared to the reaction between the thioredoxin and the
polyclonal sera when both proteins were used at similar concentrations, ELISA
(tables 3.2 and 3.3).
3. 3.4 Expression of GST-P-1 fusion
To determine whether the pGST-P-1 recombinants and pGST were expressed in
IPTG-induced JM109 bacterial cells, the cells were lysed and the resulting pellets
and supernatants analysed for protein on polyacrylamide gels. Protein profiles
showed that both the GST and the P-l fusion were soluble with molecular weights of
approximately 27K and 42K respectively (Figure 3.2). Recombinant clones
produced a protein of the same molecular weight as the GST but at a lower yield
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suggesting GST or a protein of similar molecular weight is encoded chromosomally
and is therefore produced endogenously by E. coli.
The recombinant protein appeared to be susceptible to degradation, presumably by
proteases as this was inhibited by A-PMSF. Attempts to perform western blots using
an anti-GST antibody (Pharmacia) have been unsuccessful as the anti-GST
monoclonal antibody reacted with all bacterial proteins in the lysates.
The fusion protein was used to raise antiserum in rabbits. However, the sera obtained
from the immunised rabbits could not be tested for anti P-l antibody as the fusion
protein was degraded very easily and could not be therefore used to coat plates in an
indirect ELISA.
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Lane 1 Molecular wt. markers (kiloDaltons)
Lane 2 Uninduced cellstransformed with recombinant
pTRX
Lane 3, 4 & 5 sonicates of of uninduced cells
transformed with recombinant pTRX
Lane 6 Lysate of induced cells transformed with
recombinant pTRX showing the P-5 fusion proteins
Lane 7, 8 &9 Sonicates of induced cells transformed
with recombinant pTRX
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Figure 3.2; PAGE Showing the molecular wt. of P-l AND GST
Lane 1 - Molecular wt. markers(kiloDaltons)
Lane 2 & 3 - Lysates of induced pGEX transformed
cells
Lane 4 - Lysates of uninduced pGEX transformed
cells
Lane 5 - Lysates of uninduced P-l and pGEX
recombinant transformed cells




3.3 5 Expression of P-l and P-5 in LCL and PBL's
Both proteins were detected by indirect immunofluorescence in bovine turbinate cell
infected with either C500 or WC11 as well as in LCL infected with either AHV1 and
OHV2. Results for C500 and LCL are shown (Figure 3.3-3.10).The results showed
that there was diffuse cytoplasmic fluorescence and particulate intranuclear
fluorescence in BT cultures infected with the virulent C500 isolate when using the P-
5 and P-l antisera respectively. BT cultures infected with the attenuated WC11
isolate showed both intranuclear and cytoplasmic fluorescence and nuclear
fluorescence when using P-l and P-5 respectively. Uninfected cells did not show
fluorescence.
Diffuse cytoplasmic fluorescence was seen in cells immortalised by either AHV1 or
OHV2 when reacted with antisera to both P-l and P-5.
No evidence of P-l or P-5 was seen in peripheral blood lymphocytes obtained from
cattle infected with either AHV-1 or BHV1.
3.3.6 PCR and RT-PCR on peripheral blood lymphocytes
Samples were collected before inoculation and then every 5 days until the C500
inoculated cattle showed pyrexia (described in section 3.3.8). Samples were collected
on the day of fever and then daily for a further 3 days before the reacting animals
were sacrificed. All blood samples collected after onset of pyrexia were AHV-1 PCR
positive.
There was no evidence of P-5 or P-l mRNA in lymphocytes obtained from cattle
infected with either the attenuated or virulent virus. One sample obtained from a steer
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inoculated with C500 was faintly positive. This was from buffy coat collected two
days after onset of fever.
3.3 7 Transcription of P-l and P-5 in LCL ofOHV-2 and AHV-1
Synthesis of cDNA was successfully achieved from LCL immortalised by either
OHV-2 or AHV-1 using the "Invitrogen kit". 2pl of this reaction mixture was used to
amplify P-l and P-5 sequences in the cDNA using specific primers for each ORF and
the amplified products visualised in agarose gels. To confirm that the PCR was
amplifying the cDNA and not contaminating viral DNA, a control experiment was
also performed using RNA that was digested with DNAse and then phenol extracted
before the RT step and the results showed that the DNA amplified was from the
cDNA. PCR reactions were set up using the equivalent volume of LCL RNA. The
results showed that there was trace amplification of viral DNA. However, the amount
of DNA so amplified was insignificant when compared to the amount of DNA that
was amplified using the cDNA.
Southern blots on the P-l and P-5 PCR products were performed to confirm that the
RT-PCR products were P-l and P-5 (Figures 3.11 & 3.12). The results show that
LCL transcribe mRNA for both proteins.
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3.3.8 Reaction to infection and sampling of cattle used for P-5 ELISA
Cattle inoculated with the Oxford strain of BHV1 developed fever 8 days post
inoculation (d.p.i.) whereas those animals inoculated with the C500 strain of AHV1
reacted 14d.p.i. Animals inoculated with the attenuated WC11 did not show any
clinical disease.
The disease in BHV-1 infected cattle was characterised by a mild fever (39.1° C -
39.7° C), and ocular discharge. The animals recovered 4 days after onset of fever.
The animals inoculated with C500 developed severe disease characterised by high
fever 14 days post inoculation (40.5° C and 41.2° C). There was conjunctivitis which
was accompanied by severe serous nasal discharge. The animals were killed 3 days
after clinical disease and peripheral lymph node samples collected for virus isolation
and PCR.
Serum samples were collected before inoculation and then on day 5 and 10. Sera was
thereafter collected on day 14 when the C500 inoculated cattle reacted and on each of
three subsequent days.
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Figure 3.3. Diffuse cytoplasmic fluorescence in bovine turbinate cells infected with
AHV-1 strain C500 in an indirect immunofluorescence (IIF) test using P-5
antiserum (x 100).
Figure 3.4. Particulate intranuclear fluorescence in bovine turbinate cells infected with
AHV-1 strain C500 in an IIF test using P-l antiserum (x 200).
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Figure 3.5. Diffuse cytoplasmic and nuclear fluorescence in AHV-1 LCL in an IIF
test using a P-5 antiserum (x 200).
Figure 3.6. Diffuse cytoplasmic and nuclear fluorescence in OHV-2 LCL in an IIF
test using a P-5 antiserum (x 100).
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Figure 3.7. Particulate and diffuse intranuclear nuclear fluorescence in bovine turbinate
cells infected with WC11 in an IIF using a P-l antiserum (x 200).
Figure 3.8. Diffuse cytoplasmic fluorescence in bovine turbinate cells infected with
WC11 in an IIF using a P-5 antiserum (x 200).
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Figure 3.9. Diffuse cytoplasmic and nuclear fluorescence in AHV-1 LCL in an IIF
using a P-l antiserum (x 200).
Figure 3.10. Diffuse cytoplasmic and nuclear fluorescence in OHV-2 LCL in an IIF
using a P-5 antiserum (x 200).
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Figure 3.11-Southern blot of RT-PCR using P-l primers
and DIG labelled viral DNA PCR products as the probe.
Lanel-cDNA from RNA extracted from AHV-1 LCL
Lane2-cDNA extracted from RNA derived from OHV-2 LCL
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Figure 3.12-Southern blot of RT-PCR using P-5 primers
and DIG labelled viral DNA PCR products as the probe
Lane land 3-cDNA from RNA extracted from AHV 1
and OHV-2 LCL using S21 and S20 primers
Lane2-cDNA extracted from RNA deived from AHV-1
LCL using primers S21 and T64
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3.3.9 ELISA results
The antisera to P-5 were tested in triplicate against the antigen P-5 and against its
fusion partner thioredoxin and the average OD readings recorded (tables 3.2 and 3.3).
OD readings at the same serum dilution and at the same time post inoculation for the
same rabbit, were consistently higher with the recombinant P-5 protein than with the
fusion partner thioredoxin alone.
However, the results in table 3.4 indicate that the inoculated cattle did not develop
antibody against polypeptide 5.
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TABLE 3.2: RESULTS OF INDIRECT ELISA OF SERA OBTAINED FROM
TWO RABBITS IMMUNISEDWITH P-5 (values in P.P. at 492 nm) USING P-
5 RECOMBINANT PROTEIN AS ANTIGEN).
Rabbit no. 21 Rabbit no. 22
SERUM 0* 25 60 0 25 60
1;500x 0.231 2.071 2.377 0.114 3.126 3.177
1;1000 0.051 1.674 2.150 0.043 2.887 2.000
1;2000 0.088 1.396 2.215 0.056 2.712 2.215
1; 4000 0.034 1.041 2.024 0.074 1.954 1.75
1;8000 0.057 0.842 1.667 0.072 1.243 1.662
* = Day post inoculation. X = Serum dilution
TABLE 3.3: RESULTS OF INDIRECT ELISA OF SERA OBTAINED FROM
TWO RABBITS IMMUNISED WITH P-5 (values in P.P. at 492 nm) USING
THIOREDOXIN AS ANTIGEN
Rabbit no. 21 Rabbit no. 22
SERUM 0* 25 60 0 25 60
1; 500x 0.263 1.390 1.379 0.184 1.400 2.060
1; 1000 0.081 0.888 1.050 0.113 0.902 1.238
1; 2000 0.089 0.789 0.694 0.106 0.722 1.046
1; 4000 0.047 0.641 0.602 0.074 1.539 0.458
1; 8000 0.042 0.342 0.408 0.172 0.243 0.366
* = Day post inoculation. X = Serum dilution
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TABLE 3.4: P-5 INDIRECT ELISA RESULTS (values in P.P. at 492 nm) ON
CATTLE INOCULATEDWITH AHV-1 OR BHV-1.
Serum used at 1:50 dilution
C500 WC11 BHV-1 Control
D.P.I.XX G01* G02 G04 G06 G07 G10 G09 G08
0 0.077 0.091 0.067 0.06 0.128 0.071 0.058 0.071
5 0.073 0.116 0.098 0.052 0.114 0.088 0.088 0.067
10 0.082 0.034 0.102 0.087 0.063 0.099 0.045 0.102
15 0.056 0.034 0.076 0.088 0.056 0.131 0.119 0.08
16 0.082 0.092 0.036 0.066 0.077 0.094 0.046 0.044
17 0.094 0.107 0.04 0.083 0.057 0.089 0.066 0.065
18 0.069 0.083 0.114 0.079 0.06 0.045 0.042 0.058
xx = Days post inoculation, * = Steer number.
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3.4 DISCUSSION
The results show that the complete ORF of polypeptide 5 and part of the polypeptide
1 ORF were successfully cloned and expressed in E coli. Initial attempts to clone and
express peptide 5 in pGEX were abandoned because of poor yield and reproducibility
and because the product was insoluble (Dr. A. Rae, MRI, personal communication).
pTRXfus was then chosen because thioredoxin is an E. coli protein which is highly
soluble and also accumulates in the periplasmic space and is thus easily purified from
the lysed cells. It was therefore assumed that this would help to make the
recombinant protein soluble.
The expressed products have been used to raise polyclonal sera in rabbits and
preliminary results from western blots using lysates from cells transformed with P-5
recombinants indicate that the immunisation was successful. Results using the P-5
fusion protein in an indirect ELISA show that the rabbit sera is reacting to both the
fusion protein and the thioredoxin protein. However the reaction to the fusion protein
is stronger than the reaction to Thioredoxin alone. Attempts to adsorb out the anti-
thioredoxin activity by incubating the polyclonal sera with thioredoxin overnight at
room temperature was unsuccessful. The ELISA results presented here show that
though protein 5 is a strong immunogen the protein does not confer protection
against virulent challenge. Rabbits immunised with P-5 reacted following challenge
indicating that this protein is not protective.
The inability to detect mRNA specific for P-5 in cattle experimentally infected with
AHV-1 indicates that this protein is not expressed in PBL in vivo. DNA extracted
from the PBL from cattle infected with C500 during the clinical disease was however
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AHV-1 PCR positive. P-5 antigen was not detected in PBL derived from cattle
infected with either AHV-1 or BHV-1
The results could indicate that these proteins are not transcribed in vivo. The results
may also suggest that very few cells express this protein in vivo and confirm results
obtained by Edington and Patel (1981) who showed that AHV-1 antigens are
expressed in 1/104 of lymphocytes in experimentally infected rabbits.
Both P-l and P-5 were detected in immortalised LCL, and also in cells infected with
the virulent and the attenuated viruses, showing that both viral proteins are expressed
in vitro by cells infected productively and non-productively. The presence of both
antigens in AHV-1 and OHV-2 indicates that genes for P-l and P-5 are conserved in
both viruses.
The expression of P-5 in the attenuated virus was surprising in view of the reported
truncation of P-5 in the attenuated genome (Handley et al, 1995). The clone ATT1
described by the authors was derived from CFA viral DNA.
During the course of this work, the complete nucleotide sequence of virulent AHV-1
has been published (Ensser et al, 1997). These authors have shown the sequences for
P-l and P-5 to be located in the middle of the 130 kbp L-DNA and identified P-l as
part of ORF50 which encodes an R Transactivator and P-5 as ORF A7 that encodes a
C-type lectin..
The virulent virus (strain C500) that has been used in molecular studies in AHV-1
was isolated at least 24 years ago (Plowright et al, 1975). The virulent virus used to
obtain the complete AHV-1 genome sequence was a cell free but virulent derivative
of C500 which has undergone various passages in cell culture and also in cattle or
rabbits since it was isolated in 1975. There is therefore need to obtain fresh isolates
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of AHV-1 and use viral DNA from the wild-type isolates that have not undergone
passage in cattle or culture to confirm the genome organisation in AHV-1.
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CHAPTER 4




Characterisation of the AHV-1 genome (high passage attenuated, WC11 isolate) was
initially conducted by Bridgen et al (1989). They showed that the genome comprises
of approximately 130Kbp of unique DNA flanked by up to thirty lkb tandem
terminal repeats. Subsequently, the virus was classified as a gamma herpesvirus
(Roizman et al, 1992). Handley et al (1995) cloned and sequenced DNA from the
unique region adjacent the terminal repeats of the virulent C-500 isolate and its
attenuated derivatives.The C500 isolate used in the study had been serially cloned
using the limiting dilution method. The gene coding for one polypeptide, designated
protein 5 (P-5) was found to be truncated in the attenuated virus. The authors
suggested that this protein may be responsible for virulence. Another open reading
frame, encoding putative protein 1 (P-l) was considered on structural grounds to be
the equivalent of Herpesvirus saimiri transforming protein (STP-A11) (Beisinger et
al, 1992). Ensser et al (1997) have published the complete sequence of the AHV-1
genome. The virus used was a cell free but virulent derivative of the C500 strain.
The P-5 has now been identified as a putative protein encoded by an ORF, A7, with
low homology to the family of cellular genes that code for C-type lectins. P-l is part
of a protein encoded by ORF50 which has a limited homology to the R-
transactivators encoded by BRLF1 in Epstein Barr Virus (Hardwick et al, 1988),
and ORF50 in Herpesvirus saimiri (Biesinger et al, 1992) (Ensser et al 1997). These
proteins have now been shown to be encoded by sequences located in the middle of
L-DNA in AHV-1 (Ensser et al, 1997) as indeed are their homologs in EBV
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(Hardwick et al, 1988) and HVS (Nicholas et al, 1991). This is in contrast to the
terminal location of these genes as reported by Handley et al, (1995).
Results of an RT-PCR using RNA extracted from AHV-1 and OHV-2 LCL showed
that P-l and P-5 are transcribed in vitro (Chapter 3). Results of indirect
immunofluorescence on LCL immortalised by AHV-1 or OHV-2 and also on cell
culture monolayers infected with AHV-1 indicate that these proteins are expressed in
vitro.
The complete ORF of P-5 and part of the P-l ORF were successfully cloned and
expressed in E coli The expressed products were used to immunise rabbits but the
rabbits succumbed to virulent challenge showing that immunisation against these
proteins was not protective.
There is therefore a need to obtain fresh isolates of AHV-1 and determine the extent
to which the putative genes for virulence are conserved between isolates. The aim of
this work was to isolate and characterise fresh strains of AHV-1 from the natural host
and cattle with MCF grazing close to wildebeest.
4.2 MATERIALS AND METHODS
4.2.1 History of wildbeest herds sampled
The wildebeest herds from which samples were obtained were located approximately
200 kilometres from the NVRC laboratories where isolation of virus was attempted.
(Figure 4.1).These were resident herds in groups of approximately 50-300 which
graze freely in an area outside the Maasai Mara game reserve called Aitong (Figure
4.1). The herds share common pasture with cattle since this land is owned by a
Maasai Cattle Ranching group.
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Permission to obtain samples was kindly granted by the Kenya Wildlife Services and
shooting of the wildebeest was conducted by their staff. The cropping of wildebeest
calves was conducted from April-July which was during and immediately after the
calving season (Plowright, 1964). A maximum of four calves were shot during any
one field trip. Samples were obtained from newborn calves upto 3 months of age.
Newborn wildebeest calves have "brown" hair coat which is shed when they are three
months old and the calves become more uniformly grey (Plowright, 1964) thus
confidence in the age of the calves was assured..
Blood in EDTA, thyroid glands, kidneys and cornea were obtained asceptically from
wildebeest the calves.
4.2.2 Preparation of cell cultures from Wildebeest
4.2.2.1 Trypsinisation cell culture
Wildebeest thyroid cells were prepared in an attempt to isolate AHV-1 which may be
present in such tissues in a 'latent' form. The cells were prepared according to the
method described by Plowright et al, (1960) with slight modifications. The tissues
were washed with 3 changes of PBS and chopped into small (l-2mm) fragments
using crossed scalpels and the fragments transferred into trypsinising flasks or
transferred to cell culture flasks for explant culture. The tissue fragments transferred
to trypsinising flasks were washed with 3 changes of PBS and then washed once with
MEM (GIBCO). The supernatant was discarded and prewarmed trypsin (0.05%
trypsin, 0.08% versene in Melnick buffer pH 7.4) added (approximately 100ml per
gland or tissue) to the washed fragments. The contents were gently agitated with a
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magnetic stirrer in an incubator at 37°C. Trypsinisation was allowed to proceed for
30 minutes. The contents were centrifuged for 10 minutes at 400x g and the
fragments resuspended in similar amount of trypsin. The cells were trypsinised for a
further lhr and the supernatant filtered through double muslin gauze. The supernatant
was centrifuged at 800x g for 5 minutes and the cell pellet resuspended in an equal
volume of MEM containing 10% ox serum and antibiotics (10pg streptomycin, 100IJ
penicillin per ml). The cells were then counted using a haemocytometer and the
concentration adjusted to 1-2 x 105cells/ ml. The cells were then seeded into cell
culture flasks and incubated at 37° C. Cells were examined after 3 days when the
media was changed to MEM + 5% ox serum + antibiotics. When the cell monolayer
was confluent, cells were thereafter maintained with MEM containing 2% ox serum
and antibiotics. Such cells were maintained for 14 days when they were passaged. To
passage cell monolayers, media was decanted from culture flasks and the cells
washed with prewarmed PBS and 10ml of prewarmed trypsin added. The trypsin was
allowed to adsorb for 2 min and then discarded. The cultures were incubated for 10
min at 37° C and the loosely attached cells released from the flask surface by gentle
pipetting with 5ml of ox serum. The cells were pelleted by centrifugation at 800xg
for 5 min and the cells resuspended in 10ml of growth media. The cells were counted
using a haemocytometer and the concentration adjusted to 2xl05 cells/ml before
seeding into fresh culture flasks. The cells were then incubated at 37° C for the cells
to form a monolayer.
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4.2.2.2 Explant culture of wildebeest tissues
To prepare explant cultures, approximately lg of kidney or thyroid and whole cornea
was chopped into small fragments using crossed scalpels in 5 ml of growth media
and the chopped fragments placed in 25cm cell culture flasks. The flasks, were
incubated at 37° C without agitation for 72 hours. The media was decanted and the
visible tissue lumps loosely attached to the flask surface removed gently using sterile
pipettes. The attached cells were gently overlaid with growth media cells incubated at
37°C until they were confluent. The monolayers were thereafter maintained with
MEM containing 2% ox serum and antibiotics. These primary cell cultures could be
maintained for 14 days when they were passaged as described in 4.2.2.1.
Wildebeest cell cultures or explants that did not show cpe after 42 days were
discarded.
4.2.3 History of infected cattle sampled
Samples from clinical cases of MCF were obtained from cattle observed at a
slaughter house located in Isinya in Kajiado district which is located approximately
200Km from the wildebeest herds used during the cropping exercise (Figure 4.1).
The samples were therefore identified as Isinya 1 or Isinya 2 or Isinya 3 to denote the
location and the animal number sampled. The animals were transported to the
slaughterhouse from grazing ranches which were also inhabited by a resident group
of approximately 1000 wildebeest composed of many herds. Normally the owners of
the sick animals were identified with the assistance of the Veterinary staff at the
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abattoir and the farms visited. Isinya 1 was an adult cow from a Zebu herd of about
600 animals of mixed ages which graze freely with the wildebeest. There was a small
flock of local Red Maasai sheep. The farmer, Mr. Joseph Salaash informed us that
the first case of MCF was observed in May 1997. The farm was visited on 18/8/97
and the owner informed us that he had sold 53 animals which he suspected to be
MCF cases.
The other two cases obtained (Isinya 2 and Isinya 3) were from a ranch located near
the town called Emali which is about 60 kilometers from Isinya. The ranch consists
of approximately 1,200 Zebu cattle and 800 Black head somali sheep and Red maasai
sheep and which graze freely together with wildebeest. One of the farmers, Mr. Paul
Mokoa informed us that there are only sporadic cases but morbidity figures were not
available.
104



















4.2.4 Isolation of virus from cattle
Samples from clinical cases were collected on 13/8/97. The animals looked dejected,
with stringy mucoid nasal discharge, enlargement of prescapular, precrural and
submandibular lymph nodes and serous ocular and mucopurulent nasal discharge.
Samples taken from clinical cases of MCF for virus isolation were blood in EDTA
vacutainer tubes and prescapular lymph nodes. Approximately 20ml of EDTA blood
was collected in vacuum tubes and approximately 5g of lymph node tissues were
collected into MEM. All samples were transported to the laboratory on ice and
processed for virus isolation on the same day.
Lymph node tissues were chopped into small fragments (l-2mm cubes) and
resuspended in 20% (w/v) PBS. The fragments or EDTA blood were centrifuged at
800xg for 10 minutes. The buffy coat layer was collected and resuspended in an
equal volume of PBS. The tissue fragments were also resuspended in equal volume
of PBS. The buffy coat and tissue suspensions were then centrifuged at 800xg for 10
minutes. The pellets were resuspended in an equal volume of MEM and 2 ml
inoculated into 25cm secondary bovine thyroid cell cultures. The rest of the samples
were stored at -70°C in MEM containing 10% DMSO and 20% ox serum. The cells
were allowed to adsorb for 2 hours at 37° C and the cells overlaid with 10 ml of
maintenance media. The cells were incubated at 37° C for 48hr. The monolayers were
washed 2x with PBS and the maintenance media added. The cultures were then
observed daily for development of cpe for 14 days. The cultures were passaged
(described in 4.2.2.1) and observed for a further 14 days. Cell cultures that did not
show cpe were then discarded. Cells showing cpe were trypsinised and used for
106
extraction of DNA. Some of these cells were stored at -70° C in MEM containing
10% DMSO and 20% ox serum.
4.2.6 Extraction of DNA from tissue culture cells
Cell cultures showing cpe characteristic of AHV-1 were detached from culture flasks
by trypsinisation and the cells pelleted by centrifugation at 800 x g for 10 minutes.
The cells were washed twice with PBS and the cell concentration adjusted to 1 x 106
cells per ml. The cells were aliquoted into 1ml volumes and the cells pelleted using a
microfuge at 10,000xg for 2 minutes. The supernatant was decanted, the pellet
vortexed and 600pl of extraction buffer (150mM NaCl, lOmM Tris-HCl, pH 8.0,
lOmM EDTA, 0.1% SDS) added to lyse the cells. The contents were mixed
thoroughly and 600pl of phenokchloroform (6:4) added to the mixture. The contents
were centrifuged at 10,000x g using a microfuge for 10 minutes and 500pl of the
upper aqueous layer removed. The aqueous layer was added to 500pl chloroform and
the contents mixed vigorously for 2 minutes. The mixture was centrifuged again for
10 minutes at 10,000 x g using a microfuge and 400pl upper aqueous layer removed
and 200pl of 7.5.M ammonium acetate added. To precipitate DNA, 800pl of ethanol
was added to the contents and the mixture transferred to -20°C for 2 hours. DNA was
pelleted by spinning the contents in a microfuge at 10,000x g for 5 minutes. The
DNA was resuspended in 100 pi of T.E. (pH 7.4). DNA was then used for PCR or
stored at -20° C for further analyses.
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4.2.7 Extraction of DNA from tissue samples
Approximately 0.5 g of tissue was chopped finely with a "criss-cross" action using
scalpel blades and the tissues transferred to a 1.5ml centrifuge tube. The tissue was
washed by addition of small volume of PBS and the contents centrifuged at 6000x g
for 2 minutes in a microcentrifuge. The supernatant was discarded and the fragments
washed again in PBS. The supernatant was discarded and 1 ml of Ammonium
Chloride lysis buffer (0.17M Ammonium chloride, 0.17M EDTA, pH7.6) added to
lyse any contaminating erythrocytes. The contents were centrifuged at 6000x g for 2
minutes using a microfuge and the supernatant discarded. 500pl of extraction buffer
(150mM NaCl, lOmM Tris-HCl, lOOmM EDTA, 0.1% SDS, 200pg Proteinase
K/ml pH 8.0) was added to the tissue pellet. Digestion was carried out overnight at
37°C or for 2hr at 55°C. Proteinase K was then inactivated by boiling the contents for
5 minutes. The sample was used immediately for PCR or stored at -20°C until
required for PCR analysis.
4.2.8 Extraction of DNA from PBL
PBL was prepared by lysing 200pl whole blood obtained from cattle or wildebeest in
Tris-EDTA buffer (0.1M Tris-HCl, ImM EDTA, pH 7.6). DNA was extracted by
incubating the PBL at 56°C for 45 minutes in a buffer containing 50mM KC1, 20mM
Tris-HCl, pH 8.0, 2.5 mM MgC^, 0.5% (v/v) Tween 20 to which was added
lOOmg/ml of freshly prepared proteinase K. The contents were boiled for 10 minutes
to inactivate the protease before testing using PCR.
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4.2.9 PCR
PCR was conducted to detect AHV-1 or OHV-2 sequences in DNA obtained from
field cases of MCF. In all cases, AHV-1 and OHV-2 positive controls (kindly
provided by Miss I. Pow, MRI) were included. AHV-1 PCR was conducted on DNA
obtained from samples derived from cattle experimentally inoculated with fresh
isolates of AHV-1.
4.2.9.1 PCR for detection of OHV-2 sequences
This reaction was conducted in two amplification cycles following the method
described by Baxter et al, (1993) who amplified section of the tegument gene which
corresponds to a position approximately 120kbp in the AHV-1 genome. In the




DNA was denatured by boiling for 3 minutes followed by 25 cycles at 94° C for 30
sec, 60° C for 30 sec, and 72° C for 30 sec.
The secondary reaction involved amplification of 5pl of the DNA amplified in the
primary reaction using primer sets;
555: 5' TTCTGGGGTAGTGGCGAGCGAAGGCTTC 3' and 556
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Twenty five cycles of 94° C for 30 sec, 60° C for 30 sec, 72° C for 3 min were
performed and one extension cycle at 72° C for 5 min. The PCR products were ran on
agarose gels to confirm presence of fragment.
4.2.9,2 PCR for detection of AHV-1 sequences
Amplification of AHV-1 sequences was carried out using primers C317 and C318
primers as described in 3.2.2 (and see appendix 6.1). PCR products were analysed by
electrophoresis on 1 % agarose gel .
4.2.10 Virus neutralisation test
This test was conducted to screen cattle for AHV-1 antibodies before the animals
could be used for inoculation with fresh isolates of AHV-1. The test was conducted
as described in 3.2.21
4.2.11 Inoculation of cattle
Two steers, seronegative for AHV-1, were each inoculated with 2.5ml cell
suspensions obtained from tissue culture flasks showing cpe after inoculation with
samples from the field. This was approximately 1/4 of the cells obtained following
trypsinisation of a 25cm2 tissue culture flask.
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4.3 RESULTS
4.3.1 Isolation of AHV-1 and PCR
Ten primary thyroid cell cultures out of 28 thyroid glands were established using the
trypsinisation technique. Four out of 10 thyroid cultures were established by explant
culture. All these cultures were successfully maintained but 6 were lost following
passage due to bacterial contamination. Corneal explant culture was attempted from
six wildebeest calves but only four cell culture monolayers were successfully
established. Ten kidney explant cultures were established but five were lost during
passage due to bacterial contamination.
AHV-1 was isolated from 2 out of 28 wildebeest calves sampled. However tissue
samples obtained from 16 of these calves were positive by AHV-1 PCR alone (Table
4.1 and 4.2). One isolate (WC8) was recovered from corneal explants. The other
isolate was recovered from bovine thyroid cultures inoculated with buffy coat
obtained from another wildebeest calf (WC28)
Two isolates were obtained from 2/3 Zebu cattle showing clinical MCF at Isinya.
One isolate was derived from buffy coat (Isinya 1) and the other isolate was derived
from prescapular lymph node (Isinya 2) in thyroid cell culture monolayers. No cpe
was observed in cultures inoculated with buffy coats or lymph node cell suspensions
derived from Isinya 3. EDTA blood and lymph node tissues from all three animals
were however PCR positive for AHV-1 DNA. The size of the PCR products was
400bp in all cases. None of the samples obtained from the three animals was OHV-2
PCR positive.
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The time taken to observe cpe in these cultures was 18 days for Isinya 1 and 20 days
for Isinya 2. The cpe was characterised by one or two syncytia on the 25cm** flask.
These foci of cpe did not spread to affect adjacent cells after further incubation.
Cultures were harvested 3 days after appearance of cpe. Some of the infected cells
were used to inoculate cattle. The rest of the cells were used for DNA extraction and
PCR conducted using AHV-1 primers. All DNA samples were positive on PCR test.
Table 4.1; AHV-1 PCR RESULTS CONDUCTED ON WILDEBEEST
SAMPLES.
CALF NO. BLOOD THYROID KIDNEY CORNEA
1 -VE -VE ND ND
2 -VE -VE ND ND
3 +VE -VE ND ND
4 +VE -VE ND ND
5 +VE -VE ND ND
6 -VE +VE ND ND
7 -VE +VE ND ND !
8 -VE +VE ND ND
9 +VE +VE ND ND
10 -VE +VE ND ND
11 +VE +VE ND ND
12 +VE +VE ND ND
13 +VE -VE ND ND
14 -VE -VE ND ND
15 +VE +VE ND ND
16 +VE -VE ND ND
17 +VE +VE ND ND
18 +VE +VE +VE +VE
19 -VE -VE +VE +VE
20 +VE +VE +VE +VE
21 -VE -VE -VE -VE
22 -VE -VE -VE -VE
23 -VE -VE ND ND
24 +VE +VE +VE -VE
25 -VE -VE -VE -VE
26 +VE +VE +VE -VE
27 -VE -VE -VE +VE
28 +VE +VE +VE +VE
Indices; -ve = PCR positive +ve = PCR positive ND = Not Done
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Table 4.2; SUMMARY OF RESULTS OF PCR CONDUCTED ON
WILDEBEEST SAMPLES.
SAMPLE NO. TESTED NO. POSITIVE




Two isolates (WC28 and Isinya 2) were used to inoculate cattle. Steers inoculated
intravenously with the WC28 isolate reacted 51 days after inoculation. One of the
steers inoculated with the Isinya 2 isolate reacted 55 d.p.i. The other steer reacted 61
d.p.i. The disease was characterised by fever and nasal and ocular discharge. The
animals were killed 3 days after appearance of clinical signs and tissues taken for
PCR and virus isolation. PCR conducted on DNA extracted from prescapular and
mesenteric lymph nodes from all the animals killed were positive for AHV-1. Virus
isolation attempts were however unsuccessful due to bacterial contamination of cell
cultures.
Post-mortem lesions observed in animals inoculated with either virus isolate were
generally similar (Table 4.3) and compatible with a diagnosis ofMCF.
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TABLE 4.3: PATHOLOGY IN CATTLE INOCULATED WITH FRESH







G22 (lsinyal) G23 (Isinya 2)









Pharynx NVLXX Petechiae Petechiae Petechiae
Abomasum NVL NVL Congested Congested
Rectum Petechiae Petechiae NVL NVL
Liver Mottled NVL NVL Mottled
Kidney NVL NVL NVL Mottled

























Congested Congested Congested NVL
* = Animal No. xx = No Visible Lesions
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4.4 DISCUSSION
Two fresh isolates of AHV1 have been made from the natural host of the virus, and a
further two from clinical bovine cases of MCF. Success rate in isolation of virus from
affected cattle was high (2/3). The success rate in virus isolation from wildebeest
calves reported in this work is low (2/28) although the number of wildebeest
samples positive by PCR was high (16/28). Infection rate calculated from isolation of
virus in blood obtained from wildebeest calves during the first 3 months of life has
been reported to be 31% (Plowright, 1965b). The low success rate reported here was
mainly due to contamination of cultures during the preparation of primary cultures or
following passage of explant cultures or cell culture monolayers. In addition cpe due
to AHV-1 is difficult to detect (Plowright, 1965a). Some inoculated cultures may
have therefore been falsely recorded as negative and the cultures discarded due to
inability to recognise cpe.
Two of the four isolates were experimentally inoculated into cattle and the cattle
reacted. The cattle showed clinical disease typical of the "head and eye form" of
MCF (Daubney and Hudson, 1936). Virus isolation attempts from experimentally
infected cattle were unsuccessful due to problems of contamination of cell cultures.
Blood and lymph node tissues obtained from these animals were however positive on
PCR.
The wildebeest population from which two of the isolates were recovered could not
have interacted with the clinically affected cattle as the wildebeest populations were
resident of an area located approximately 200km from where the sick cattle were
observed.
115
The prevalence of the disease could not be established during the period of study.
This was mainly because the exercise to isolate virus from wildebeest calves (April-
July) coincided with the period when the disease incidence in cattle is high
(Plowright et al, 1960, 1965b). AHV1 genomic studies have depended on two virus
strains isolated in Kenya many years ago (Plowright et al, 1960, 1975). There is no
recent data available on the incidence or prevalence of the disease but a study of the
economic impact of the disease in Kajiado district and Narok districts of Kenya is
being conducted (Dr P. Mirangi-personal communication). Plowright et al (1975)
reported that in 1970, the incidence rate in both districts was 7%.
Ensser et al, (1997) have described the complete nucleotide sequence of the C500
isolate of AHV1 and they have shown the sequences for P-l and P-5 to be located
between 73-79kbp on the 130kbp. The availability of DNA obtained from fresh
AHV-1 isolates provides an opportunity to map the genes of these two proteins and
determine the extent to which these putative determinants of virulence are conserved
between isolates. This is the aim of the next chapter.
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CHAPTER 5
COMPARISONS BETWEEN GENOMIC DNA DERIVED FROM




Studies of AHV-1 have largely been with one of two isolates. Isolate WC11 was
recovered from wildebeest (Plowright, 1965b) and following many passages in tissue
culture is non-pathogenic for cattle. The C500 isolate was recovered from an ox
reacting with MCF (Plowright et al, 1975) and exists in two forms. The virulent form
is largely cell-associated though low tissue culture passage cell free virus is also
pathogenic for rabbits (Russel , 1980). Following additional passage however, the
virus no longer causes MCF following inoculation into rabbits. The genomes of these
C500 derivatives were compared by restriction enzyme analysis (Handley et al,
1995). Differences in Sma 1 profiles of the C500 forms were described and three
restriction fragments designated vir 1, vir 2 and att 1 were cloned and sequenced. The
clones were mapped to a terminal location in the viral genome based on their
hybridisation to the ladder of restriction fragments which results from the variable
number of tandem repeat units at each end of the unique DNA. Differences in the
nucleotide sequence of parts of these clones were interpreted to be due to deletions
which occurred on rearrangement of the genome during the transition from virulence
to attenuation. ORFs 1 and 5 were described which because of limited structural
homology and their position in the genome adjacent to the terminal repeats, were
considered to be AHV-1 homologues of the STP and TIP genes of HVS (Murphy et
al, 1989, Beisinger et al, 1990). Furthermore, the differences in the sequences of the
clones from the attenuated and virulent viruses indicated that some of these ORFs
were altered in the change from virulence to attenuation and were therefore of
importance to the viral pathogenesis.
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The publication during this study of the complete sequence of the AHV-1 genome
(Ensser at al, 1997) has necessitated a reassessment of the Handley et al (1995)
clones for two reasons. Firstly, there were differences in detail between the two
sequences. Secondly, while the sequence of the vir2 clone of Handley et al (1995)
came entirely from the middle of the genome around 75kbp, the virl clone contains
sequence from the middle of the genome linked to sequence from the 3' end. This
raised the question as to whether virl was an artefact of the cloning procedure.
The first objective of this chapter was to establish whether the sequence differences
were real polymorphisms between the two viral genomes which were sequenced or
were they sequencing errors. The second objective was to use PCR and sequencing to
prove the presence of the rearranged clone in the viral genome we were dealing with
which was not observed by Ensser et al (1997).
Re-sequencing has allowed the identification of ORFs in the Handley et al (1995)
clones which have now been shown to have homologues in other
gammaherpesviruses. This will be described here.
With the availability of new virulent isolates of AHV-1, a third objective was the
sequencing of those ORFs in the block of DNA around 75kbp which are involved in
the rearrangement to determine whether or not there are any differences between
isolates in this interesting region
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5.2 MATERIALS AND METHODS
5.2.1 Target viral DNA used in PCR.
(1) DNA extracted from 4 fresh isolates of AHV-1 (CHAPTER 4) i.e. Isinya 1, Isinya
2, WC 8 and WC 28.
(2) Low passage C500 isolate (Plowright et al, 1975) biologically cloned from an
infected rabbit by three sequential passages by limiting dilution in bovine turbinate
(BT) cell cultures. The infectivity was largely cell associated (CA). DNA from this
derivative designated CA.
(3) Intermediate passage (I.P.) PP that was cell free. DNA extracted from this
derivative was designated I.P.
(4). CA that had been attenuated after 30 serial passages in BT. Infectivity was
largely cell free. This derivative was designated CFA.
(5) CA that had been serially passaged 464 times in BT. The virus was mainly cell
free. This derivative of C500 was designated high passage (HP).
5.2.2 PCR and cloning
PCR was conducted to establish the presence of specific DNA fragments in the
various AHV-1 DNA samples and also to obtain products for sequencing. The
sequences of the oligonucleotide primers were taken from the published C500
genome (Ensser et al, 1997) are given in table 5.1. The respective positions of the
primers on the genome are given for each primer.
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PCR products were cloned into either pGEM-T or pBluescript (KS")(described in
section 2.4). Amplification used Taq or polymerase mix (described under section
2.5.15). Taq adds an extra Adenine diphosphate at the 3'of the PCR product. Such
products can therefore be cloned directly into pGEM-T. Amplification using the
polymerase mix protocol has the advantage in that this method can be used to
amplify longer fragments of DNA and without significant sequencing error.
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Table 5.1; Primers used to conduct PCR for genomic comparisons. Position of
the primers in the AHV-1 genome are shown in appendix 6.1
Primer Sequence Position in genome R.E°
V5582 5'-acact£tcgactatggctatggtct££tca-3' 73600-73571 Sail
V7335(R) 5' -gaaccaggatccaatgtttagcggaggga-3' 74919-74890 Bam HI
Z4878 5'-tggctggatcctgagatgttggcagaaatg-3' 76554-76583 Bam HI
Z4849(R) 5' -gctagtcgacagttatccatggacgggtgc-3' 77283-77312 Sail
14 5' -ataaccttcaacagcacc-3' 77431-77448
14(R) 5' -tcatccccagtaaaagta-3' 78971-78989
V0144(R) 5'-aaccttcttggcggcattcatcat- 3' 73608 -73631
Y0332(R) 5-gca ggcgccacttggtctgttggttagatg-3' 72601-72630
V7822 5' -tctttgggatcccatgcataagcactctgc-3' 75213-75242
P7 5' -gggcttgctgggtcgtagt-3' 129004-129028
LUCS1 5' -ttgtgactcgagttaaaaaaaagtaggtg-3' 72664-72692 Xho I
LUCS2 5' -catactctcgaggttttctggatacaccc-3' 72356-72384 Xho I
LUCRR 5' -gttggcagatcttttgggtagtcaaattt-3' 72808-72836 Bgl II
1040(R) 5' -tgctgatggtcgtttatgtgctgt-3' 1040-1064
1991 (R) 5' -gacatggtctgggaataacactac-3' 1991-2014
3153(R) 5' -gttgtgagataggtctacatgtcc-3' 3153-3177
RP2 5'cgggtgctcagcctcacaga- 3' 1083-1102*
RP1 5' -tctgtgaggctgagcacccg-3' 30-50*
0 =The enzyme restriction sites. Sites on the sequence are underlined. *= Sequences
from L DNA
5.2.2.1 PCR to amplify a region within ORF 50 and sequences immediately
upstream of QRF 50
This PCR was performed to prove the terminal location of the clones vir 1 and att 1
(Handley et al, 1995). The amplification reaction was conducted using Taq PCR. The
PCR was also used to determine the extent to which the genomic rearrangements
occur during attenuation of the virus with respect to the ORF50 and its promoter.
The reaction was conducted using primer RP1 which corresponded to a sequence
from the terminal repeat unit at position 50-30bp on the H-DNA relative to the first
Sac I site, together with primer V0144 (Table 5.1) on the complementary strand.
Primer V0144 was also used as a downstream primer together with primerY0332
(table 5.1 and appendix 6.1) to determine whether there has been a translocation or a
translocation/duplication as reported by Handley (1993).
To prove that clone vir 1 was not a cloning artefact, a PCR was conducted using
primers from the middle of the genome and primers designed from the 3'end of L-
DNA. This reaction was performed on viral DNA obtained from wild-type virus, low
passage, intermediate passage and CFA C500, and WC11 with primers V7822 and
P7 (see table 5.1 and appendix 6.1)
This product was cloned into pGEMT and sequenced.
5.2.2.2 Primers used to amplify viral DNA sequences at the left end of the
genome adjacent the terminal repeat
A primer from the terminal repeat, RP2 (table 5.1) was used in conjuction with
reverse primers from within the left end of the L-DNA to try to obtain information
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about the extent to which a translocation to the left hand end of the L-DNA had
occurred. The reverse primers were at positions, 1040, 1991 and 3153 and their
sequences are given in table 5.1 and their position in the AHV-1 is shown in
appendix 6.1.
RP2 corresponds to the sequences 31 to 50 relative to the end of the first terminal
repeat adjacent the 5' end of the unique DNA sequences (Handley et al, 1995).
Annealing temperature for the four primers was 51°C.
5.2.2.3 PCR to amplify a region immediately upstream of QRF50
These primers were initially constructed to clone the putative promoter for ORF 50
for assay of promoter activity in vitro (Chapter 6). The target DNA was from CA and
CFA virus and DNA obtained from the fresh isolates of AHV-1. PCR was conducted
with primers LUCS1 and LUCS2 as upstream primers in conjunction with LUCRR
which was a 3' primer situated at start of exon 1 of R transactivator (table 5.1 and
appendix 6.1).
5.2.2.4 Cloning and sequencing of ORF 50
Target DNA was genomic DNA from field isolates of AHV-1. This fragment was
amplified using the Long Template PCR with primer V5582 and V7335 (table 5.1),
annealing temperature of 57° C. The PCR products (Figure 5.1) were extracted from
agarose gels, enzyme restricted using Sal I and Bam HI and cloned into pBluescript
(KS~) which had been digested with the same enzymes. Ligation mixtures were used
to transform competent JM109 cells and clones containing the recombinant plasmid
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were confirmed following digestion with Sal I and Bam HI. DNA concentration was
adjusted to 200ng/pl for sequencing.
5.2.2.5 Cloning and sequencing of ORF A7 (peptide 5)
PCR was performed using Taq polymerase to generate fragments of ORF A7 from
genomic DNA obtained from field isolates for sequencing. Annealing temperature
was 60°C. PCR was conducted using primers Z4878 and Z4879 (Table 5.1 and
appendix 6.1)
The PCR products were cloned into pGEM-T and the recombinant plasmids used to
transform JM109 cells. Miniprep DNA was prepared and then digested with Sal I and
Bam HI to confirm presence of insert in the recombinants. ssDNA was prepared from
clones constructed using viral DNA from wild-type virus, ds DNA was prepared
from CFA for sequencing.
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Figure 5.1 ; PCR using DNA from the four wild-type isolates and ORF50 primers





Lanel and 6- Molecular wt. markers
Lane 2-5- PCR results on the four new isolates
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5.2.2.6 Cloning and sequencing of ORF A8 .
This ORF is predicted to be 1559bp in length (Ensser et al, 1997). Taq PCR was
conducted to determine whether the A8 PCR fragment was present in the wild-type
virus, high passage C500 and also in the attenuated WC11. Primers 14 and 14
(R)(Table 5.1 and appendix 6.1) were constructed to amplify full length A8, the ORF
which encodes the putative virus attachment protein.
5.2.3 Nucleotide analysis and amino acid analysis.
Nucleotide analysis was conducted as described in 2.5.10. Translation of nucleotide
sequence to amino acid sequences was done using the programs of UWGCG
package. Potential coding regions were identified using TESTCODE (Fickett, 1982).
Searches for amino acid homologies were conducted using PROSRCF1 programme
(Lipman and Pearson, 1985)
5.3 RESULTS
5.3.1 Location of peptide 1 in the attenuated genome
The sequence of the PCR product amplified using the RP1 primer from the tandem
repeats in conjunction with the gene-specific primer for peptide 1 is shown in figure
5.2 together with the translation of peptide 1 up to the location of the second primer.
The first 288 bp of sequence, shown in capitals in figure 5.2, are > 92% homologous
127
to the sequence of the tandem repeats from position 50 back through the Sac I site to
position 867 bp of another repeat unit. The rest of the clone is 100% homologous to
the unique DNA starting at 72673 bp and includes the gene for peptide 1 which is
normally found at position 72825-74903. The transcriptional direction of peptide 1 in
this PCR product is away from the sequence of the tandem repeat. Because of the
orientation of the RP1 in the tandem repeats, this implies that this clone comes from
the right hand or 3'end of the L-DNA.
PCR reactions using primers Y0332 from 72601 (i.e. upstream of peptide 1 ORF) (see
appendix 6.1) and V0144 from position 73631(which is within the P-l ORF) were
positive for only the wild-type and CA C500 isolates amplifying a fragment of
lOOObp as expected from the AHV-1 sequence (see figure 5.3)
Figure 5.2 Sequence of the PCR fragment obtained from CFA C500 using
primer RP1 from the terminal repeats and a primer V0144 from position
73631bp.
The figure shows the sequence and aminoacid acid alignment for the PCR fragment.
Details are explained in 5.3.1
The repeat sequence is in capitals, primers and informative restriction sites are in







































5.3.2 Validation of the vir 1 clone and its location at the 3'end of the genome
When the primers located at positions 75213 (V7822) and 129004 bp (P7) (appendix
6.1) in the virulent cell free derivative of the C500 isolate were used to amplify DNA
from the low passage derivative of C500 (CA), new virulent isolates and the CFA
preparations, only the CFA DNA was positive. The sequence of this PCR fragment is
shown in figure 5.4. Comparison with the published sequence shows that a block of
DNA from position 75481 bp to position 72673 (see section above), has been
translocated and placed between position 129840 bp of the unique DNA and the
terminal repeat position in an inverted orientation. In this position the promoter
region of the R transactivator has been truncated and this will be discussed further in
chapter 6. Furthermore, ORF A10 (at position 130229-12881 lbp) which encodes a
putative glycoprotein (Ensser et al, 1997) is interrupted by this translocation as is
ORF A6 (72226-75858), a potential transactivator. The genomic rearrangement that
occurs following attenuation of AHV-1 is summarised in figure 5.5
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Figure 5.3 ; PCR of the wild-type and attenuated C500 isolates
using primers V0332 and Y0144






Lane 1 and 7= MolecularWt. Markers
Lane 2= Low passage C500 (CFA) DNA
Lane 3= Isinya 1 DNA
Lane 4= High passage C500 (CFA) DNA
Lane 5= CA (C500) DNA
Lane 6= WC11 (CFA) DNA
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Figure 5.4. BESTFIT of the sequence of the PCR fragment obtained from AHV1
CFA C500 target DNA using primers P7 and V7822 (see Appendix 6.1)
compared with the AHV1 sequence of Ensser et al 1997. Note the breakpoint in
the sequence at 129846 bp where sequence from the middle of the genome at 75483
bp has been inserted.
Primer 7
2 GGGCTTGCTGGGTTCGTAGTCCCTAGGTGGTAAAGGAGGAGGTTCTTGCC 51
129004 GGGCTTGCTGGG TCGTAGTCCCTAGGTGGTAAAGGAGGAGGTTCTTGCC 129052
52 TGCCTCTACCTGCAGGAGCTTTGCTACGTGGAGTAGCCCCACTCAGACCA 101
I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I I ! I I I I I I I II I
129053 TGCCTCTACCTGCAGGAGCTTTGCTACGTGGAGTAGCCCCACTCAGACCA 129102
102 CTGCTCGTAGATTCCTTGCTCTGTGGAGTAGGACCACGCTGACCACTTCC 151
111! II11111 i 1111111111111111111II11111111111111111
129103 CTGCTCGTAGATTCCTTGCTCTGTGGAGTAGGACCACGCTGACCACTTCC 129152
152 TGCAGGATCTCTGCTTGGAAGAGGGGGCTTTTTAGGACCACCTCCTGCAG 201
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750
129703







I 1 1 1 1 II 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
885
75483
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
CGGTCTCATAGTTACCCCACGGTAGTCCTCAAAGGCAGGTCTCCATATCT 75434
886 TAT.CATCGCA.GCGCA.GCTGATAATTAACAAACTGATTTATAGGAG.T
III 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1
931
75433
III 1 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 II 1 1
TATCCATCGCAGGCGCAGGCTGATAATTAACAAACTGATTTATAGGAGTT 75384
932 ATTGCCG..AGGCAGGGGAAAG.CTGGAAA.GGACA.GAGTAGTAGT.GC
1 1 1 1 1 1 1 1 1 1 II 1 1 1 II 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 II
975
75383





1 1 1 1 1 1 1 1 1 II II 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 II 1
75283
1 1 1 1 1 1 1 1 1 II II 1 1 1 1 1 1 1 1 1 1 1 1 II 1 1 1 1 1 1
TCAGAGGGCTAAATGCTGAAATGGGTAGCATGTCAGCTGTAGCAGA 7523 8
5.3.3 Comparison of the predicted amino acid sequences of peptide-1 and
peptide-5 with sequences in the SwissProt database.
Ensser et al (1997) have designated the ORFs corresponding to peptide 1 and peptide
5 ORF50 and A7 respectively. In SwissProt database searches for similarities to ORF
50, the best matches were to three gammaherpesvirus R transactivators, namely, from
EBV, an immediate early (IE) gene ORF BRLF1 (Baer et al, 1984), from HVS, an
IE, R encoded by ORF 50 (Nicholas et al, 1991) and from BHV-4 an IE gene IE-2
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(Van Santen, 1993). The percentage identities and similarities at the amino acid level
between these putative proteins are given in Table 5.2
Overall percentage identities between the amino acid sequences range from 20.6 to
25.7 while the percentage similarities range from 43.4-49.0.
Table 5.2; Percentage amino acid identity and similarity (italics) between AHV-
1 peptide 1 (ORF 50) and the R transactivators from BHV-4, EBV, and HVS
Virus AHV-1 BHV-4 EBV HVS
AHV-1 - 43.7 44.7 45.3
BHV-4 21.6 - 49.0
EBV 20.6 21.4 - 43.4
HVS 22.9 25.7 22.7 ~
A similar analysis of ORF A7 (peptide 5) revealed DNA homology to EBV ORF
BZRF2 and to the family of cellular C-lectin proteins (Spriggs et al, 1996). A
multiple alignment of the amino acid sequences with gaps inserted to optomise the
alignment of peptide 5(AF1V-1), EBV ORF BZRF2 and the human CD23 protein are
shown in figure 5.6. The overall amino acid identity/similarity between the various
ORFs is similar to that between the R transactivators described above, however in the
case of the lectin homologs, there are also conserved structural motifs in the
extracellular domain of the protein.
Published C-type lectin sequences contain a highly conserved WIGL motif indicated
in bold type in figure 5.6. In the EBV this motif has been altered to WVGV, whereas
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in AHV-1 the sequence is WIGT. Furthermore there are six cysteine residues
conserved between the lectins which are also highlighted in bold in figure 5.6.
Figure 5.6; Alignment of the AHV-1 peptide 5 (ORF A7) with the EBV ORF
BZLF2 and the C-type lectin protein, human CD23.
Conserved motifs are in bold. + indicates that an amino acid in this position is shared
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AHV1 IPPVN DSVDF-NPGFRLS-WLNTLSPLSDGPYDSWSQCEICPGR FVGQKACYY
EBV PPPVNFNKTAEQEYGDKEVKLPHWTPTLHTFQVPQNYTKANCTYCNTREYTFSYKGCCFY
CD2 3 VCNTCPEKWINFGRK- -CYY
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5.3.4 PCR using primers V0144 and Y0332 (see appendix 6.1)
The results are presented in figure 5.3. PCR using primers V0144 and Y0332 only
amplified DNA obtained from the wild-type isolates and cell associated (CA) C500
but not from the intermediate or the high passage cell free (CFA) C500. This
indicated that these sequences are not adjacent in the intermediate and high passage
C500 genome and that the block of DNA which is translocated is not also duplicated

















5.3.5 Genome organisation at the left end of L-DNA
PCR using primers Lucrr/Lucs4 amplified a 170bp fragment with sequences
homologous to the predicted AHV-1 sequences. However the LUCS2/LUCRR
primers amplified a 250bp fragment in the intermediate passage cell free C500. The
PCR fragment from low passage C500 and wild-type isolates was 450bp. The
sequence of the 250bp PCR product showed that this fragment was made up of
sequences from position 609-676 of the H-DNA and 72356-72565 of L-DNA. The
orientation of the sequences in the H DNA fragment showed that this sequence was
derived from the last terminal repeat at the left end of the genome. The L-DNA
sequences were therefore translocated to the left end of the genome. These results
indicated that LUCS2 had annealed at the correct position in the L-DNA and that the
same primer inappropriately annealed within the terminal repeat. The size of the
fragment translocated from the middle of the genome could not be established from
this result. PCR was therefore conducted using intermediate passage DNA and
primers designed from position 72450 (reverse) in conjuction with primers, 1040R,
1991R and 3153R to establish the size of sequences translocated to the left end of the
genome in the cell free virus (see appendix 6.1). It was assumed that sequences
translocated to the left end of the genome would be reversed in orientation as is
shown to occur in the attenuated virus. A control reaction was also conducted with
the three primers and RP2 as the upstream primer (section 5.2.2.8). The results
showed that RP2 amplified fragments of predicted sizes with the 3 primers. Primer
72450 only amplified a fragment, of approximately 1350bp with the 1040 reverse
primer. This fragment was cloned into pGEM-T and sequenced. The sequences
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generated showed that the 72450 primer had annealed at the correct position in the
middle of the genome but had also inappropriately annealed down stream of its
correct position. The fragment did not contain sequences from the either end of L-
DNA.
5.3.6 Sequence homologies for wild-type isolates
The results of ORF50 and A7 PCR are presented in figures 5.1 and 5.7 respectively.
The results show PCR amplified fragments of the predicted sizes. The sequences
generated from these fragments were homologous to the published sequences. There
was therefore no significant difference between viral DNA obtained from the wild-
type isolates and the virulent C500 sequences described by Ensser et al, 1997 in
respect to the ORF 50 and ORF A7.
5.3.7 PCR to amplify ORF A8 (gp350/220
Using primers 14 and 14R a fragment of expected size was amplified using DNA
from the wild-type virus and the low passage C500. In the intermediate passage and
high passage cell free C500, two fragments of different sizes were observed; one
fragment was equivalent in size to the fragment from the wild-type and low passage
virus and the other fragment was smaller (approximately 1350bp). When WC11
DNA was amplified using the same primers, a PCR product equivalent in size to the
smaller PCR fragment observed in high passage C500 was amplified (figure 5.8).
One possibility was that this WC11 fragment had suffered a deletion compared with
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the virulent virus or the PCR amplified a different fragment. The fragments generated
from wild-type viral DNA and WC11 were extracted from gels, Genecleaned and
precipitated with ethanol to remove residual salts (Chapter 2). The DNA
concentration was adjusted to 200 ng pi"1. Restriction maps of AHV-1 L-DNA
sequences between 77431-78989bp showed that this region contained 2 restriction
sites for Sma I and Stu I and one restriction site for Xba I Dra I, Kpn I and Pst I.
200ng of DNA extracted from the wild-type, low passage cell associated C500 and
WC11 were digested with these enzymes in appropriate buffers to generate
restriction maps to determine homology to C500 described by Ensser et al, (1997).
The restriction map profiles for the wild-type viral DNA were homologous to the low
(CA) passage C500 as the restriction fragment sizes were as predicted from the
database. However, the pattern for WC11 was different. The WC11 fragment was
therefore cloned into pGEM-T and sequenced. The sequence was compared with the
known AHV-1 L-DNA sequences in the database and the results indicated that
primer 14 had annealed inappropriately at position 21694-21713 and position 22976-
22996. The sequence of the PCR product amplified using primers 14F/R was
identical to the AHV-1 DNA polymerase sequence. These sequences were therefore
not related to the A8 sequence. It is not clear why the WC11 DNA was PCR negative
for gene A8. It is possible that the sequences are deleted in this attenuated virus. It is
likely that the smaller fragment in the PCR using 14/14R with CA DNA is also part
of the polymerase gene.
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Figure 5.7 ; PCR of the four wild-type isolates using ORF A7 primers
Size (bp)
Lanel&6- Molecular wt. markers
Lane 2-5-PCR results on all the four isolates
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Lane 1= Molecular Wt. Markers
Lane 2= CA viral DNA
Lane 3= WC11 viral DNA
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5.4 DISCUSSION
The publication of the complete sequence of the AHV-1 genome (Ensser et al, 1997)
raised questions about the validity of the clones described by Handley et al, (1995).
While clone vir 1 corresponded to the Hind HI fragment at 73564-77088bp, the
clones vir2 and att 1 were shown to be admixtures of sequence from this Hind HI
fragment and sequences from the 3'end of the genome. The question as to whether
these clones were chimaeric artefacts of cloning or were genuine clones from a
rearranged viral genome was addressed here by sequencing PCR fragments obtained
with pairs of primers which should not amplify DNA from virulent virus according to
the sequence described by Ensser et al, (1997).
The results show that rearrangements take place in the C500 viral genome during
serial passage in tissue culture. The DNA sequence rearrangement results in AHV-1
virus which is no longer pathogenic for rabbits (Handley et al, 1995). The authors
suggested that the rearrangements occur at the 5'of the genome and that the
rearrangements involve deletions and truncations of the ORFs designated peptide 1
and peptide 5. The genomes of y-herpesviruses are generally collinear. These
peptides were therefore considered on positional and structural grounds to be
equivalents of the HVS transforming proteins STP (saimiri transforming proteins
STP-A11 and STP-C488, Murphy et al, 1989, Biesinger et al, 1990) and TIP
(Tyrosine Kinase interacting protein, Biesinger et al, (1995). The genes for these
proteins are located close to the 5'end of the HVS L DNA (Albrecht et al, 1992)
However, the sequences of the PCR fragments presented here, together with the
ladder of bands produced on hybridisation blots of viral DNA which has been
digested with restriction enzymes such as Hind III, Bam HI and Eco R1 which do not
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cut within the tandem repeats, with peptide 1 DNA (Handley et al, 1995),
demonstrates the proximity of P-l to terminal repeats in the attenuated virus. The
presence of a product when primers Y0332 and V0144 were used to amplify CA and
wild-type viral DNA and its absence in the CFA DNA would indicate a translocation
rather than a duplication/ translocation.
The sequence from the repeat unit starts at -152bp with respect to the initiation codon
of peptide 1 (ORF 50) (figure 5.2). This sequence may not be long enough to encode
crucial upstream regulatory sequences. There is therefore need to determine whether
the regulatory factors, i.e. promoter for this immediate early protein are functional.
This is discussed in chapter 6.
Whatever the consequence of this rearrangement may be for AHV-1 pathogenicity,
the attenuated viruses are clearly able to productively replicate in vitro producing
viable virions that cause cytopathology in cell cultures.
The sequence of the PCR product obtained using LUCS2/LUCR with intermediate
viral DNA provided evidence that the block of DNA at around 75,000bp in the
genome may also be translocated to the left end of the genome as indicated by
Handley et al, (1995). However, no further PCR products using primer 1991R,
1090R , 2053R and primer RP2 were obtained which could define the extent of the
translocation to the left end.
Protein alignment for peptide 5 show a high percentage of conserved amino acid
motifs with BZLF2 amino acid sequences in EBV and the human CD23 , indicating
that this peptide in AHV-1 may play the same functional role as this protein.
There are no sequence differences in DNA derived from wild-type isolates and the
laboratory adapted virulent C500 isolate in respect of ORFs, 50 (peptide 1), A7
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(peptide 5) and A8 that have been shown to be truncated or deleted in the attenuated
virus.
It is now clear however that P-l is the AHV-1 equivalent of the R transactivators of
EBV, BHV-4 and HVS while peptide 5 is a homologue of C-type lectins. The genes
for these proteins are located in the central position in the unique DNA of both EBV
(Baer et al, 1982) and HVS (Albrecht et al, 1992). Furthermore, Ensser et al (1997)
have now sequenced the whole genome from the virulent albeit cell free C500 isolate
and place the genes for the peptides 1 and 5 at 72825-74903bp and 76569-77300bp
respectively, the total length of the unique DNA being 130kbp.
AHV-1 in wildebeest calves multiplies most probably in the upper respiratory tract
(Mushi et al, 1980b). The virus then infects peripheral blood lymphocytes and a
vireamia can be detected in such animals (Plowright et al, 1960, Plowright et al,
1965). Infected wildebeest continue to shed cell free virus in nasal and ocular
discharges for a limited period of time (Mushi et al, 1980b). Cessation in virus
shedding is associated with development of humoral and surface antibody (Plowright
1967, Rurangirwaet al, 1982).
AHV-1 infection in cattle leads in development of severe MCF and recovery is rare
(Plowright 1986). Cattle infected with AHV-1 do not shed cell free virus (Mushi et
al, 1981c), suggesting that lytic replication does not occur in infected cattle.
One cow that recovered from AHV-1 was shown to transmit disease to 3 out of four
offspring over a period of 4 years though the animal had a high level of humoral
neutralising antibody to AHV-1 indicating that cell mediated immunity may be
important in the maintenance of latency in cattle that recover from clinical MCF
(Plowright et al, 1972).
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Since R has been shown to be crucial in lytic phase of infection in EBV this protein
may be important in the epidemiology and pathogenesis of MCF.
The results presented in Chapter 3 show that peptide 1(R transactivator) is expressed
in vitro (i.e. in infected cell culture) but not in vivo (in peripheral blood lymphocytes
derived from cattle infected with virulent AHV-1) though failure to detect proteins
may be due to very low frequency of virus infected cells.
C-type lectins are transmembrane glycoproteins, common in eukaryotic cells
(Yokoyama et al, 1989), and also in blood cells that possess natural killer
characteristics (Spriggs et al, 1996). The glycoproteins present on these cells are
important in MHC class II antigen recognition and lysis (Li et al, 1997).
In cattle the target cell for AHV-1 is the T lymphocyte (Rurangirwa et al, 1981,
Mushi et al, 1984) although probably limited replication occurs in the oculo-nasal
epithelia. Expression of this protein on the surface of infected T cell may therefore
phenotypically alter such cells so that they acquire NK function.
The mechanisms involved in the pathogenesis of AHV-1 are poorly understood as
direct viral cytopathology cannot be demonstrated. The most probable hypothesis is
that infected T cells are deregulated so that they acquire NK activity (Reid and
Buxton, 1984). It is therefore tempting to speculate that infection of the target cell
leads to expression of C-type lectins and that such altered T cells are responsible for
the cell destruction observed in MCF.
Ensser et al (1997) also showed that AHV-1 encodes a putative glycoprotein with
limited homology to the gp350/220 described in EBV. The results presented here
show that this sequence encoding this putative glycoprotein was amplified in virulent
viral DNA but not in DNA derived from the attenuated virus. This result suggests
that this protein may be truncated or deleted during the process the attenuation.
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In EBV this glycoprotein is essential in the attachment of the virus to B cells during
the infection cycle in vitro. This glycoprotein may have the same function in AHV-1
but may only be important in vivo as lytic virus replication occurs following infection
of cell cultures with the attenuated virus (Plowright et al, 1965a,b).
Another ORF was shown to share positional but limited structural homology to the
ORF 50 in HVS and BRLF1 in EBV. The ORF was designated ORF50 to denote its
positional albeit limited structural similarity to the HVS ORF. In HVS, ORF50 codes
for a transactivator that is essential in the transition from latency to lytic replication
in B cells infected in vitro. This putative protein is discussed in chapter 6.
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CHAPTER 6
ACTIVITY OF THE PUTATIVE QRF 50 PROMOTER
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6.1 INTRODUCTION
Malignant catarrhal fever is a pathological syndrome characterised by generalised
lymphocytic hyperplasia and disseminated necrosis (Plowright 1986). Virus cannot
be demonstrated in tissues of infected cattle and viral antigen can only be
demonstrated in 1 out of 104 lymphocytes from infected rabbits (Edington and Patel,
1980) and viral DNA in the same proportion of cells (Bridgen et al, 1989). The
pathogenesis of this disease is therefore poorly understood and no direct virus
cytopathology can be demonstrated. One hypothesis is that infection of T cells leads
to deregulation of these cytotoxic cells such that they acquire natural killer cell
characteristics and hence the cellular necrosis observed (Reid and Buxton, 1984). In
wildebeest associated MCF however, the virus is readily isolated by co-cultivation of
lymphocytes obtained from infected animals with cell cultures (Plowright et al 1960,
1965b). In the natural host, the wildebeest, animals acquire infection in utero or
perinatally and such animals continue to shed cell free virus in nasal and ocular
secretions for a few months (Plowright 1965a, Mushi et al, 1980, 1984). Cessation in
virus shedding is accompanied by the development of humoral and mucosal surface
antibody (Mushi et al, 1981c, Rurangirwa et al 1982, Plowright, 1965b). AHV-1 has
however been isolated from adult wildebeest following treatment with corticosteroids
or under the stress of confinement, malnutrition and pregnancy (Rweyemamu et al,
1974, Plowright, 1965b). Such animals may be latently infected and remain carriers
although virus shedding can be induced by stress.
OHV-2 has been shown to immortalise lymphocytes derived from MCF affected
rabbits (Reid et al, 1983). Similar cells are immortalised by AHV-1 (Reid-personal
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communication). The LCL are latently infected as viral DNA can be detected in
these cells and such cells induce typical MCF following infection of rabbits
(Bridgen et al, 1989, Reid et al, 1983, 1989). Intact virus cannot be detected as viral
DNA is probably present in an episomal form (Reid-personal communication)
In EBV, a gene product encoded by ORF BZLF1 has been shown to induce the
transition from latency to the lytic productive cycle in latently infected lymphocytes
(Chevalier-Greco et al, 1986, Countryman et al, 1987). Another transacting
immediate early protein, designated R and transcribed from the EBV BRLF1 gene
(Hardwick et al, 1989) has been shown to induce productive cycle of EBV
replication only in conjunction with the EB1 (Manet et al, 1989). Indeed, this
transactivator has been shown to interact with the BZLF1 protein and retinoblastoma
protein (Rb) in a mechanism that leads in the hyperphosphorylation of Rb and thence
induction of the lytic cycle (Canned et al, 1996). This transactivator may therefore
be important in the pathogenesis ofEBV.
AHV-1 has now been shown to contain putative homologues of these genes (Chapter
5). ORF 50 has been designated the R transactivator while ORF A6 may be the
equivalent ofBZLF2, the Z transactivator.
Sinclair et al (1991) have reported that the BZLF1 gene product in EBV can activate
the BRLF1 promoter and have suggested that disruption of latency may be mediated
at the BZLF1 promoter, with the Z (previously designated EB1) protein activating
the BRLF1 promoter. The authors also showed that R is transcribed together with Z
as a bicistronic mRNA from the BRLF1 promoter and that this promoter is activated
by both viral proteins.
The results presented in Chapter 5 show that attenuation of AHV-1 is associated with
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The results presented in Chapter 5 show that attenuation of AHV-1 is associated with
translocation and inversion of ORF 50 together with a short stretch of sequence
upstream of ORF 50 which is also inverted and inserted between ORF 50 and the
terminal repeats at the 3' end of the genome.
Analysis of the AITV-1 genome suggests that ORF 50 may be transcribed as two
exons (Ensser et al, 1997). Similarly, ORF 50 in HVS is transcribed from two
distinct promoters to yield two gene products, ORF 50a and ORF 50b (Whitehouse
et al, 1998). ORF 50a was shown to encode an IE protein, while ORF 50b, is a DE
protein with a promoter within the ORF 50a. Transient transfection assays showed
both promoters to be functional and that the ORF 50a gene product acts as an
immediate early transactivator. The authors however did not establish the role of
ORF 50b but suggested that this may act as a negative regulator of the ORF 50a
promoter. Another gene product, encoded by ORF57 in HVS has been shown to
repress the transactivation capability ofORF 50a via post-transcriptional splicing and
slightly activate ORF 50b transcription (Whitehouse et al, 1998). This repression was
also dependent on the presence of an intron within the ORF 50a.
Since the HVS and AHV-1 genomes are generally homologous, it was assumed that
ORF 50a in AHV-1 could possess the same functional role as in HVS.
In HVS, 50a is transcribed from a promoter located at least 417bp upstream of the
start codon within the adjacent ORF 49 (Whitehouse et al, 1998). ORF 50b is a
delayed early spliced transcript with a promoter located within the non-coding 50b
ORF. The function of this latter protein has not yet been established.
Sinclair et al, (1991) reported that BZLF1 can reactivate BRLF1 in vitro. Zalani et
al, (1992) showed that BRLF1 promoter contains two transactivator binding sites and
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suggested that R can activate its own promoter. R, transcribed by ORF 50a in HVS
has a classic eukaryotic promoter motif, putative TATA and CCAAT consensus
sequences at -99bp and -183bp upstream of the ATG translation codon respectively.
In EBV infection of lymphocytes in vitro is characterised by immortalisation and
virus latency whereas infection of the epithelial cells in vitro is associated with
productive infection and cell lysis. It has now been shown that the R transactivator
can induce the lytic cycle genes and disrupt latency in B cells as well (Ragoczy et al,
1998).
It is therefore possible to speculate that the latency observed in AHV-1 could be due
to the inactivity of the promoter controlling ORF 50.
There is no information on the functions of the ORF 50 promoter or gene product in
AHV- 1. The results presented in chapter 3 indicate that this protein is transcribed
and translated in vitro. Since it is now clear that this protein is an I.E. protein it
would be useful to determine whether this protein is transcribed in cultures infected
with the virulent and the attenuated viruses in the presence of cycloheximide.
Cycloheximide inhibits translation of mRNA. There is therefore increased
production of viral mRNA in cultures infected with virus in the presence of
cycloheximide. An aim of this chapter is therefore to determine whether the R
transactivator is transcribed in cultures infected with the virulent and the attenuated
derivatives of AE1V-1 in the presence of cycloheximide.
The other aim of this chapter is to determine whether the putative ORF 50 promoter
in the virulent virus and the truncated promoter in the attenuated virus are functional
using the American firefly (Photinus pyralis) luciferase gene as a reporter gene in
transient transfection assays.
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6.2 Materials and methods
6.2.1 Preparation of Immediate Early (I.E.) RNA.
Growth media (Iscoves modification of Dulbecco's medium (GIBCO), supplemented
with 10% Foetal bovine serum, 100 IU/ml penicillin, 50 IU/ml streptomycin, 2 IU/ml
fungizone (Rousell) containing cycloheximide at a concentration of 100 pg/ml was
added to confluent monolayers of BT cells in 25cm tissue culture flasks and infected
at high multiplicity of infection (approximately 2 TCID5o/cell) with either WC11,
C500 CA or CFA. After 8 hr, the medium was poured off and total cellular RNA
prepared as described in 3.2.13 except that 10 ml of GITC was added on to the cell
culture monolayers. The RNA precipitate was dissolved in lOOpl of water and the
RNA concentration obtained by spectrophotometry.
6.2.2 Analysis of RNA by Northern Blotting
10 pg of total RNA were run on a 1% denaturing gel as described in section 3.2.14.
DNA was transferred to Hybond-N membrane (Amersham) by capillary blotting as
• ^9
described in section 3.2.16. DNA was labelled with [a PJdCTP using Rediprime
(Amersham) and hybridised in RapidHyb hybridisation buffer (Amersham) to the
transferred RNA at a temperature of 65° C (sections 6.2.5 and 6.2.6). The membrane
was washed in 0.2x SSC, 0.1% SDS at 65° C and exposed to X-ray film overnight.
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6.2.3 Isolation ofAHV-l-derived promoter sequences
AHV-1 genomic DNA from virulent and attenuated virus was extracted as described
previously (Chapter 3). The complete sequence for AHV-1 is available from
Genbank (Ensser et al, 1997). The AHV-1 sequences upstream of the initiation
codon of P-l, the R transactivator, were amplified from the CA and CFA viruses
using Taq PCR (section 2.5.15.1). The primers used and the positions of these
primers with respect to the AHV-1 L-DNA are listed below (see also appendix 6.1).
The primers were engineered to contain suitable restriction sites for ligation into the
vector pGL2 which carries the luciferase gene.
6.2.4 Description of primers
The primers were designed to allow ligation of the PCR fragments into the plasmid
pGL2 upstream of the luciferase reporter gene. The positions of the primers in the
AHV-1 genome are shown diagrammatically in Appendix 6.1.
Lucs4 : This was used to prime the truncated part of the promoter of the R
transactivator in attenuated AHV-1 (CFA).




Lucs3 : This was used to prime the promoter of the R transactivator of virulent C500
AHV-1 (CA).
5' (71828) -AAGGGAGGTACCTGCTGCTATGGGAAAC - (71855) 3'
1 AAGGGAGGTACCTGCTGCTATGGGAAAC 28
Kpnl
Lucr2 : This is a primer reversed at start of exon 1 of the R transactivator.
5' (72808) -AAATTTGACTACCCAAAATGAGTGCCAAC- (72836) 3'
29 AAATTTGACTACCCAACTCGAGTGCCAAC 1
Xhol
Lucrl : A 5' primer for the promoter region of the R transactivator of AHV-1 for
ligation into the luciferase reporter gene
5' (72808) -AAATTTGACTACCCAAAATGAGTGCCAAC- (72836) 3'
29 AAATTTGACTACCCAAAAGATCTGCCAAC 1
Bgl II
RP1 : This is a primer located in the terminal repeat H-DNA at a position close to the





Taq PCR was used to amplify the viral sequences. Reactions were set up using
primer pairs lucs4/lucrl and lucs3/lucrl to amplify fragments of 467 bp and 984 bp
upstream of the initiation codon of the R transactivator (ORF 50 or P-l) in C500
(CA). These are coded pGL2-CAl and pGL2-CA2 respectively in table 6.1.
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Lucs4/lucrl were also used to amplify the equivalent region in WC11 and the
construct is coded pGL2-WCll. The region upstream of the R transactivator in its
inverted orientation adjacent to the H-DNA in the attenuated C500 (CFA) genome
were amplified using primer pair RP1/ lucr2 and is coded CFA in table 6.1.
6.2.6 Plasmids used for cloning ORF 50 promoter
The pGL2 Luciferase Reporter Vectors used were purchased from Promega. These
plasmids are designed to support convenient analysis of promoter sequences using
the firefly Photinus pyralis as the genetic reporter. Two plasmids were used as
positive and negative controls in the experiment in order to assess the efficiency of
the luciferase assay procedure. The genotype and cloning sites for the pGL2 plasmid
are described in tables 2.2 and 2.3. Controls were:
pGL2 Control. This plasmid contains the enhancer and promoter sequences for the
luciferase gene. Cells transfected with this plasmid will therefore produce luciferase
enzyme.
pGL2 Basic. This plasmid does not contain either the promoter or the enhancer
sequences. Cells transfected with this plasmid do not therefore produce luciferase.
6.2.7 Cloning of R transactivator sequences into pGL2 plasmids
The PCR fragments were digested with appropriate restriction enzymes and ligated
into plasmids that had been linearised following digestion with the respective
enzymes. Ligations were conducted with T4 ligase and the ligation mixture used to
154
the cells to grow in LB agar containing ampicillin. Single colonies were then grown
in LB and the plasmid extracted as described previously. Colonies containing
recombinant plasmid were selected following demonstration of insert in the
recombinants after digestion with the appropriate restriction enzymes. Since two
different restriction enzymes were used to make recombinant plasmids the ligation
was assumed to be possible in only one direction. Large scale plasmid DNA was
prepared and an aliquot sequenced using forward and reverse pGL2 primers to
confirm presence and orientation of the inserts.
PCR fragments pGL2-CAl, pGL2-CA2 and pGL2-WCl 1 were digested with Bgl II
and Kpn I before ligation into the pGL2 plasmid. Fragment pGL2-CFA was digested
with SacI and Xho I.
6.2.8 Preparation of 32P labeled probes for colony lifts and hybridisation
This method was used to confirm that competent JM109 cells transformed with
pGL2 plasmids ligated with ORF 50 promoter sequences contained the desired
insert. This technique was used since colonies transformed with recombinant plasmid
could not be selected using the IPTG/X-gal "blue" or "white" marker system. DNA
used as the probe were PCR products used to construct the respective recombinant
plasmids. lOng of probe DNA was denatured by boiling for 5 min in a total volume
of 45 pi of water and then chilled quickly on ice. Denatured DNA was added to a
Rediprime tube containing random hexanucleotides, dNTPs and polymerase enzyme
provided in the "Rediprime DNA labelling kit" (Amersham). 5pl of a-P32-dCTP at
3000Ci/mmol was added and the mixture incubated at 37°C for 1 hour.
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3000Ci/mmol was added and the mixture incubated at 37°C for 1 hour.
6.2.9 Hybridisation of 32P labeled probes
Hybond N membranes (Amersham) were placed on the bacterial colonies until the
membranes were wet through. The orientation of the colonies on the plate and on the
membrane was fixed by puncturing holes through the membrane. The membrane was
then carefully peeled off the bacterial cells and placed on a Whatman 3MM filter
paper soaked in 10% SDS for 3 minutes and then transferred to one soaked in 0.5 M
NaOH/1.5 M NaCl for 5 minutes to lyse the colonies. The membrane was neutralised
by being placed on a filter of 0.5 M Tris/HCl pH 7.0/1.5M NaCl for 5 minutes. It was
then placed on a filter soaked in 2x SSC for 5 minutes before being allowed to dry in
air. The membrane was wetted in 2x SSC and the bacterial debris wiped off carefully
with tissues. The membrane was dried and the plasmid DNA fixed to the Hybond-N
by exposure to UV for 1 minute on the surface of the transilluminator. The
membranes were wetted by placing them briefly in 2x SSC and then prehybridised in
RapidHybR (Amersham) (20 ml 100cm"2 of membrane) for lhr at 65° C. The solution
was decanted and fresh hybridisation buffer containing denatured probe added.
Hybridisation was carried out for 2-16 hr at 65°C and the filters washed twice in 0.1 x
SSC, 0.1% SDS at the same temperature for 30 min. The filters were dried with
paper towels and bound radiolabeled probe detected by exposing the membrane to X-
ray film in the dark for 12 hours. The films were developed using an automatic
processor (Compact X2, Kodak) and the colonies containing insert determined by
aligning the bacterial plates with the autoradiograph.
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6.2.10 Transfection of BT cell cultures with plasmid
Five micrograms of plasmid DNA were added to 150pl serum free MEM. Three
hundred microlitres of Superfect Transfection Reagent™ (Qiagen) was added to the
DNA and the contents vortexed lightly. The mixture was left to stand at room
temperature for 10 minutes and 1 ml of ISCOVES media (GIBCO) added. Media
was removed from BT cell culture monolayers showing approximately 80%
confluence in 60mm culture flasks and the cells washed once with PBS. The
monolayer was overlaid with the plasmid DNA/Transfect mixture and the cultures
incubated for 3 hours at 37°C. DNA/Transfect mixture was removed from the culture
flasks and 10ml of media containing antibiotics and 10% foetal calf serum added.
The cultures were incubated for 48 hours at 37°C when the cells were harvested for
luciferase enzyme activity assay.
6.2.11 Transfection and infection / Infection and transfection
This experiment was carried out to determine whether virus replication would
influence the ORF 50 promoter activity in vitro. BT cultures were infected at a
multiplicity of infection of approximately 2TCID5o/cell with either WC11 or C500
(CA) and the cells transfected 24 hr later. The cells were assayed for luciferase
activity 24 hr after transfection. For the transfection and infection assay, the cells
were transfected with the constructs and then infected 24 hr later at a multiplicity of
infection of approximately 2TCID50/ cell with either the virulent C500 or attenuated
WC11 isolate. The cells were harvested for assay after 48 hr.
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6.2.12 Luciferase activity assay.
This assay was performed using reagents purchased from Promega. The method used
was as described by the manufacturers. Media was removed from cell culture
monolayers and the cell sheet rinsed twice with PBS, taking care not to dislodge the
cells. Two hundred and fifty microlitres of lx cell culture lysis reagent was added to
a 60mm cell culture flask and the attached cells scraped from the culture flasks. The
cells and the solution were spun for 5 seconds in a microfuge at 12,000 g to pellet the
cell debris and the supernatant transferred to a new tube. This cell extract could be
used immediately or aliquoted and stored at -70°C until required. For assay, 20pl of
cell extract was mixed with lOOpl of luciferase assay reagent at room temperature.
The sample was then assayed in a liquid scintillation counter (Packard, Model 2500
TR) set up with the coincidence circuitry switched off. The counts were recorded
every 30 sec for 4 minutes. Assays were conducted in replicate and cells not
transfected with plasmid (mock transfected) were included as controls in all cases.
6.3 RESULTS
6.3.1 Northern analysis of RNA from infected BT cells.
The results of Northern analysis of RNA from cell cultures infected with WC11,
C500 (CA) or C500 (CFA) in the presence of cycloheximide are presented in figure
6.1. Substantial amounts of RNA which hybridised to an AF1Y-1 R transactivator
gene probe were produced in only in those BT cells infected with the virulent, low
passage form of AHV-1 C500 (CA). The attenuated forms, WC11 and C500 (CFA)
were negative, as were the uninfected cells.
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Figure 6.1. Northern blot of total RNA from cycloheximide-treated BT cells.
BT cells were treated with virus as indicated below and in the text. The blot was
hybridised with a 32P labelled DNA probe from ORF 50 (peptide 1). The blot was
washed in 0.2 x SSC, 0.1% SDS at 65°C and exposed to X-Ray film overnight at -
70°C. Arrows indicate the positions of the ribosomal RNAs. The 28S RNA is
approximately equivalent to a 5kbp dsDNA fragment while the 18S is equivalent to a
2 kbp ds DNA fragment.
Track Sample Track Sample
no. no.
1 Control BT 3 BT + C500 (CA)








6.3.2 PCR of ORF 50 promoter fragments
PCR fragments of the predicted sizes were amplified using different combination of
primers and target DNA (table 6.1). The amplified products were used for ligation
into the pGL2-basic plasmid.
Table 6.1. Fragments used for ligation into the pGL2
Target DNA Primers Size (bp) Position in genome Code
C500 (CA) LucS4/LucRl 467 72357-72824 pGL2-CAl
C500 (CA) LucS2/ LucRl 984 71851-72824 pGL2-CA2
C500 (CFA) RPl/Lucr2 344 1150-1035* +
72550-72824
pGL2-CFA
WC11 LucS4/LucRl 467 72357-72824 pGL2-WCl 1
^position in H-DNA. CA = Cell associated. CFA = Cell free attenuated.
6.3.3 Sequences ofORF 50 promoter fragments cloned into PGL2
The pGL2 clones were sequenced to confirm the identity of the inserts and the
sequences are given in figure 6.2. The sequences of the L-DNA were identical to
those of Ensser et al. (1997) The results also show that the promoter for the R
transactivator is truncated and inserted at the right end of the L-DNA adjacent to the
terminal repeats (see also figure 5.2).
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Figure 6.2a. Sequence homology of PCR fragments cloned into pGL2. The complete
sequence of the insert in pGL2-CA2 is shown and the DNA homology to L-DNA of
AHV-1 indicated. The sequences of clone pGL2-CAl and pGL2-WCll are
represented in bold.
1 GAAACTTAACTACATTTTTATTTCCACCCATAAAAGCTCCCCTCTCTTTA
I II I I II I I I II I I I I I I I II II I I I I I I I I II I I I I I II II I I II I I I I
71851 GAAACTTAACTACATTTTTATTTCCACCCATAAAAGCTCCCCTCTCTTTA
51 ATCTTTTTTAGCAGCCTTACATCTAATCTACAGAGGTCCCTTTTAGACTC
I I I I I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I II II I I I I I II I I I I
71901 ATCTTTTTTAGCAGCCTTACATCTAATCTACAGAGGTCCCTTTTAGACTC
101 TAGAGGTATTTTATAGGTCACAGCAAACTGCATCATGTCTTCAAAAATGT
I I I I I I I I II I I I II I I I I I I I I I I II II II I I I II I II I I II I I I I I I I
71951 TAGAGGTATTTTATAGGTCACAGCAAACTGCATCATGTCTTCAAAAATGT
151 CCTCCAAAGCACCAGTTACTGTCTGCTGCATTTTGTAAAATAGCCAGCAG
I I I II II II I I I I I I I I II I I I I II I I I I I II I II I I I I I I I I I I I II II
72001 CCTCCAAAGCACCAGTTACTGTCTGCTGCATTTTGTAAAATAGCCAGCAG
201 AAAGTTATACATATAGCTAATAAACTCGCTTCTTTTTTAGCTTCTATGCT
I I II I I I II I I I II II I II I I II I I I I I II I I I I I I I I I I I II II I II II
72051 AAAGTTATACATATAGCTAATAAACTCGCTTCTTTTTTAGCTTCTATGCT
251 AAAGCCCCCTTCAAAGTGCGACCCCATGACTATGTCACGGAGCAGATCCT
I I I II I I I I I I I I I I II I I I I I I I I I I I I I I I I I I I I I I I I I II I I I I II
72101 AAAGCCCCCTTCAAAGTGCGACCCCATGACTATGTCACGGAGCAGATCCT
301 TAGAAACTGGAACACTGTTACACAAGACAGCACTGTTGTAAACTGAAGAC
I I II I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I II I I I I II I I I II
72151 TAGAAACTGGAACACTGTTACACAAGACAGCACTGTTGTAAACTGAAGAC
351 AATGTAAACTCATAAGAGGAAATTTCATGTGGGTTTAATCTAGGCATCCT
II II I I II II I I I I I I I I I II I I I II I I I I I I I I II II II I I I I I I II I I
72201 AATGTAAACTCATAAGAGGAAATTTCATGTGGGTTTAATCTAGGCATCCT
401 ATAGGAAATTTGTGCCTTCTGTAGCCCCTTCACTGTTTCCAAGCACTCCA
I I I I I II I I I II II I I I I I II I I I I I I I I I I I I I I I I I I I I I I II I I II I
72251 ATAGGAAATTTGTGCCTTCTGTAGCCCCTTCACTGTTTCCAAGCACTCCA
451 TACATCCACATTCACATTCCAACAGCAGAGCTAACCTCCTACTGCATTCT
I I I I I I II I I I I I I I I I I I I I I I I II I II II I I I I I I I I I I I I I I I I I II
7 2301 TACATCCACATTCACATTCCAACAGCAGAGCTAACCTCCTACTGCATTCT
501 GTAAACATACTCTCAATGTTTTCTGGATACACCCGTTGAAAAATTTCATC
I I I I II I I I I I I I I I I I II I I I I I I I I I I II I II I II II I II II I I I II I
72351 GTAAACATACTCTCAATGTTTTCTGGATACACCCGTTGAAAAATTTCATC
551 AAAACAATATTCTGCTAAACTTCTTACCAGAATTGCCATCTGGATAACTC
I I I I I I I I I I II I I II I II II I I I II I I I I II II II I I I I I I I I I I I II I
724 01 AAAACAATATTCTGCTAAACTTCTTACCAGAATTGCCATCTGGATAACTC
601 TGTCCTTTTCAATCATATTGTCTTCTGTTTGAATCAGGCTAACTAGCACC




I I I I I I II I I I I I I I I I I I I I I II I I I I I I I I I II I I I I II I I I I I I I II
72501 AAGAGGCCAGCACAGTAGCAGTCATCTGTTTTACAAAAAGTCCCCCTTAA
7 01 AAAATTAAGGCAGGCTTGGGTATTTTTATGTGAGCTAAAGCTTGCTATCA
I I I I I I I I I II II I I I I I I I I I I I I I I I I I I I I I I I I II I I II I II I I I I
72551 AAAATTAAGGCAGGCTTGGGTATTTTTATGTGAGCTAAAGCTTGCTATCA
751 GCAGGCGCCACTTGGTCTGTTGGTTAGATGTAAGAATAGCAACAGGAACT
I I I I I I I I I I I I II I I I II I I I I I I I I I I II I I I I I I II I I I I I I I I I I I
72601 GCAGGCGCCACTTGGTCTGTTGGTTAGATGTAAGAATAGCAACAGGAACT
801 GGAAGCTCCATGGTTGTGAATCAAGTTAAAAAAAAGTAGGTGACAGGCTT
I I I I II I II I II II II I I I I I I II II I I I I I I I I I I I I I I I I I I I I II I I
72651 GGAAGCTCCATGGTTGTGAATCAAGTTAAAAAAAAGTAGGTGACAGGCTT
851 AAATAACAAGCCACAGGAACTGTACTCACTAAATCTGACCAGATTGTTTA
I I I I I II II I I I I I I I II I II I II I II I I I II I I II I I II I I I I I II I I I
72701 AAATAACAAGCCACAGGAACTGTACTCACTAAATCTGACCAGATTGTTTA
901 AGCAGCCAGTGAGTAAGCTCACATTTATTTCTCTAAGGCTTCATTTCACA
I I I I I I I I I I I I I I I I I I I I I I I II I I I I I I I I I I I I I I II I I I I I I I II
72751 AGCAGCCAGTGAGTAAGCTCACATTTATTTCTCTAAGGCTTCATTTCACA
951 GGCACACAAATTTGACTACCCAAAA 975
I I I I I II I I I I I I I I I I I II I I I I I
72801 GGCACACAAATTTGACTACCCAAAA 72825
Figure 6.2b. Sequence of the insert in clone pGL2-CFA showing the homology of
the first 77 bp to AFIV-1 Fl-DNA (in bold typeface) and the homology of the rest of
the clone to AHV-1 L-DNA. The start codon for the R transactivator is underlined.
1 TTCGGGCCAGAGA.CCGGAGAGAGGGGAAAAAAAACCAGGGG
II II I II II II I I I I I I I I I I I I I I I I II I I I I I I I I I I
1113 GAGCTCTGTTGGGCCCAGAGACCCGGAGAGAGGGGAAAAAAAACCAGGGG
42 GACGGGCCGCGGGGGGCTCGGGGGCCGGGCGATGCC 77
I I I I I I I II I I II I I I I I I I I I II II I I III
1063 GACGGGCCGCGGGGGGCTCGGGGGGCGGGGAGGGCCGCGGAGCGACAAAA
7 8 AAGTTAAAAAAAAGTAGGTGACAGGCT
I I I I I I I II I I I I I I I I II I I I I I I II
72650 TGGAAGCTCCATGGTTGTGAATCAAGTTAAAAAAAAGTAGGTGACAGGCT
105 TAAATAACAAGCCACAGGAACTGTACTCACTAAATCTGACCAGATTGTTT
I I I I I II I I I I II II I I I I I I I II I I I I I I I I I I I II I I I I II II I I I I I
727 00 TAAATAACAAGCCACAGGAACTGTACTCACTAAATCTGACCAGATTGTTT
155 AAGCAGCCAGTGAGTAAGCTCACATTTATTTCTCTAAGGCTTCATTTCAC
I II I I I I I I I I II I I I I I I II II II I I II I I I I I I I I I I II I I I I I I I II
72750 AAGCAGCCAGTGAGTAAGCTCACATTTATTTCTCTAAGGCTTCATTTCAC
205 AGGCACACAAATTTGACTACCCAA
I I I II II I I I I I I I II I I I I II II
72800 AGGCACACAAATTTGACTACCCAAAATGAGTGCCAACAACCCCTCATGTG
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6.3.4 Luciferase activity assay
Initially, the experiment was conducted in a COS cell line. This is a fibroblastic cell
line of monkey origin purchased from Qiagen. COS cells were transfected with the
pGL2 basic and pGL2 control as well as the constructs. The results indicated that the
ORF 50 promoter was not functional in COS cells although the SV40 promoter in
pGL2 control was functional (result not shown). The experiments were therefore
performed in BT cells, a bovine cell line in which the virus multiplies. The results of
the luciferase assays are presented in Figures 6.3 (a-f) and are summarised in table
6.2.
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Figure 6.3 a-f; The graphs show results of Luciferase assay (photon counts) in
BTcells transfected with plasmids and constructs
Indices; BT-uninfected cells,
*- Cells infected with either virus before transfection,
'-BT cells that are transfected and then infected with the named isolate






BT WC11* C500* C500' WC11'
Infected and uninfected cells








BT WC11* C500* C500' WC11'
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WC11* C500* C500' WC11'
Infected and uninfected cells









BT WC11* C500* C500'
Infected and uninfected cells
WC1V
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BT WC11* C500* C500'
Uninfected or Infected cells
WC11'






BT WC11* C500* C500' WC11'
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Table 6.2. Promoter activities of the pGL2-Control plasmid and the AHV-1
constructs relative to the promoter activity of the pGL2-Basic plasmid taken as one.









C500 (CA) WC11 C500 (CA) wen
Control 68.8 76.5 127.7 149.3 33.5
CA1 46.8 8.5 17.9 23.5 3.0
CA2 3.0 1.2 1.2 1.6 0.8
CFA 1.3 1.8 3.4 10.4 1.4
WC11 1.0 1.0 0.9 1.5 0.7
None 1.0 1.0 0.9 1.0 1.0
The promoter in the pGL2-control plasmid was activated to drive the luciferase gene
in uninfected BT cells. The relative activity compared to pGL2-basic which lacks a
promoter for the luciferase gene was 68.8 fold. When the assay was applied to the
constructs, the ORF 50 promoter in pGL2-CAl was functional with 46.8 fold the
activity of the pGL2-basic plasmid. However, the activity of the constructs pGL2-
CA2, pGL2-CFA and pGL2-WCll were not sufficiently above background to be
considered positive.
Reporter gene activity assay was also carried out on BT cells that were infected with
either the virulent cell associated C500 or the attenuated WC11 24 hr after
transfection to determine whether viral infection had an influence on the ORF 50
167
promoter activity. The enzyme activity in the cells transfected with pGL2-control
increased almost two times to 127.7 fold that of the pGL2-basic plasmid in cells
infected with WC11, but the activity was only slightly increased in cells infected
with C500. The promoter activity of construct pGL2-CAl was reduced to 17.9 fold
in cells infected with WC11, and was reduced even further in cells infected with
C500 to 8.5 fold. The ORF 50 promoter in the other constructs was not functional.
Assay in cells infected before transfection showed that the activity of the control
plasmid was almost 150 and 33.5 fold in cells previously infected with C500 and
WC11 respectively. In cells infected prior to transfection the promoter activity of
pGL2-CAl was reduced to 23.5 fold and 3 fold in cells infected with C55 and WC11
respectively. The ORF 50 promoter in the other constructs was not functional. No
activity was demonstrated in any of the cell cultures transfected with the construct
pGL2-CFA.
In all the cell cultures the cpe was extensive but the cells were still loosely attached
to the cell culture flasks when they were harvested for assay.
6.4 DISCUSSION
The results demonstrate that the ORF 50 promoter construct pGL2-CAl is functional
in uninfected BT cells. pGL2-CAl is a construct which contains 464 bp of DNA
sequence derived from virulent C500 located immediately upstream of the ORF 50
start codon. Construct pGL2-WCll, which contains the 456 bp located upstream of
the ORF 50 start codon but derived from the WC11 viral DNA was not functional,
neither was pGL2-CA2 which contains a longer fragment, 950bp upstream of the
start codon, derived from the virulent C500 viral DNA. It is possible that the longer
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fragment may contain sequences that bind cellular repressors of ORF 50 promoter or
cellular inhibitory factors. These inserts do however contain a consensus TATAA
box at -274 bp relative to the ORF 50 ATG start codon. Another explanation for the
inactivity of the ORF 50 promoter in pGL2-CA2 could be that the longer fragment
may form secondary or tertiary conformational structures that make the promoter
binding site inaccessible to the cellular transactivators.
Transient transfection assays were initially conducted in a COS cell line that is of
monkey origin. There was no ORF 50 promoter activity in these cells although the
pGL2-control SV40 promoter was activated to drive the luciferase gene. This
indicated that these cells lacked a transactivator for the AHV-1 promoter suggesting
that the ORF 50 promoter is activated by a specific transactivator. Zalani et al (1992)
showed that the BRLF1 promoter in EBV, which is the equivalent of ORF 50
promoter could be activated by a transactivator, Spl. Spl is an ubiquitous cellular
transcription factor first described in HeLa cell cultures (Dynan and Tjian 1983)
which has also been shown to transactivate the EBV BRLF1 promoter in transient
transfection assays in epithelial cells but not in B cells. The authors suggested that in
B cells the promoter may be negatively regulated by additional cellular factors. This
transactivator binds to specific consensus binding sites, CCGCCC, CCACC and
CCAAT. These Spl binding sites are present in BRLF1 promoter but are absent in
the ORF 50 promoter. The ORF 50 promoter may therefore be transactivated by
different proteins.
The results presented here provide further evidence that the putative ORF 50
promoter isolated from the attenuated C500 derivative (CFA) is non-functional.
pGL2-CFA is composed of 274 bp identical to the sequence in AHV-1 (CA), at
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positions 72550-72824 but inverted in orientation and ligated to 76 bp of sequence
derived from H-DNA. The putative promoter is inactive probably because the
transactivator does not recognise the inverted sequences, or the 274 bp fragment is
too short to contain all the regulatory sequences required for activation of the ORF
50 promoter. It is also possible that the presence of H-DNA at the 3' end of the 274
bp sequence inhibits the binding of the cellular regulatory factor(s) for this promoter.
Interpretation of the results obtained in the experiments involving
transfection/infection and infection/transfection is difficult for a number of reasons.
Firstly, if the experiments were to be repeated, a co-transfected vector such as
pCAT3 (Promega) which contains the chloramphenicol acetyltransferase reporter
gene should be included to control for potentially variable transfection efficiencies.
This does not affect the results discussed above where the differences between for
example, pGL2-CAl results for uninfected BTs and those for pGL2-CFA were too
large to be accounted for by transfection efficiencies. However, discussion of the
results where the differences were smaller is more problematical. Secondly, the way
the experiment was set up, it must be borne in mind that we are dealing with an
"immediate early" viral gene at "late" times i.e. 48 hours post infection when an
"immediate early" promoter might not be expected to be activated. In the case of the
transfection followed by infection experiments, this did not present a problem as the
"immediate early" times began when the virus was added to the cells. The luciferase
produced then may persist in the cells to be assayed 48 hours later. In the other
experiments where the cells were infected and then transfected, the problem revolves
around the question of multiplicity of infection and synchronicity of infection. If
uninfected cells are still being infected when the transfections were occurring, then
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clearly in those cells "immediate early" activity still prevails and the promoter may
still be activated. Certainly, in the case of the virulent C500 strain, the virus is cell-
associated and synchronicity of infection may be difficult to achieve.
Broadly, the results obtained in the infection and transfection assays demonstrate that
for the pGL2-CAl construct, the promoter function was reduced in virally infected
cells, although for reasons discussed above it is difficult to be categorical. Certainly,
in all experiments the level of activation of the promoters in the constructs other than
pGL2-CAl remained very low.
Generally speaking, the results are consistent with the observation that the gene for
ORF 50 is transcribed in cell cultures infected with virulent virus and not in cells
infected with the attenuated derivative of C500 (CFA) or WC11. Although
transcription in herpesviruses is from either strand, the translocation and inversion of
ORF 50 may be the reason for the trancriptional silencing of ORF 50. The other
possibility may be that crucial regulatory sequences that are inverted following





The first characterisation of the AHV-1 genome was conducted using viral DNA
derived from the attenuated WC11 isolate ( Bridgen et al, 1989). The genome was
shown to comprise of up to 30 direct lkbp repeats flanking a low G+C unique DNA
(L-DNA) of approximately 130 kbp in length. The virus was therefore classified as a
B- group gammaherpesvirus, the prototype of which is the Herpesvirus saimiri
(HVS) (Roizman et al, 1992). The virulent pathogenic form is largely cell associated
(CA), while the high passage cell free (CFA) derivative is non-pathogenic
(Plowright, 1986). The genomes of these forms of the C500 virus isolate were
compared by restriction enzyme analysis and southern blotting with a 3.8 kbp clone
of CFA (Handley et al, 1995). Differences in the smal profiles of the two forms were
described and three restriction fragments designated virl, vir2 and attl were cloned
and sequenced. The clones were mapped to a terminal location in the genome based
on their hybridisation to the ladder of restriction fragments which result from the
variable number of the tandem repeat units at the end of the unique DNA.
Differences in the nucleotide sequence were interpreted to be due to deletions which
occurred on the rearrangement of the genome during the transition from virulence to
attenuation. The results indicated that a fragment of approximately 500 bp was
deleted in the attenuated genome. An analysis of the cloned DNA also indicated that
there were nine putative open reading frames in these clones (Handley, 1993,
Handley et al, 1995). The 500 bp fragment present only in vir2 was shown to encode
a highly antigenic protein, designated polypeptide 5 (P-5). Comparisons with the
HVS indicated that this putative protein would be the positional equivalent of the
HVS transforming proteins STP All and STP C488 which are only present in the
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virulent derivatives of strains A11 and C488 but are deleted following attenuation of
these HVS sub-types (Albrecht et al, 1992, Beisinger et al, 1990). Another protein,
present in both clones, and designated peptide 1 was shown to share limited
homology to the Tyrosine Kinase Inhibitor Protein (TIP) in HVS (Murphy et al,
1989, Beisinger et al, 1990). Based on these suggestions, the aim of this study
initially was to clone and express these putative proteins and assess their protective
role and also determine whether these proteins are expressed in vivo and in vitro with
the objective of using them as diagnostic reagents in AHV-1.
The results presented here show that these proteins were successfully expressed in
E.coli and the recombinant proteins used to immunise rabbits. However, neither of
the two proteins was protective although both proteins were immunogenic. P-5
cloned as a fusion protein with thioredoxin was evaluated as an antigen in an indirect
ELISA and the results show that this protein is not recognised by sera obtained from
cattle experimentally infected with either the virulent or attenuated virus. It was not
possible to use peptide 1/GST fusion as the protein degraded very rapidly and use of
the protease inhibitor, A-PMSF did not stabilise the protein. mRNA for both proteins
was however detected in LCL derived from rabbits infected with either AHV-1 or
OHV-2. This indicated that genes for both proteins are conserved in the two viruses.
Both proteins were also detected in LCL as diffuse cytoplasmic antigen in an indirect
immunofluorescence test. Both proteins were also detected in cultures infected with
the virulent C500 and attenuated WC11. Detection of P-5 in cultures infected with
WC11 was rather surprising as Handley et al (1995) indicated that the sequence
encoding this protein is deleted in the attenuated virus. The attenuated virus used in
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this study is the WC11 isolate whereas the attl was derived from cell free attenuated
C500. However, P-l antigen detected in cells infected with WC11 was located in the
nucleus whereas P-1 antigen was located in the cytoplasm and also in the nucleus in
cultures infected with virulent virus. This may indicate that the sera was recognising
different antigens in these cultures.
This study was carried out before the publication of the complete sequence of
virulent C500 (Ensser et al, 1997). The sequence published is consistent with the
findings of Bridgen et al. (1989) with regard to the organisation of the AHV-1
genome. The sequence also shows that the AHV-1 genome is generally collinear with
that of other gammaherpesviruses. Ensser et al. (1997) have also described the
potential open reading frames encoding genes for AHV-1. The C500 sequence shows
that the genes encoding P-l and P-5 were longer in size than described by Handley et
al. (1995) and that these genes are located in the middle of the genome and not near
the terminal repeats as previously noted. P-l and P-5 would therefore represent parts
of the ORFs 50 and A7 respectively. Although there were these two discrepancies
with the Handley sequence in respect of these reading frames, the sequences which
were cloned in these studies are in frame. The P-l and P-5 fusion protein described
here therefore represent parts of the proteins 50 and A7 respectively. These proteins
could therefore represent antigenic epitopes in the ORFs described by Ensser et al.
(1997).
It was however important to re-assess the sequences described by Handley et al.
(1995) and Ensser et al. (1997) to confirm the sizes and positions of these ORFs in
AHV-1. As the laboratory strains of AHV-1 have been propagated for many years,
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two virus isolates were obtained from cattle showing clinical MCF and a further two
isolates were also obtained from wildebeest. Viral DNA was extracted from the new
isolates before they had undergone passage in culture. PCR using viral DNA from
these new isolates with primers designed to amplify full length ORF 50 and A7
showed that fragments of predicted size were obtained. Sequences of the PCR
fragments showed that the DNA was 100% homologous to C500 viral DNA. The
results therefore confirm that the two ORFs were conserved between isolates.
Restriction maps generated for ORF A8, which is adjacent to ORF A7 also showed
that this ORF is also conserved.
This finding necessitated a re-assessment of clones virl, vir2 and attl to determine
whether they were genuine clones or cloning artefacts. The Ensser et al. (1997)
sequence had shown that although vir2 was a Flind III fragment derived from the
middle of the genome, virl contained sequence from vir2 joined to the sequence
from the 3' end of the genome around 129 kbp. PCR and sequence results presented
here show that ORF 50, half of ORF A6 and 140 bp upstream of ORF 50 are
translocated to a position adjacent to the terminal repeats in the attenuated virus. The
sequences were mapped to the 3' end of the genome. It is therefore likely that the
virl clone of Flandley et al. (1995) was derived from the attenuated virus, probably
because the virulent virus preparation contained a proportion of virus which had been
rearranged.
Northern blot analysis of viral mRNA derived from cell cultures infected with the
virulent and attenuated virus showed that ORF 50 is only transcribed in cultures
infected with the virulent virus. In this study, luciferase was used as a reporter gene
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to assay the activity of the ORF 50 promoter sequences in the attenuated and virulent
virus. The results show that the promoter is functional in the virulent virus but is
non-functional in the attenuated virus. Thus the transcriptional silencing of ORF 50
in vitro could be attributed to the inactivity of the promoter in the attenuated virus.
During the process of attenuation, not only are crucial ORF 50 promoter sequences
truncated, but the regulatory sequences of ORF 48, a putative glycoprotein encoded
on the (-) DNA strand, are also translocated to the 3' end of the genome. It has now
been shown that ORF A6 is also truncated. Whatever the consequence of this
rearrangement during the process of attenuation however, the virus productively
replicates in vitro.
Most studies on the molecular basis of pathogenesis of gammaherpesviruses have
been conducted with EBV (Rickinson and Kieff, 1996). EBV is a gammaherpesvirus
that has been implicated as a cause of various forms of tumour and other
lymphoproliferative conditions in humans (Kieff and Liebowitz, 1990, 1996). The
virus latently infects and immortalises B lymphocytes such that the cells grow
continuously in culture (Pope et al, 1968, Nilsson and Klien, 1982). Only a few of
the approximately 100 genes of the virus are expressed when B cells are latently
infected with EBV virus (Dambaugh et al, 1986). Some latently infected B cells
however spontaneously enter the lytic phase of virus replication. Latently infected
cells can also be induced to enter the lytic phase of virus replication with production
of mature EBV particles using chemicals like 12-O-tetradecanoylphorbo-l 3-acetate
(TPA) (Zur Hansen et al, 1978). During the lytic infection, immediate early (I.E.),
delayed early (D.E.) and late (L) proteins are expressed. One I.E. protein, encoded by
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BRLF1 is designated R in EBV (Hardwick et al, 1989). The equivalent of this protein
in AHV-1 and HVS is encoded by ORF 50 (Ensser et al, 1997, Nicholas et al, 1991).
Although this ORF is a positional equivalent of BRLF1, there is only limited
sequence homology in the AHY-1 genome.
The BRLF1 gene in EBV is transcribed as a bicistronic mRNA which also encodes
another immediate early protein, designated BZLF1. The Northern blot result
presented here provides some evidence that ORF 50 mRNA in AHV-1 may also be
bicistronic as the size of the mRNA which hybridises to a peptide 1 (ORF 50) probe
is larger than expected. Both of these immediate early transcripts in EBV have been
studied extensively and are now known to be critical in the induction of the lytic
cycle of replication in latently infected cells in vitro. Expression of these proteins in
B lymphocytes and epithelial cells latently infected with EBV can be induced by
TPA (Zur Hansen et al, 1978). Initially R was shown to activate the delayed early
gene, BZLF2, which codes for a protein that is an essential component of EBV viral
DNA polymerase activity (Kenney et al, 1989). R protein together with Z are
essential in activation of lytic replication in B cells latently infected with EBV but Z
alone was sufficient to induce replication in latently infected epithelial cells (Kenney
et al, 1989). This was an important finding as lytic replication occurs in epithelial
cells before infection and establishment of latency in peripheral blood lymphocytes
during EBV infection cycle in vivo. The proteins were shown to function by
activating viral and cellular promoters leading to an ordered cascade of viral gene
expression and release of mature virions (Parker et al, 1990). It has now been
established that in EBV infection, R activates lytic cycle genes and can disrupt
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latency in B lymphocytes (Ragoczy et al, 1998). The authors suggest a co-operation
model for EBV entry into the lytic cycle. Expression of either R or Z triggers
expression of the other I.E. factor and together these activators act individually or in
synergy on downstream targets to activate the viral lytic cycle.
Although ORF 50 in AHV-1 shows positional homology but only limited structural
homology to BRLF1, the gene products may perform the same function in cells
infected by these viruses. This transactivator may be important in the establishment
of latency in infected T cells. However, the attenuated virus which does not have a
functional ORF 50 cannot establish latency in vivo. The protein was however
detected in LCL derived from rabbits infected with AHV-1 and OHV-2. Productive
replication does not occur in these cells (Reid-personal communication). Probably
the establishment of latency is necessary in the pathogenesis of MCF. However
rnRNA for ORF 50 was not detected in peripheral blood lymphocytes obtained from
cattle experimentally infected with either the virulent or attenuated AHV-1 using RT-
PCR. In affected tissues from an animal with MCF only a few cells express AHV-1
antigen in vivo (Edington and Patel, 1981) and viral DNA can only be detected in
1/1000 infected T cells from clinically affected rabbits (Bridgen et al, 1992). The
inability to detect ORF 50 mRNA may therefore be genuine or the result may reflect
the sensitivity of the RT-PCR test.
The results presented here show that ORF 50 is translocated and its promoter
truncated in the attenuated form of AHV-1. The overall effect of this is that ORF 50,
a putative R transactivator is silenced in vitro.
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The results also show that during the process of AHV-1 attenuation following
passage of the virus in culture, sequence encoding a putative glycoprotein, A8
(Ensser et al, 1997) is truncated/translocated or deleted.
The putative glycoprotein ofAHV-1 encoded by ORF A8 shows structural homology
to gp350/220 encoded by BZLF3 in EBV. These are two glycoproteins that are
transcribed from the same gene (Hummel et al, 1984, Beisel et al, 1985). Gp220 is
spliced in frame but gp350 is translated from the un-spliced transcript (Hummel et al,
1984, Billaud et al, 1989).
In EBV this glycoprotein mediates attachment to B cells in vitro via the CR2 receptor
on the surface on these cells (Fingeroth et al, 1984). CR2 is a type 2 complement
factor that binds C3d component of complement. The glycoprotein mediates
adsorption of EBV to CR2. The interaction may therefore mimic C3d binding and
lead to receptor mediated endocytosis (Nemerow et al, 1985, 1987). Saturation of B
cell receptors with anti-CR2 antibody blocks EBV adsorption, indicating that this
receptor may be crucial in infection of B cells by EBV (Tanner et al, 1987, 1988).
Entry of virus into cells in addition seems to require two other glycoproteins, gp85
and gp25 but the specific role that these latter glycoproteins play is not clear
(Yaswen et al, 1993, Pulford et al, 1995).
The cotton tail tamarin (Saguinus oedipus oedipus), a laboratory model for EBV, has
been shown to resist challenge with a lethal dose of EBV following vaccination with
a replication defective EBV expressing purified gp350/220 (Ragot et al, 1993) and
also with a subunit gp350/220 vaccine with adjuvant (Finerty et al, 1994) indicating
that this glycoprotein plays a significant role in the pathogenesis ofEBV.
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In OHV-2 infection, the target cell in sheep is the B lymphocyte (Baxter et al, 1997).
The lymphocyte sub-type associated with infectivity for AHV-1 in wildebeest is not
known although the target cell for the virus in rabbit is the T-lymphocyte (Mushi et
al, 1984). Although the CR2 is a receptor found only on the surface of B cells, this
receptor has been found in a small proportion of human T- lymphoblastoid cells
immortalised by Human T Cell Leukemia virus (Koizumi et al, 1992). These cells
were successfully infected with EBV. It is possible therefore that a proportion of T
cells in cattle and other susceptible species possess the CR2 receptor. No studies
have yet been conducted on the adsorption and entry of cells during infection with
AHV-1. This is difficult to investigate experimentally as only cell associated virus is
available at primary isolation of the virus.
Virulent as well as attenuated AHV-1 are however able to replicate in vitro. This
glycoprotein may therefore not be required for virus replication in culture. However,
this receptor protein may be essential for virus transmission and replication in vivo.
This study has shown that genomic rearrangements occur following attenuation of
AHV-1 with respect to ORF 50, ORF 48 and ORF A8. It has now also been shown
that ORF A6 is also truncated. In the process of translocation of these genes, ORF
A10 located at the 3' end ofL-DNA is truncated.
Some of the pathological processes which characterise MCF may be precipitated by
at least four bovid gammaherpesviruses. These include AHV-1 (Plowright et al,
1960), AHV-2 (Reid and Rowe, 1973), HipHV-1 (Reid and Bridgen, 1991), and
OHV-2 ( Reid et al, 1984). This suggests that the viral transcripts which precipitate
the reaction are highly conserved. They must therefore have important biological
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functions in the natural history of these viruses. The work described in this thesis has
further characterised some of these candidate virus products.
The publication of the complete sequence of the AHV-1 genome provides an
opportunity to study the putative genes, especially so those genes that may be
important in elucidating the molecular basis of virulence in this enigmatic virus.
Homologues to 60 conserved herpesvirus ORFs have been described. These include
some putative genes that may be important in the pathogenesis of AHV-1. The
mechanisms that probably play a role in the pathogenesis of MCF include those
genes that may activate or suppress the immune system and also genes that may be
responsible for the T-cell dysfunction. Genes that may have these roles in AHV-1
have now been described. Studies should be conducted on the role of ORF 57, a
putative regulator of transcription to determine the role and function of this protein in
vivo and in vitro and also on ORF A5, a putative G protein-coupled receptor that may
modulate the host immune system and also deliver activation signals to transformed
cells. Another open reading frame that may encode a putative determinant of
virulence in AHV-1 is protein A9 that shares homology to the Bcl2 family of
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